tetraphene - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	tetraphene	go back to main search page
Accession:	CHEBI:51348	browse the term
Definition:	An angular ortho-fused polycyclic arene consisting of four fused benzene rings.
Synonyms:	related_synonym:	1,2-Benzanthracene; 1,2-Benzanthrazen; 2,3-benzphenanthrene; Benz[a]anthracene; Formula=C18H12; InChI=1S/C18H12/c1-2-7-15-12-18-16(11-14(15)6-1)10-9-13-5-3-4-8-17(13)18/h1-12H; InChIKey=DXBHBZVCASKNBY-UHFFFAOYSA-N; SMILES=c1ccc2cc3c(ccc4ccccc34)cc2c1; benzanthrene; naphthanthracene
	alt_id:	CHEBI:33088; CHEBI:34557
	xref:	Beilstein:1909298; CAS:56-55-3; Gmelin:244702; KEGG:C14317
	xref_mesh:	MESH:C030935
	xref:	PMID:25528193; PMID:25528488; PMID:26720419; PMID:7561049; Patent:DE481819; Patent:DE486766; Reaxys:1909298; Wikipedia:Tetraphene

show annotations for term's descendants Sort by:
Rat (1218) Mouse (1323) Human (1248) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (1218)

tetraphene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

APOBEC1 complementation factor

decreases expression

benz(a)anthracene results in decreased expression of A1CF mRNA

NCBI chr 1:229,736,037...229,823,499
Ensembl chr 1:229,736,106...229,824,354

G

aladin WD repeat nucleoporin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AAAS mRNA

NCBI chr 7:133,464,315...133,483,961
Ensembl chr 7:133,464,315...133,483,961

G

aminoadipate-semialdehyde dehydrogenase

affects expression

benz(a)anthracene affects the expression of AASDH mRNA

NCBI chr14:31,255,019...31,281,802
Ensembl chr14:31,255,310...31,281,796

G

apoptosis-associated tyrosine kinase

increases expression

benz(a)anthracene results in increased expression of AATK mRNA

NCBI chr10:105,290,752...105,327,219
Ensembl chr10:105,291,585...105,327,112

G

ATP binding cassette subfamily C member 3

increases expression

benz(a)anthracene results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 5

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ABCC5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABCC5 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ATP binding cassette subfamily C member 9

decreases expression

benz(a)anthracene results in decreased expression of ABCC9 mRNA

NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356

G

abhydrolase domain containing 15

increases expression

benz(a)anthracene results in increased expression of ABHD15 mRNA

NCBI chr10:62,363,209...62,368,600
Ensembl chr10:62,363,209...62,368,600

G

abhydrolase domain containing 6, acylglycerol lipase

increases expression

benz(a)anthracene results in increased expression of ABHD6 mRNA

NCBI chr15:16,859,740...16,907,094
Ensembl chr15:16,859,738...16,906,985

G

ABI family member 3 binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABI3BP mRNA

NCBI chr11:43,912,187...44,128,888
Ensembl chr11:43,913,043...44,128,929

G

actin-binding LIM protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ABLIM1 mRNA

NCBI chr 1:256,083,747...256,372,075
Ensembl chr 1:256,084,297...256,371,969

G

abraxas 2, BRISC complex subunit

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ABRAXAS2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABRAXAS2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:187,647,078...187,672,660
Ensembl chr 1:187,647,067...187,672,655

G

1-aminocyclopropane-1-carboxylate synthase

increases expression

benz(a)anthracene results in increased expression of ACCS mRNA

NCBI chr 3:79,805,254...79,820,830
Ensembl chr 3:79,806,587...79,820,835

G

apoptotic chromatin condensation inducer 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ACIN1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACIN1 mRNA

PMID:26377693 PMID:27858113

NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001

G

acyl-CoA thioesterase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACOT1 mRNA

NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163

G

acyl-CoA oxidase 1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of ACOX1 mRNA; benz(a)anthracene results in increased expression of ACOX1 protein
benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

acyl-CoA oxidase-like

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ACOXL mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACOXL mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:115,061,069...115,367,032
Ensembl chr 3:115,061,060...115,364,686

G

acrosin binding protein

affects expression

benz(a)anthracene affects the expression of ACRBP mRNA

NCBI chr 4:157,851,149...157,864,211
Ensembl chr 4:157,841,841...157,864,213

G

activin A receptor type 1B

increases expression

benz(a)anthracene results in increased expression of ACVR1B mRNA

NCBI chr 7:132,286,266...132,329,679
Ensembl chr 7:132,286,275...132,329,673

G

ADAM metallopeptidase domain 22

increases expression

benz(a)anthracene results in increased expression of ADAM22 mRNA

NCBI chr 4:25,716,055...25,970,932
Ensembl chr 4:25,715,990...25,964,962

G

ADAM-like, decysin 1

increases expression

benz(a)anthracene results in increased expression of ADAMDEC1 mRNA

NCBI chr15:42,900,629...42,921,684
Ensembl chr15:42,900,636...42,921,712

G

ADAM metallopeptidase with thrombospondin type 1 motif, 14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ADAMTS14 mRNA

NCBI chr20:29,143,029...29,219,846
Ensembl chr20:29,144,354...29,219,866

G

adenylate cyclase 7

increases expression

benz(a)anthracene results in increased expression of ADCY7 mRNA

NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311

G

adducin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ADD3 mRNA

NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124

G

adhesion G protein-coupled receptor E4

increases expression

benz(a)anthracene results in increased expression of ADGRE4 mRNA

NCBI chr 9:9,758,106...9,901,908
Ensembl chr 9:9,760,355...9,900,760

G

adhesion G protein-coupled receptor L4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ADGRL4 mRNA

NCBI chr 2:240,354,909...240,457,231
Ensembl chr 2:240,354,941...240,457,225

G

adrenomedullin

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ADM mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ADM mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

adenosine A1 receptor

increases expression

benz(a)anthracene results in increased expression of ADORA1 mRNA

NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801

G

adrenoceptor alpha 1B

decreases expression

benz(a)anthracene results in decreased expression of ADRA1B mRNA

NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919

G

adrenoceptor beta 3

affects expression

benz(a)anthracene affects the expression of ADRB3 mRNA

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

apoptosis enhancing nuclease

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AEN mRNA

NCBI chr 1:132,815,094...132,824,522
Ensembl chr 1:132,815,142...132,824,523

G

AGBL carboxypeptidase 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of AGBL2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AGBL2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:76,764,893...76,800,071
Ensembl chr 3:76,764,238...76,800,214

G

argonaute RISC catalytic component 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AGO2 mRNA

NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974

G

argonaute RISC component 4

decreases expression

benz(a)anthracene results in decreased expression of AGO4 mRNA

NCBI chr 5:138,780,446...138,825,898
Ensembl chr 5:138,783,069...138,825,632

G

agouti related neuropeptide

increases expression

benz(a)anthracene results in increased expression of AGRP mRNA

NCBI chr19:33,447,992...33,481,602
Ensembl chr19:33,447,992...33,449,584

G

angiotensin II receptor, type 1a

increases expression

benz(a)anthracene results in increased expression of AGTR1A mRNA

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

adenosylhomocysteinase-like 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AHCYL2 mRNA

NCBI chr 4:58,381,290...58,531,061
Ensembl chr 4:58,381,218...58,531,060

G

AHNAK nucleoprotein

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of AHNAK mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AHNAK mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926

G

AHNAK nucleoprotein 2

decreases expression

benz(a)anthracene results in decreased expression of AHNAK2 mRNA

NCBI chr 6:131,830,668...131,876,311

G

aryl hydrocarbon receptor

affects response to substance
increases activity
increases response to substance
multiple interactions
affects binding

AHR affects the susceptibility to benz(a)anthracene
benz(a)anthracene results in increased activity of AHR protein
AHR results in increased susceptibility to benz(a)anthracene
[benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with 1,2,5,6-dibenzanthracene co-treated with pyrene] results in increased activity of AHR protein; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [indeno(1,2,3-cd)pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene] promotes the reaction [pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with pyrene] promotes the reaction [fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [chrysene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(k)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(j)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [Benzo(a)pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with TNF protein] results in increased activity of AHR protein; [Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benz(a)anthracene results in increased activity of AHR protein]; AHR protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]; AHR protein affects the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]; AHR protein promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; benz(a)anthracene promotes the reaction [AHR protein results in increased expression of CYP1A1 mRNA]
benz(a)anthracene binds to AHR protein
AHR protein affects the reaction [benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]]; benz(a)anthracene binds to and results in increased activity of AHR protein; benz(a)anthracene inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]
AHR affects the reaction [benz(a)anthracene results in increased expression of CCNA2 protein]; AHR affects the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; benz(a)anthracene binds to and results in increased activity of AHR protein; benz(a)anthracene inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]

PMID:1650214 PMID:1654865 PMID:1658612 PMID:2154949 PMID:3005314 More...

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aryl-hydrocarbon receptor repressor

increases expression
multiple interactions

benz(a)anthracene results in increased expression of AHRR mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AHRR mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:28,993,634...29,088,673
Ensembl chr 1:28,993,634...29,088,673

G

allograft inflammatory factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AIF1 mRNA

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

apoptosis inducing factor, mitochondria associated 3

increases expression

benz(a)anthracene results in increased expression of AIFM3 mRNA

NCBI chr11:83,504,859...83,523,630
Ensembl chr11:83,504,861...83,521,248

G

A-kinase anchoring protein 13

decreases expression

benz(a)anthracene results in decreased expression of AKAP13 mRNA

NCBI chr 1:129,313,183...129,619,647
Ensembl chr 1:129,314,402...129,619,646

G

A-kinase anchoring protein 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AKAP7 mRNA

NCBI chr 1:20,087,190...20,217,799
Ensembl chr 1:20,087,373...20,217,797

G

A-kinase anchoring protein 8

increases expression

benz(a)anthracene results in increased expression of AKAP8 mRNA

NCBI chr 7:11,316,224...11,332,523
Ensembl chr 7:11,316,228...11,332,399

G

A-kinase anchoring protein 8 like

increases expression

benz(a)anthracene results in increased expression of AKAP8L mRNA

NCBI chr 7:11,332,671...11,362,287
Ensembl chr 7:11,332,672...11,362,275

G

aldo-keto reductase family 1 member B10

increases expression

benz(a)anthracene results in increased expression of AKR1B10 mRNA

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

aldo-keto reductase family 1, member C1

increases expression

benz(a)anthracene results in increased expression of AKR1C1 mRNA

PMID:17253728 PMID:22236718

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C3

increases expression

benz(a)anthracene results in increased expression of AKR1C3 mRNA

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

aldehyde dehydrogenase 1 family, member L1

decreases expression

benz(a)anthracene results in decreased expression of ALDH1L1 mRNA

NCBI chr 4:123,059,989...123,106,471
Ensembl chr 4:123,060,008...123,106,465

G

aldehyde dehydrogenase 3 family, member A1

increases expression

benz(a)anthracene results in increased expression of ALDH3A1 mRNA

NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681

G

ALG6, alpha-1,3-glucosyltransferase

increases expression

benz(a)anthracene results in increased expression of ALG6 mRNA

NCBI chr 5:114,404,972...114,454,440
Ensembl chr 5:114,405,010...114,454,439

G

ALK and LTK ligand 1

increases expression

benz(a)anthracene results in increased expression of ALKAL1 mRNA

NCBI chr 5:13,019,729...13,049,913
Ensembl chr 5:13,019,429...13,049,948

G

arachidonate 12-lipoxygenase, 12S type

increases expression

benz(a)anthracene results in increased expression of ALOX12 mRNA

NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542

G

arachidonate 5-lipoxygenase

increases expression

benz(a)anthracene results in increased expression of ALOX5 mRNA

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

alkaline phosphatase, biomineralization associated

increases expression

benz(a)anthracene results in increased expression of ALPL mRNA

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

ALS2 C-terminal like

affects expression

benz(a)anthracene affects the expression of ALS2CL mRNA

NCBI chr 8:110,863,753...110,884,434
Ensembl chr 8:110,864,975...110,884,419

G

amidohydrolase domain containing 2

increases expression

benz(a)anthracene results in increased expression of AMDHD2 mRNA

NCBI chr10:13,187,579...13,196,148
Ensembl chr10:13,187,578...13,196,095

G

angiopoietin 2

increases expression

benz(a)anthracene results in increased expression of ANGPT2 mRNA

NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804

G

angiopoietin-like 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANK3 mRNA

NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300

G

ankyrin repeat domain 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANKRD12 mRNA

NCBI chr 9:105,583,273...105,687,957
Ensembl chr 9:105,584,065...105,687,911

G

ankyrin repeat domain 16

affects expression

benz(a)anthracene affects the expression of ANKRD16 mRNA

NCBI chr17:66,735,325...66,748,533
Ensembl chr17:66,737,261...66,748,533

G

ankyrin repeat and zinc finger peptidyl tRNA hydrolase 1

increases expression

benz(a)anthracene results in increased expression of ANKZF1 mRNA

NCBI chr 9:76,688,194...76,695,162
Ensembl chr 9:76,688,194...76,696,469

G

acidic nuclear phosphoprotein 32 family member A

increases expression

benz(a)anthracene results in increased expression of ANP32A mRNA

NCBI chr 8:62,829,099...62,865,443
Ensembl chr 8:62,827,456...62,865,443

G

alanyl aminopeptidase, membrane

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANPEP mRNA

NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789

G

annexin A10

increases expression

benz(a)anthracene results in increased expression of ANXA10 mRNA

NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648

G

adaptor related protein complex 5 subunit sigma 1

increases expression

benz(a)anthracene results in increased expression of AP5S1 mRNA

NCBI chr 3:118,429,618...118,432,929
Ensembl chr 3:118,429,637...118,432,926

G

adaptor related protein complex 5 subunit zeta 1

affects expression

benz(a)anthracene affects the expression of AP5Z1 mRNA

NCBI chr12:12,093,834...12,109,043
Ensembl chr12:12,093,834...12,108,511

G

amyloid beta precursor protein binding family B member 3

affects expression

benz(a)anthracene affects the expression of APBB3 mRNA

NCBI chr18:28,273,168...28,280,347
Ensembl chr18:28,270,545...28,280,094

G

apolipoprotein B mRNA editing enzyme catalytic subunit 3

increases expression

benz(a)anthracene results in increased expression of APOBEC3 mRNA

NCBI chr 7:111,433,789...111,453,032
Ensembl chr 7:111,433,764...111,452,922

G

apolipoprotein L9a

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of APOL9A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of APOL9A mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649

G

adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2

increases expression

benz(a)anthracene results in increased expression of APPL2 mRNA

NCBI chr 7:20,135,248...20,184,757
Ensembl chr 7:20,135,375...20,184,754

G

aquaporin 4

decreases expression

benz(a)anthracene results in decreased expression of AQP4 mRNA

NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856

G

androgen receptor

increases activity
multiple interactions

benz(a)anthracene results in increased activity of AR protein
benz(a)anthracene binds to and results in decreased activity of AR protein; benz(a)anthracene inhibits the reaction [Androgens results in increased activity of AR protein]

PMID:10771140 PMID:28377212

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2

decreases expression

benz(a)anthracene results in decreased expression of ARAP2 mRNA

NCBI chr14:46,717,657...46,917,326
Ensembl chr14:46,718,760...46,917,154

G

amphiregulin

increases expression
multiple interactions

benz(a)anthracene results in increased expression of AREG mRNA
bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of AREG mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of AREG mRNA]
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AREG mRNA

PMID:22643241 PMID:27858113

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

arginine and glutamate rich 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ARGLU1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARGLU1 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:80,753,300...80,777,350
Ensembl chr16:80,753,315...80,777,349

G

Rho GTPase activating protein 20

decreases expression

benz(a)anthracene results in decreased expression of ARHGAP20 mRNA

NCBI chr 8:52,074,472...52,155,739
Ensembl chr 8:52,074,158...52,155,739

G

Rho GTPase activating protein 23

decreases expression

benz(a)anthracene results in decreased expression of ARHGAP23 mRNA

NCBI chr10:82,437,578...82,496,846
Ensembl chr10:82,394,648...82,496,504

G

Rho GTPase activating protein 4

increases expression

benz(a)anthracene results in increased expression of ARHGAP4 mRNA

NCBI chr X:151,636,071...151,651,528
Ensembl chr X:151,632,454...151,651,128

G

Rho GTPase activating protein 45

increases expression

benz(a)anthracene results in increased expression of ARHGAP45 mRNA

NCBI chr 7:9,674,873...9,690,286
Ensembl chr 7:9,674,897...9,690,268

G

Rho guanine nucleotide exchange factor 38

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARHGEF38 mRNA

NCBI chr 2:221,610,212...221,739,841
Ensembl chr 2:221,613,070...221,740,079

G

Rho guanine nucleotide exchange factor 40

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ARHGEF40 mRNA

NCBI chr15:24,672,645...24,696,510
Ensembl chr15:24,672,763...24,696,510

G

AT-rich interaction domain 4A

decreases expression

benz(a)anthracene results in decreased expression of ARID4A mRNA

NCBI chr 6:89,522,459...89,593,868
Ensembl chr 6:89,522,442...89,593,510

G

ariadne RBR E3 ubiquitin protein ligase 2

increases expression

benz(a)anthracene results in increased expression of ARIH2 mRNA

NCBI chr 8:109,296,738...109,355,909
Ensembl chr 8:109,296,738...109,355,852

G

ADP-ribosylation factor like GTPase 5C

increases expression

benz(a)anthracene results in increased expression of ARL5C mRNA

NCBI chr10:82,985,213...82,993,425
Ensembl chr10:82,985,216...82,992,002

G

armadillo repeat containing 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARMC6 mRNA

NCBI chr16:19,191,106...19,201,528
Ensembl chr16:19,191,093...19,206,047

G

arrestin domain containing 2

affects expression

benz(a)anthracene affects the expression of ARRDC2 mRNA

NCBI chr16:18,601,897...18,606,029
Ensembl chr16:18,601,897...18,606,029

G

arrestin domain containing 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARRDC4 mRNA

NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290

G

ADP-ribosyltransferase 4

increases expression

benz(a)anthracene results in increased expression of ART4 mRNA

NCBI chr 4:169,740,331...169,751,571
Ensembl chr 4:169,740,331...169,750,665

G

activating signal cointegrator 1 complex subunit 3

decreases expression

benz(a)anthracene results in decreased expression of ASCC3 mRNA

NCBI chr20:53,510,137...53,795,446
Ensembl chr20:53,510,184...53,790,165

G

asialoglycoprotein receptor 1

decreases expression

benz(a)anthracene results in decreased expression of ASGR1 mRNA

NCBI chr10:54,775,727...54,779,642
Ensembl chr10:54,776,024...54,779,631

G

asialoglycoprotein receptor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ASGR2 mRNA

NCBI chr10:54,821,407...54,834,624
Ensembl chr10:54,821,438...54,834,617

G

aspartate-beta-hydroxylase

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ASPH mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ASPH mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876

G

ATPase family, AAA domain containing 2B

decreases expression

benz(a)anthracene results in decreased expression of ATAD2B mRNA

NCBI chr 6:27,914,546...28,070,103
Ensembl chr 6:27,912,862...28,067,047

G

autophagy related 16-like 2

affects expression

benz(a)anthracene affects the expression of ATG16L2 mRNA

NCBI chr 1:155,687,386...155,703,419
Ensembl chr 1:155,684,564...155,703,420

G

atos homolog A

increases expression

benz(a)anthracene results in increased expression of ATOSA mRNA

NCBI chr 8:75,694,828...75,772,565
Ensembl chr 8:75,695,022...75,772,549

G

ATPase phospholipid transporting 11A

increases expression

benz(a)anthracene results in increased expression of ATP11A mRNA

NCBI chr16:76,657,752...76,767,640
Ensembl chr16:76,657,752...76,767,640

G

ATPase 13A3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ATP13A3 mRNA

NCBI chr11:70,364,998...70,442,005
Ensembl chr11:70,365,322...70,441,235

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ATP2A2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ATP2A2 mRNA

PMID:26377693 PMID:27858113

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

ATPase, H+ transporting V0 subunit e2

decreases expression

benz(a)anthracene results in decreased expression of ATP6V0E2 mRNA

NCBI chr 4:77,484,868...77,488,016
Ensembl chr 4:77,482,226...77,488,777

G

arginine vasopressin receptor 1A

decreases expression

benz(a)anthracene results in decreased expression of AVPR1A mRNA

NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215

G

antizyme inhibitor 1

affects expression

benz(a)anthracene affects the expression of AZIN1 mRNA

NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578

G

beta-1,4-galactosyltransferase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of B4GALT1 mRNA

NCBI chr 5:55,935,614...55,982,461
Ensembl chr 5:55,935,615...55,982,461

G

beta-1,4-galactosyltransferase 5

decreases expression

benz(a)anthracene results in decreased expression of B4GALT5 mRNA

NCBI chr 3:156,018,056...156,033,983
Ensembl chr 3:156,018,053...156,070,074

G

bile acid CoA:amino acid N-acyltransferase

decreases expression

benz(a)anthracene results in decreased expression of BAAT mRNA

NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685

G

BTB domain and CNC homolog 2

increases expression

benz(a)anthracene results in increased expression of BACH2 mRNA

NCBI chr 5:46,632,338...46,982,676
Ensembl chr 5:46,638,317...46,977,877

G

BAG cochaperone 3

decreases expression

benz(a)anthracene results in decreased expression of BAG3 mRNA

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

G

B-cell scaffold protein with ankyrin repeats 1

increases expression

benz(a)anthracene results in increased expression of BANK1 mRNA

NCBI chr 2:224,530,475...224,800,420
Ensembl chr 2:224,530,475...224,800,405

G

Btg3 associated nuclear protein

decreases expression

benz(a)anthracene results in decreased expression of BANP mRNA

NCBI chr19:50,007,710...50,082,742
Ensembl chr19:50,007,881...50,082,738

G

basic leucine zipper ATF-like transcription factor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BATF mRNA

NCBI chr 6:105,353,715...105,376,051
Ensembl chr 6:105,353,715...105,376,051

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BAX mRNA

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl2-like 14

increases expression

benz(a)anthracene results in increased expression of BCL2L14 mRNA

NCBI chr 4:167,217,561...167,258,723
Ensembl chr 4:167,219,871...167,258,086

G

BCL3, transcription coactivator

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BCL3 mRNA

NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607

G

BCL6B, transcription repressor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BCL6B mRNA

NCBI chr10:54,940,908...54,947,022
Ensembl chr10:54,940,909...54,945,974

G

BAF chromatin remodeling complex subunit BCL7B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BCL7B mRNA

NCBI chr12:21,496,860...21,510,079
Ensembl chr12:21,496,856...21,510,202

G

BCL2-associated transcription factor 1

increases expression

benz(a)anthracene results in increased expression of BCLAF1 mRNA

NCBI chr 1:15,088,436...15,117,666
Ensembl chr 1:15,070,894...15,148,832

G

BEN domain containing 3

increases expression

benz(a)anthracene results in increased expression of BEND3 mRNA

NCBI chr20:46,980,246...47,017,059
Ensembl chr20:46,979,831...47,014,671

G

beaded filament structural protein 2

increases expression

benz(a)anthracene results in increased expression of BFSP2 mRNA

NCBI chr 8:104,006,226...104,063,399
Ensembl chr 8:104,006,226...104,063,399

G

basic helix-loop-helix family, member e40

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BHLHE40 mRNA

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

baculoviral IAP repeat-containing 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BIRC5 mRNA

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

biogenesis of lysosomal organelles complex-1, subunit 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BLOC1S2 mRNA

NCBI chr 1:243,024,611...243,031,749
Ensembl chr 1:243,024,614...243,031,653

G

basic helix-loop-helix ARNT like 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of BMAL1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BMAL1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

Bcl2 modifying factor

increases expression

benz(a)anthracene results in increased expression of BMF mRNA

NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145

G

bone morphogenetic protein 7

decreases expression

benz(a)anthracene results in decreased expression of BMP7 mRNA

NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788

G

bone morphogenetic protein receptor type 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BMPR2 mRNA

NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809

G

BMX non-receptor tyrosine kinase

increases expression

benz(a)anthracene results in increased expression of BMX mRNA

NCBI chr X:30,227,251...30,290,015
Ensembl chr X:30,227,251...30,289,993

G

bromodomain and WD repeat domain containing 1

decreases expression

benz(a)anthracene results in decreased expression of BRWD1 mRNA

NCBI chr11:35,286,364...35,378,768
Ensembl chr11:35,288,313...35,378,768

G

BSCL2 lipid droplet biogenesis associated, seipin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA

NCBI chr 1:205,731,828...205,743,430
Ensembl chr 1:205,733,872...205,743,421

G

BTG anti-proliferation factor 1

decreases expression

benz(a)anthracene results in decreased expression of BTG1 mRNA

NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649

G

BTG anti-proliferation factor 2

increases expression

benz(a)anthracene results in increased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

B and T lymphocyte associated

increases expression
multiple interactions

benz(a)anthracene results in increased expression of BTLA mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BTLA mRNA

PMID:26377693 PMID:27858113

NCBI chr11:55,563,683...55,588,187
Ensembl chr11:55,564,899...55,587,181

G

complement C2

decreases expression

benz(a)anthracene results in decreased expression of C2 mRNA

NCBI chr20:3,951,474...3,970,376
Ensembl chr20:3,951,474...3,976,505

G

C2 domain containing 3 centriole elongation regulator

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of C2CD3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C2CD3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:154,715,151...154,812,955
Ensembl chr 1:154,715,310...154,812,520

G

complement C5

increases expression
multiple interactions

benz(a)anthracene results in increased expression of HC mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HC mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994

G

complement C5a receptor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C5AR2 mRNA

NCBI chr 1:76,930,381...76,945,432
Ensembl chr 1:76,930,383...76,959,517

G

complement C7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C7 mRNA

NCBI chr 2:54,088,116...54,165,102
Ensembl chr 2:54,088,116...54,158,535

G

calcium binding protein 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CABP5 mRNA

NCBI chr 1:74,350,811...74,363,830
Ensembl chr 1:74,350,811...74,363,830

G

calcium voltage-gated channel subunit alpha1 I

increases expression

benz(a)anthracene results in increased expression of CACNA1I mRNA

NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688

G

calcyclin binding protein

decreases expression

benz(a)anthracene results in decreased expression of CACYBP mRNA

NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177

G

calcitonin receptor

increases expression

benz(a)anthracene results in increased expression of CALCR mRNA

NCBI chr 4:31,661,270...31,736,392
Ensembl chr 4:31,661,273...31,736,392

G

calcium/calmodulin-dependent protein kinase II gamma

increases expression

benz(a)anthracene results in increased expression of CAMK2G mRNA

NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050

G

calpain 11

increases expression

benz(a)anthracene results in increased expression of CAPN11 mRNA

NCBI chr 9:15,344,059...15,365,604
Ensembl chr 9:15,344,089...15,365,601

G

calcyphosine 2

increases expression

benz(a)anthracene results in increased expression of CAPS2 mRNA

NCBI chr 7:47,580,636...47,641,598
Ensembl chr 7:47,581,137...47,639,229

G

carbonic anhydrase 14

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of CAR14 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CAR14 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:183,442,263...183,449,231
Ensembl chr 2:183,441,667...183,449,693

G

caspase recruitment domain family, member 11

increases expression

benz(a)anthracene results in increased expression of CARD11 mRNA

NCBI chr12:13,621,140...13,758,115
Ensembl chr12:13,621,087...13,758,112

G

caveolin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CAV1 mRNA

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

CBFA2/RUNX1 partner transcriptional co-repressor 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CBFA2T3 mRNA

NCBI chr19:50,679,897...50,750,028
Ensembl chr19:50,680,729...50,749,610

G

collagen and calcium binding EGF domains 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCBE1 mRNA

NCBI chr18:59,579,851...59,823,977
Ensembl chr18:59,580,768...59,824,400

G

coiled-coil domain containing 121

increases expression

benz(a)anthracene results in increased expression of CCDC121 mRNA

NCBI chr 6:24,970,845...24,973,451
Ensembl chr 6:24,970,833...24,973,478

G

coiled-coil domain containing 184

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCDC184 mRNA

NCBI chr 7:129,297,635...129,301,961
Ensembl chr 7:129,298,212...129,304,494

G

coiled coil domain containing 28B

increases expression

benz(a)anthracene results in increased expression of CCDC28B mRNA

NCBI chr 5:141,962,275...141,967,278
Ensembl chr 5:141,962,276...141,967,382

G

coiled-coil domain containing 30

increases expression

benz(a)anthracene results in increased expression of CCDC30 mRNA

NCBI chr 5:132,926,767...133,019,635
Ensembl chr 5:132,926,615...133,019,659

G

coiled-coil domain 39 molecular ruler complex subunit

increases expression

benz(a)anthracene results in increased expression of CCDC39 mRNA

NCBI chr 2:116,665,651...116,703,354
Ensembl chr 2:116,665,261...116,703,350

G

coiled-coil domain containing 68

affects expression

benz(a)anthracene affects the expression of CCDC68 mRNA

NCBI chr18:63,541,828...63,584,122
Ensembl chr18:63,541,896...63,584,119

G

coiled-coil domain containing 78

increases expression

benz(a)anthracene results in increased expression of CCDC78 mRNA

NCBI chr10:14,808,355...14,812,284
Ensembl chr10:14,807,710...14,812,282

G

coiled-coil domain containing 81

increases expression

benz(a)anthracene results in increased expression of CCDC81 mRNA

NCBI chr 1:143,739,472...143,791,026
Ensembl chr 1:143,739,474...143,790,926

G

coiled-coil domain containing 82

increases expression

benz(a)anthracene results in increased expression of CCDC82 mRNA

NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963

G

C-C motif chemokine ligand 11

increases expression

benz(a)anthracene results in increased expression of CCL11 mRNA

NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926

G

C-C motif chemokine ligand 2

multiple interactions

[benz(a)anthracene co-treated with TNF protein] results in increased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 27

decreases expression

benz(a)anthracene results in decreased expression of CCL27A mRNA

NCBI chr 5:56,941,402...56,948,511
Ensembl chr 5:56,941,402...56,948,506

G

C-C motif chemokine ligand 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCL4 mRNA

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine ligand 9

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCL6 mRNA

NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369

G

CCM2 like scaffold protein

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CCM2L mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCM2L mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:141,533,470...141,549,136
Ensembl chr 3:141,533,511...141,549,140

G

cyclin A2

multiple interactions
increases expression

AHR affects the reaction [benz(a)anthracene results in increased expression of CCNA2 protein]; benz(a)anthracene results in increased activity of [CCNA2 protein binds to CDK2 protein]

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin D1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCND2 mRNA

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin G1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCNG1 mRNA

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

cyclin J-like

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of CCNJL mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCNJL mRNA

PMID:26377693 PMID:27858113

NCBI chr10:27,995,682...28,053,428
Ensembl chr10:27,995,679...28,053,426

G

cyclin L1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of CCNL1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCNL1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368

G

cyclin L2

affects expression

benz(a)anthracene affects the expression of CCNL2 mRNA

NCBI chr 5:166,416,940...166,428,997
Ensembl chr 5:166,417,508...166,436,882

G

C-C motif chemokine receptor 3

increases expression

benz(a)anthracene results in increased expression of CCR3 mRNA

NCBI chr 8:123,586,100...123,634,178
Ensembl chr 8:123,616,236...123,634,990

G

C-C motif chemokine receptor 6

increases expression

benz(a)anthracene results in increased expression of CCR6 mRNA

NCBI chr 1:52,474,477...52,508,301
Ensembl chr 1:52,474,168...52,498,603

G

C-C motif chemokine receptor 7

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CCR7 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCR7 mRNA

PMID:26377693 PMID:27858113

NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309

G

CD151 molecule (Raph blood group)

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CD151 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD151 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753

G

CD19 molecule

increases expression

benz(a)anthracene results in increased expression of CD19 mRNA

NCBI chr 1:180,987,286...180,993,920
Ensembl chr 1:180,987,286...180,993,975

G

Cd200 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD200 mRNA

NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648

G

CD300C molecule 2

increases expression

benz(a)anthracene results in increased expression of CD300C2 mRNA

NCBI chr10:100,253,312...100,258,553
Ensembl chr10:100,253,624...100,258,323

G

Cd300 molecule-like family member F

increases expression

benz(a)anthracene results in increased expression of CD300LF mRNA

NCBI chr10:100,359,942...100,376,130
Ensembl chr10:100,359,943...100,376,041

G

CD34 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD34 mRNA

NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832

G

CD37 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD37 mRNA

NCBI chr 1:95,719,171...95,724,662
Ensembl chr 1:95,719,190...95,724,648

G

Cd48 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD48 mRNA

NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142

G

Cd69 molecule

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CD69 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD69 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542

G

CD79a molecule

increases expression

benz(a)anthracene results in increased expression of CD79A mRNA

NCBI chr 1:80,493,581...80,497,936
Ensembl chr 1:80,493,581...80,497,935

G

CD79b molecule

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CD79B mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD79B mRNA

PMID:26377693 PMID:27858113

NCBI chr10:91,239,354...91,242,500
Ensembl chr10:91,239,356...91,242,625

G

CD84 molecule

increases expression

benz(a)anthracene results in increased expression of CD84 mRNA

NCBI chr13:84,327,580...84,367,153
Ensembl chr13:84,327,553...84,362,076

G

CD8 subunit beta

increases expression

benz(a)anthracene results in increased expression of CD8B1 mRNA

NCBI chr 4:103,312,596...103,328,523
Ensembl chr 4:103,312,578...103,328,553

G

CD99 molecule (Xg blood group)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CD99 mRNA

NCBI chr20:54,418,239...54,422,882

G

cell division cycle 14B

increases expression

benz(a)anthracene results in increased expression of CDC14B mRNA

NCBI chr17:844,686...934,787
Ensembl chr17:844,685...933,235

G

cell division cycle 40

decreases expression

benz(a)anthracene results in decreased expression of CDC40 mRNA

NCBI chr20:44,273,080...44,325,605
Ensembl chr20:44,273,089...44,325,358

G

cadherin 1

decreases expression

benz(a)anthracene results in decreased expression of CDH1 mRNA

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 16

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CDH16 mRNA

NCBI chr19:360,824...371,008
Ensembl chr19:360,824...371,007

G

cadherin-related family member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CDHR4 mRNA

NCBI chr 8:108,682,594...108,690,358
Ensembl chr 8:108,682,613...108,690,367

G

cyclin dependent kinase 2

multiple interactions

benz(a)anthracene results in increased activity of [CCNA2 protein binds to CDK2 protein]

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

increases expression
decreases expression
multiple interactions

benz(a)anthracene results in increased expression of CDKN1A mRNA
benz(a)anthracene results in decreased expression of CDKN1A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CDKN1A mRNA

PMID:22236718 PMID:26377693 PMID:27858113

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

CUGBP, Elav-like family member 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CELF5 mRNA

NCBI chr 7:8,225,787...8,250,322
Ensembl chr 7:8,225,825...8,250,322

G

cadherin, EGF LAG seven-pass G-type receptor 2

decreases expression

benz(a)anthracene results in decreased expression of CELSR2 mRNA

NCBI chr 2:196,029,206...196,053,848
Ensembl chr 2:196,029,434...196,053,845

G

centrosomal protein 162

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CEP162 mRNA

NCBI chr 8:88,149,726...88,208,249
Ensembl chr 8:88,149,726...88,206,830

G

centrosomal protein 70

increases expression

benz(a)anthracene results in increased expression of CEP70 mRNA

NCBI chr 8:99,810,270...99,863,279
Ensembl chr 8:99,810,367...99,862,855

G

centrosomal protein 85-like

decreases expression

benz(a)anthracene results in decreased expression of CEP85L mRNA

NCBI chr20:32,568,417...32,739,449
Ensembl chr20:32,572,741...32,739,516

G

centrosomal protein 95

increases expression

benz(a)anthracene results in increased expression of CEP95 mRNA

NCBI chr10:91,732,111...91,760,095
Ensembl chr10:91,732,111...91,760,092

G

carboxylesterase 2C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2C mRNA

NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790

G

carboxylesterase 2E

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2E mRNA

NCBI chr19:157,447...172,822
Ensembl chr19:157,407...172,856

G

cilia and flagella associated protein 43

increases expression

benz(a)anthracene results in increased expression of CFAP43 mRNA

NCBI chr 1:246,625,259...246,712,438
Ensembl chr 1:246,625,262...246,712,443

G

cilia and flagella associated protein 65

increases expression

benz(a)anthracene results in increased expression of CFAP65 mRNA

NCBI chr 9:76,459,211...76,494,199
Ensembl chr 9:76,459,211...76,494,128

G

complement factor B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CFB mRNA

NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505

G

cofilin 1

increases expression

benz(a)anthracene results in increased expression of CFL1 mRNA

NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587

G

cingulin

increases expression

benz(a)anthracene results in increased expression of CGN mRNA

NCBI chr 2:182,308,389...182,335,747
Ensembl chr 2:182,308,714...182,334,645

G

chromodomain helicase DNA binding protein 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of CHD2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CHD2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502

G

chitinase, acidic

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CHIA mRNA

NCBI chr 2:193,614,374...193,656,532
Ensembl chr 2:193,614,114...193,656,533

G

choline kinase alpha

decreases expression

benz(a)anthracene results in decreased expression of CHKA mRNA

NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516

G

choline kinase beta

increases expression

benz(a)anthracene results in increased expression of CHKB mRNA

NCBI chr 7:120,500,960...120,504,359
Ensembl chr 7:120,500,984...120,504,461

G

charged multivesicular body protein 4B

decreases expression

benz(a)anthracene results in decreased expression of CHMP4B mRNA

NCBI chr 3:143,170,859...143,211,376
Ensembl chr 3:143,170,902...143,210,844

G

cysteine and histidine rich domain containing 1

decreases expression

benz(a)anthracene results in decreased expression of CHORDC1 mRNA

NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162

G

chondroitin polymerizing factor 2

affects expression

benz(a)anthracene affects the expression of CHPF2 mRNA

NCBI chr 4:10,578,470...10,585,940
Ensembl chr 4:10,580,462...10,585,916

G

cholinergic receptor nicotinic alpha 4 subunit

decreases expression

benz(a)anthracene results in decreased expression of CHRNA4 mRNA

NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957

G

carbohydrate sulfotransferase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CHST1 mRNA

NCBI chr 3:78,552,059...78,574,740
Ensembl chr 3:78,548,525...78,574,883

G

carbohydrate sulfotransferase 3

increases expression

benz(a)anthracene results in increased expression of CHST3 mRNA

NCBI chr20:28,114,386...28,152,046
Ensembl chr20:28,114,404...28,121,807

G

carbohydrate sulfotransferase 8

increases expression

benz(a)anthracene results in increased expression of CHST8 mRNA

NCBI chr 1:87,294,144...87,435,900
Ensembl chr 1:87,294,540...87,435,900

G

circadian associated repressor of transcription

increases expression

benz(a)anthracene results in increased expression of CIART mRNA

NCBI chr 2:183,419,819...183,424,845
Ensembl chr 2:183,419,819...183,423,313

G

calcium and integrin binding family member 3

decreases expression

benz(a)anthracene results in decreased expression of CIB3 mRNA

NCBI chr16:17,622,431...17,631,827
Ensembl chr16:17,622,501...17,631,841

G

ciliary microtubule associated protein 2

increases expression

benz(a)anthracene results in increased expression of CIMAP2 mRNA

NCBI chr 5:121,375,998...121,401,869
Ensembl chr 5:121,375,998...121,401,869

G

cold inducible RNA binding protein

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CIRBP mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CIRBP mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:9,533,857...9,538,899
Ensembl chr 7:9,424,178...9,538,818

G

cytokine inducible SH2-containing protein

decreases expression

benz(a)anthracene results in decreased expression of CISH mRNA

NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CITED2 mRNA

NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897

G

cytoskeleton associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CKAP2 mRNA

NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913

G

CLK4-associating serine/arginine rich protein

increases expression

benz(a)anthracene results in increased expression of SFRS16 mRNA

NCBI chr 1:79,232,260...79,256,462
Ensembl chr 1:79,232,261...79,256,354

G

claudin 1

decreases expression

benz(a)anthracene results in decreased expression of CLDN1 mRNA

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

claudin 17

decreases expression

benz(a)anthracene results in decreased expression of CLDN17 mRNA

NCBI chr11:27,827,454...27,828,630
Ensembl chr11:27,827,454...27,828,630

G

claudin 2

decreases expression

benz(a)anthracene results in decreased expression of CLDN2 mRNA

NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838

G

claudin domain containing 1

decreases expression

benz(a)anthracene results in decreased expression of CLDND1 mRNA

NCBI chr11:41,883,120...41,889,471
Ensembl chr11:41,883,134...41,889,354

G

C-type lectin domain family 1, member A

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CLEC1A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLEC1A mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:162,875,360...162,902,571
Ensembl chr 4:162,877,346...162,901,247

G

C-type lectin domain family 4, member A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLEC4A1 mRNA

NCBI chr 4:156,173,894...156,186,009
Ensembl chr 4:156,173,894...156,186,008

G

C-type lectin domain family 4, member G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CLEC4G mRNA

NCBI chr12:1,780,370...1,785,027
Ensembl chr12:1,780,371...1,784,985

G

CAP-GLY domain containing linker protein family, member 4

increases expression

benz(a)anthracene results in increased expression of CLIP4 mRNA

NCBI chr 6:23,616,280...23,697,625
NCBI chr 6:23,718,580...23,729,231
NCBI chr 6:23,597,729...23,601,000
Ensembl chr 6:23,616,281...23,677,874

G

CDC-like kinase 1

affects expression

benz(a)anthracene affects the expression of CLK1 mRNA

NCBI chr 9:59,947,774...59,959,002
Ensembl chr 9:59,947,764...59,957,000

G

CDC-like kinase 2

increases expression

benz(a)anthracene results in increased expression of CLK2 mRNA

NCBI chr 2:174,570,614...174,582,645
Ensembl chr 2:174,570,653...174,588,985

G

CDC-like kinase 4

increases expression

benz(a)anthracene results in increased expression of CLK4 mRNA

NCBI chr10:35,523,382...35,541,387
Ensembl chr10:35,524,755...35,541,352

G

calmin

increases expression

benz(a)anthracene results in increased expression of CLMN mRNA

NCBI chr 6:123,707,710...123,807,283
Ensembl chr 6:123,713,507...123,807,272

G

CXADR-like membrane protein

decreases expression

benz(a)anthracene results in decreased expression of CLMP mRNA

NCBI chr 8:41,060,527...41,168,841
Ensembl chr 8:41,060,799...41,168,838

G

clock circadian regulator

decreases expression

benz(a)anthracene results in decreased expression of CLOCK mRNA

NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400

G

calsyntenin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA

NCBI chr 8:98,020,406...98,637,232
Ensembl chr 8:98,021,666...98,637,731

G

cytidine/uridine monophosphate kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CMPK2 mRNA

NCBI chr 6:43,073,706...43,085,183
Ensembl chr 6:43,073,796...43,085,183

G

centriolin

increases expression

benz(a)anthracene results in increased expression of CNTRL mRNA

NCBI chr 3:18,428,147...18,500,362
Ensembl chr 3:18,428,103...18,500,380

G

cordon-bleu WH2 repeat protein

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of COBL mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COBL mRNA

PMID:26377693 PMID:27858113

NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800

G

collagen type I alpha 1 chain

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL1A2 mRNA

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type XX alpha 1 chain

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of COL20A1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COL20A1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:168,102,475...168,134,759
Ensembl chr 3:168,084,560...168,135,309

G

collagen type XXVII alpha 1 chain

decreases expression

benz(a)anthracene results in decreased expression of COL27A1 mRNA

NCBI chr 5:76,647,302...76,765,989
Ensembl chr 5:76,647,429...76,765,174

G

collagen type II alpha 1 chain

decreases expression

benz(a)anthracene results in decreased expression of COL2A1 mRNA

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

collagen type III alpha 1 chain

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL3A1 mRNA

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

collagen type IV alpha 4 chain

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of COL4A4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL4A4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:83,833,173...83,875,436
Ensembl chr 9:83,755,515...83,875,876

G

collagen type IV alpha 6 chain

decreases expression

benz(a)anthracene results in decreased expression of COL4A6 mRNA

NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500

G

collagen type V alpha 3 chain

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of COL5A3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL5A3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:19,304,564...19,349,809
Ensembl chr 8:19,304,571...19,349,853

G

COMM domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COMMD3 mRNA

NCBI chr17:81,327,444...81,331,191
Ensembl chr17:81,327,405...81,331,177

G

coenzyme Q10B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COQ10B mRNA

NCBI chr 9:56,553,751...56,573,671
Ensembl chr 9:56,553,758...56,573,663

G

coenzyme Q8A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COQ8A mRNA

NCBI chr13:91,904,731...91,933,588
Ensembl chr13:91,904,739...91,931,431

G

coronin 2A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CORO2A mRNA

NCBI chr 5:60,825,630...60,881,917
Ensembl chr 5:60,828,247...60,859,035

G

complexin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CPLX2 mRNA

NCBI chr17:10,219,577...10,292,835
Ensembl chr17:10,222,347...10,293,855

G

copine 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CPNE4 mRNA

NCBI chr 8:105,177,376...105,653,075
Ensembl chr 8:105,177,376...105,653,068

G

copine 5

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CPNE5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CPNE5 mRNA

PMID:26377693 PMID:27858113

NCBI chr20:7,206,742...7,289,309
Ensembl chr20:7,206,742...7,288,883

G

carnitine palmitoyltransferase 1c

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CPT1C mRNA

NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342

G

complement C3d receptor 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CR2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CR2 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:106,678,579...106,716,595
Ensembl chr13:106,685,413...106,716,235

G

crumbs cell polarity complex component 2

decreases expression

benz(a)anthracene results in decreased expression of CRB2 mRNA

NCBI chr 3:21,542,138...21,564,876
Ensembl chr 3:21,542,221...21,563,294

G

CREB/ATF bZIP transcription factor

affects expression

benz(a)anthracene affects the expression of CREBZF mRNA

NCBI chr 1:144,416,864...144,423,540
Ensembl chr 1:144,417,446...144,428,553

G

cysteine-rich protein 3

decreases expression

benz(a)anthracene results in decreased expression of CRIP3 mRNA

NCBI chr 9:14,554,450...14,557,344
Ensembl chr 9:14,554,450...14,557,302

G

CRK proto-oncogene, adaptor protein

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of CRK mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CRK mRNA

PMID:26377693 PMID:27858113

NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406

G

cryptochrome circadian regulator 2

increases expression

benz(a)anthracene results in increased expression of CRY2 mRNA

NCBI chr 3:78,374,995...78,405,001
Ensembl chr 3:78,374,995...78,404,965

G

colony stimulating factor 2 receptor subunit alpha

decreases expression

benz(a)anthracene results in decreased expression of CSF2RA mRNA

NCBI chr14:98,089...103,261
Ensembl chr14:89,172...103,128

G

colony stimulating factor 2 receptor subunit beta

increases expression

benz(a)anthracene results in increased expression of CSF2RB2 mRNA

NCBI chr 7:109,876,919...109,901,589
Ensembl chr 7:109,886,425...109,904,157

G

cystatin 8

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CST8 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CST8 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:136,244,586...136,255,412
Ensembl chr 3:136,244,636...136,251,273

G

cleavage stimulation factor subunit 3

decreases expression

benz(a)anthracene results in decreased expression of CSTF3 mRNA

NCBI chr 3:90,966,415...91,037,669
Ensembl chr 3:90,966,354...91,042,196

G

cullin 9

increases expression

benz(a)anthracene results in increased expression of CUL9 mRNA

NCBI chr 9:14,435,948...14,479,552
Ensembl chr 9:14,436,111...14,479,548

G

C-X-C motif chemokine ligand 12

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CXCL12 mRNA
bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [benz(a)anthracene results in increased expression of CXCL12 mRNA]]; Tetradecanoylphorbol Acetate inhibits the reaction [benz(a)anthracene results in increased expression of CXCL12 mRNA]

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 13

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCL13 mRNA

NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933

G

C-X-C motif chemokine ligand 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCL5 mRNA

NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093

G

C-X-C motif chemokine receptor 5

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CXCR5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CXCR5 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:44,842,098...44,858,425
Ensembl chr 8:44,843,413...44,857,893

G

C-X-C motif chemokine receptor 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCR6 mRNA

NCBI chr 8:123,434,417...123,439,568
Ensembl chr 8:123,416,325...123,439,526

G

CYLD lysine 63 deubiquitinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYLD mRNA

NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658

G

cytochrome P450, family 17, subfamily a, polypeptide 1

increases expression
decreases expression
multiple interactions

benz(a)anthracene results in increased expression of CYP17A1 mRNA
benz(a)anthracene results in decreased expression of CYP17A1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYP17A1 mRNA

PMID:23358148 PMID:26377693 PMID:27858113

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases metabolic processing
increases expression
increases activity

[CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of benz(a)anthracene; AHR protein promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; baicalein inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; benz(a)anthracene promotes the reaction [AHR protein results in increased expression of CYP1A1 mRNA]; Cadmium Chloride inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; CYP1A1 gene polymorphism affects the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of benz(a)anthracene]; lead nitrate inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; Mercuric Chloride inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; sodium arsenite inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]
[andrographolide co-treated with benz(a)anthracene] results in increased expression of CYP1A1 mRNA; [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYP1A1 mRNA; [CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of benz(a)anthracene; [fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A1 mRNA; Dactinomycin promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of benz(a)anthracene]; resveratrol inhibits the reaction [[andrographolide co-treated with benz(a)anthracene] results in increased expression of CYP1A1 mRNA]
benz(a)anthracene results in increased expression of CYP1A1 mRNA; benz(a)anthracene results in increased expression of CYP1A1 protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; 1-(5-isoquinolinylsulfonyl)-3-methylpiperazine inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; [chrysene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [chrysene co-treated with benz(a)anthracene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1A1 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1A1 mRNA; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; AHR affects the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; Dexamethasone promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]; Mifepristone inhibits the reaction [Dexamethasone promotes the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]]; NR3C1 protein promotes the reaction [Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]]; Staurosporine inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]

PMID:1358564 PMID:1521541 PMID:1846074 PMID:1934297 PMID:2052000 More...

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression
decreases activity
affects response to substance

[CYP1A2 protein co-treated with Trichloroepoxypropane] results in increased metabolism of benz(a)anthracene; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of benz(a)anthracene]
[andrographolide co-treated with benz(a)anthracene] results in increased expression of CYP1A2 mRNA; [CYP1A2 protein co-treated with Trichloroepoxypropane] results in increased metabolism of benz(a)anthracene; [fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A2 mRNA; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of benz(a)anthracene]
benz(a)anthracene results in increased expression of CYP1A2 mRNA
benz(a)anthracene results in decreased activity of CYP1A2 protein
CYP1A2 protein affects the susceptibility to benz(a)anthracene
[chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1A2 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1A2 mRNA

PMID:7750161 PMID:8961944 PMID:9783729 PMID:11162773 PMID:17253728 More...

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions
increases stability
increases expression

[benz(a)anthracene co-treated with TNF protein] results in increased expression of CYP1B1 mRNA; AHR protein affects the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]; baicalein inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]
[andrographolide co-treated with benz(a)anthracene] results in increased expression of CYP1B1 mRNA; [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYP1B1 mRNA; benz(a)anthracene promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; Dehydroepiandrosterone inhibits the reaction [benz(a)anthracene promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]]; Dehydroepiandrosterone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]
benz(a)anthracene results in increased stability of CYP1B1 protein
[benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [chrysene promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]]; [chrysene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; [chrysene co-treated with benz(a)anthracene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1B1 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1B1 mRNA; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]; Progesterone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]
benz(a)anthracene results in increased expression of CYP1B1 mRNA; benz(a)anthracene results in increased expression of CYP1B1 protein

PMID:7505439 PMID:8022408 PMID:8674863 PMID:9783729 PMID:10037446 More...

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases expression

benz(a)anthracene results in increased expression of CYP2E1 mRNA

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 2, subfamily j, polypeptide 4

decreases expression

benz(a)anthracene results in decreased expression of CYP2J9 mRNA

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

cystin 1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of CYS1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYS1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:41,300,836...41,318,071
Ensembl chr 6:41,300,836...41,318,071

G

dishevelled-binding antagonist of beta-catenin 2

increases expression

benz(a)anthracene results in increased expression of DACT2 mRNA

NCBI chr 1:55,181,023...55,191,026
Ensembl chr 1:55,181,024...55,191,096

G

differentiation antagonizing non-protein coding RNA

decreases expression

benz(a)anthracene results in decreased expression of DANCR mRNA

NCBI chr14:34,126,956...34,127,936

G

aspartyl-tRNA synthetase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DARS1 mRNA

NCBI chr13:39,857,936...39,913,055
Ensembl chr13:39,857,936...39,913,116

G

D-box binding PAR bZIP transcription factor

increases expression
multiple interactions

benz(a)anthracene results in increased expression of DBP mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DBP mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745

G

DDB1 and CUL4 associated factor 12-like 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of DCAF12L2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCAF12L2 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:123,293,761...123,296,550
Ensembl chr X:123,294,744...123,296,156

G

DDB1 and CUL4 associated factor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DCAF4 mRNA

NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:103,154,867...103,180,982

G

DCC netrin 1 receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCC mRNA

NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740

G

doublecortin domain containing 2

decreases expression

benz(a)anthracene results in decreased expression of DCDC2A mRNA

NCBI chr17:39,845,952...40,031,781
Ensembl chr17:39,845,952...40,030,743

G

decorin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCN mRNA

NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270

G

dimethylarginine dimethylaminohydrolase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDAH1 mRNA

NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339

G

damage specific DNA binding protein 2

increases expression

benz(a)anthracene results in increased expression of DDB2 mRNA

NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631

G

dopa decarboxylase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDC mRNA

NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208

G

DNA damage-induced apoptosis suppressor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDIAS mRNA

NCBI chr 1:146,906,150...146,930,462
Ensembl chr 1:146,906,154...146,930,462

G

DNA-damage-inducible transcript 4-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDIT4L mRNA

NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375

G

DEAD-box helicase 17

decreases expression

benz(a)anthracene results in decreased expression of DDX17 mRNA

NCBI chr 7:111,091,127...111,109,353
Ensembl chr 7:111,089,445...111,109,193

G

DEAD-box helicase 25

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DDX25 mRNA

NCBI chr 8:33,894,224...33,910,377
Ensembl chr 8:33,894,232...33,921,764

G

DEAD-box helicase 5

affects expression
multiple interactions

benz(a)anthracene affects the expression of DDX5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DDX5 mRNA

PMID:26377693 PMID:27858113

NCBI chr10:91,723,508...91,732,210
Ensembl chr10:91,723,508...91,732,283

G

DENN domain containing 1C

increases expression

benz(a)anthracene results in increased expression of DENND1C mRNA

NCBI chr 9:1,904,040...1,916,329
Ensembl chr 9:1,904,045...1,916,187

G

diacylglycerol O-acyltransferase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DGAT2 mRNA

NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428

G

diacylglycerol kinase, theta

increases expression

benz(a)anthracene results in increased expression of DGKQ mRNA

NCBI chr14:1,059,125...1,073,131
Ensembl chr14:1,059,170...1,073,131

G

dehydrogenase/reductase 7B

decreases expression

benz(a)anthracene results in decreased expression of DHRS7B mRNA

NCBI chr10:45,504,344...45,537,094
Ensembl chr10:45,504,426...45,537,076

G

DExH-box helicase 34

increases expression

benz(a)anthracene results in increased expression of DHX34 mRNA

NCBI chr 1:76,880,867...76,905,148
Ensembl chr 1:76,880,867...76,905,113

G

DEAH-box helicase 35

increases expression

benz(a)anthracene results in increased expression of DHX35 mRNA

NCBI chr 3:147,450,178...147,507,473
Ensembl chr 3:147,450,163...147,507,451

G

DEXH-box helicase 58

decreases expression

benz(a)anthracene results in decreased expression of DHX58 mRNA

NCBI chr10:85,620,352...85,631,776
Ensembl chr10:85,620,357...85,631,525

G

diaphanous-related formin 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of DIAP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DIAP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr18:29,669,659...29,769,070
Ensembl chr18:29,669,659...29,769,172

G

death inducer-obliterator 1

multiple interactions
affects expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DIDO1 mRNA
benz(a)anthracene affects the expression of DIDO1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:167,772,535...167,825,894
Ensembl chr 3:167,772,770...167,817,218

G

iodothyronine deiodinase 2

decreases expression

benz(a)anthracene results in decreased expression of DIO2 mRNA

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

divergent protein kinase domain 1B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DIPK1B mRNA

NCBI chr 3:9,455,914...9,464,169
Ensembl chr 3:9,456,409...9,464,161

G

DIRAS family GTPase 2

decreases expression

benz(a)anthracene results in decreased expression of DIRAS2 mRNA

NCBI chr17:12,730,040...12,761,511
Ensembl chr17:12,725,149...12,761,663

G

dentin matrix acidic phosphoprotein 1

increases expression

benz(a)anthracene results in increased expression of DMP1 mRNA

NCBI chr14:5,528,441...5,542,078
Ensembl chr14:5,528,431...5,539,323

G

dynein axonemal assembly factor 4

increases expression

benz(a)anthracene results in increased expression of DNAAF4 mRNA

NCBI chr 8:73,696,394...73,711,315
Ensembl chr 8:73,698,103...73,711,292

G

dynein, axonemal, heavy chain 10

increases expression

benz(a)anthracene results in increased expression of DNAH10 mRNA

NCBI chr12:31,823,451...31,946,857
Ensembl chr12:31,822,733...32,007,069

G

dynein, axonemal, heavy chain 2

increases expression

benz(a)anthracene results in increased expression of DNAH2 mRNA

NCBI chr10:54,142,648...54,268,901
Ensembl chr10:54,142,737...54,267,298

G

dynein, axonemal, heavy chain 8

increases expression

benz(a)anthracene results in increased expression of DNAH8 mRNA

NCBI chr20:8,692,939...8,946,780
Ensembl chr20:8,692,963...8,946,772

G

DnaJ heat shock protein family (Hsp40) member A1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of DNAJA1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DNAJA1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967

G

DnaJ heat shock protein family (Hsp40) member A4

decreases expression

benz(a)anthracene results in decreased expression of DNAJA4 mRNA

NCBI chr 8:55,085,246...55,102,715
Ensembl chr 8:55,085,464...55,101,207

G

DnaJ heat shock protein family (Hsp40) member B1

decreases expression

benz(a)anthracene results in decreased expression of DNAJB1 mRNA

NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DNAJB4 mRNA

NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089

G

DnaJ heat shock protein family (Hsp40) member C21

decreases expression

benz(a)anthracene results in decreased expression of DNAJC21 mRNA

NCBI chr 2:59,419,507...59,446,746
Ensembl chr 2:59,419,510...59,446,752

G

DnaJ heat shock protein family (Hsp40) member C8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DNAJC8 mRNA

NCBI chr 5:144,745,055...144,763,106
Ensembl chr 5:144,745,036...144,763,108

G

dedicator of cytokinesis 6

increases expression

benz(a)anthracene results in increased expression of DOCK6 mRNA

NCBI chr 8:20,342,430...20,394,660
Ensembl chr 8:20,342,089...20,394,552

G

docking protein 3

increases expression

benz(a)anthracene results in increased expression of DOK3 mRNA

NCBI chr17:9,109,633...9,115,188
Ensembl chr17:9,109,597...9,115,188

G

DOT1 like histone lysine methyltransferase

increases expression

benz(a)anthracene results in increased expression of DOT1L mRNA

NCBI chr 7:8,918,764...8,959,474
Ensembl chr 7:8,917,786...8,956,475

G

dystonin

decreases expression

benz(a)anthracene results in decreased expression of DST mRNA

NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615

G

denticleless E3 ubiquitin protein ligase homolog

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DTL mRNA

NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890

G

deltex E3 ubiquitin ligase 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DTX4 mRNA

NCBI chr 1:209,457,719...209,545,163
Ensembl chr 1:209,460,735...209,492,818

G

dual specificity phosphatase 2

increases expression

benz(a)anthracene results in increased expression of DUSP2 mRNA

NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499

G

dishevelled segment polarity protein 3

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of DVL3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DVL3 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462

G

dynein 2 intermediate chain 1

increases expression

benz(a)anthracene results in increased expression of DYNC2I1 mRNA

NCBI chr 6:137,133,418...137,189,937
Ensembl chr 6:137,133,418...137,188,719

G

DAZ interacting zinc finger protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DZIP1 mRNA

NCBI chr15:95,956,329...96,009,994
Ensembl chr15:95,956,398...96,010,066

G

enoyl CoA hydratase domain containing 2

decreases expression

benz(a)anthracene results in decreased expression of ECHDC2 mRNA

NCBI chr 5:122,915,874...122,934,860
Ensembl chr 5:122,916,134...122,934,859

G

extracellular matrix protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ECM1 mRNA

NCBI chr 2:183,287,491...183,292,729
Ensembl chr 2:183,287,322...183,292,671

G

endothelin 1

increases expression

benz(a)anthracene results in increased expression of EDN1 mRNA

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

estrogen-induced osteoclastogenesis regulator 1

increases expression

benz(a)anthracene results in increased expression of EEIG1 mRNA

NCBI chr 3:15,822,441...15,854,651
Ensembl chr 3:15,823,144...15,854,643

G

EF-hand calcium binding domain 12

increases expression

benz(a)anthracene results in increased expression of EFCAB12 mRNA

NCBI chr 4:148,869,381...148,892,922
Ensembl chr 4:148,869,387...148,890,560

G

EF hand domain family, member B

increases expression

benz(a)anthracene results in increased expression of EFHB mRNA

NCBI chr 9:6,372,191...6,441,678
Ensembl chr 9:6,372,194...6,441,919

G

ephrin B1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EFNB1 mRNA

NCBI chr X:64,257,351...64,270,158
Ensembl chr X:64,257,351...64,270,157

G

epidermal growth factor

multiple interactions

AHR protein affects the reaction [benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]]; benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

EGF-like-domain, multiple 7

increases expression

benz(a)anthracene results in increased expression of EGFL7 mRNA

NCBI chr 3:9,404,622...9,416,879
Ensembl chr 3:9,407,520...9,416,879

G

epidermal growth factor receptor

multiple interactions

AHR protein affects the reaction [benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]]; benz(a)anthracene inhibits the reaction [EGF protein binds to EGFR protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

EH domain binding protein 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of EHBP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EHBP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr14:96,093,327...96,380,502
Ensembl chr14:96,093,327...96,345,332

G

EH-domain containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EHD1 mRNA

NCBI chr 1:203,579,850...203,602,226
Ensembl chr 1:203,579,869...203,602,212

G

EH-domain containing 4

increases expression
multiple interactions

benz(a)anthracene results in increased expression of EHD4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EHD4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:107,058,191...107,121,985
Ensembl chr 3:107,058,958...107,122,002

G

eukaryotic translation initiation factor 2 alpha kinase 4

increases expression

benz(a)anthracene results in increased expression of EIF2AK4 mRNA

NCBI chr 3:105,356,261...105,441,630
Ensembl chr 3:105,356,261...105,441,630

G

eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked

increases expression

benz(a)anthracene results in increased expression of EIF2S3Y mRNA

NCBI chr Y:869,654...889,341
Ensembl chr Y:869,689...889,340

G

eukaryotic translation initiation factor 3, subunit J

decreases expression

benz(a)anthracene results in decreased expression of EIF3J mRNA

NCBI chr 3:108,985,103...109,007,341
Ensembl chr 3:108,985,118...109,007,953

G

ELOVL fatty acid elongase 1

increases expression

benz(a)anthracene results in increased expression of ELOVL1 mRNA

NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958

G

endomucin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EMCN mRNA

NCBI chr 2:225,891,100...225,970,932
Ensembl chr 2:225,891,100...225,970,929

G

EMAP like 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EML1 mRNA

NCBI chr 6:127,283,968...127,457,246
Ensembl chr 6:127,284,029...127,457,246

G

ectonucleotide pyrophosphatase/phosphodiesterase 3

decreases expression

benz(a)anthracene results in decreased expression of ENPP3 mRNA

NCBI chr 1:20,563,700...20,635,044
Ensembl chr 1:20,563,697...20,635,041

G

erythrocyte membrane protein band 4.1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of EPB41 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EPB41 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:144,110,010...144,264,037
Ensembl chr 5:144,111,906...144,237,821

G

Eph receptor A1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of EPHA1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPHA1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846

G

epoxide hydrolase 1

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPHX1 mRNA; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of benz(a)anthracene]; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of benz(a)anthracene]
benz(a)anthracene results in increased expression of EPHX1 protein

PMID:2208584 PMID:8961944 PMID:27858113

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

EPM2A interacting protein 1

increases expression

benz(a)anthracene results in increased expression of EPM2AIP1 mRNA

NCBI chr 8:111,233,871...111,241,219
Ensembl chr 8:111,233,826...111,241,871

G

erythropoietin receptor

increases expression
multiple interactions

benz(a)anthracene results in increased expression of EPOR mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPOR mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257

G

EPS8-like 1

increases expression

benz(a)anthracene results in increased expression of EPS8L1 mRNA

NCBI chr 1:69,343,202...69,359,778
Ensembl chr 1:69,344,243...69,363,524

G

erb-b2 receptor tyrosine kinase 2

decreases expression

benz(a)anthracene results in decreased expression of ERBB2 mRNA

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

ERCC excision repair 1, endonuclease non-catalytic subunit

increases expression

benz(a)anthracene results in increased expression of ERCC1 mRNA

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

ermin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ERMN mRNA

NCBI chr 3:42,628,160...42,633,816
Ensembl chr 3:42,626,309...42,633,744

G

estrogen receptor 1

multiple interactions
increases expression
increases phosphorylation
decreases expression
increases activity

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with chrysene] results in increased expression of ESR1 mRNA; benz(a)anthracene promotes the reaction [Estradiol results in increased activity of ESR1 protein]; fulvestrant inhibits the reaction [benz(a)anthracene promotes the reaction [Estradiol results in increased activity of ESR1 protein]]
benz(a)anthracene results in increased expression of ESR1 mRNA
benz(a)anthracene results in increased phosphorylation of ESR1 protein
benz(a)anthracene results in decreased expression of ESR1 protein
benz(a)anthracene results in increased activity of ESR1 protein

PMID:11922773 PMID:12441364 PMID:18634860 PMID:21783948 PMID:25012808

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

electron transfer flavoprotein subunit beta lysine methyltransferase

increases expression

benz(a)anthracene results in increased expression of ETFBKMT mRNA

NCBI chr 4:182,140,492...182,204,635
Ensembl chr 4:182,140,559...182,150,305

G

ETS proto-oncogene 1, transcription factor

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of ETS1 mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of ETS1 mRNA]

NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010

G

ETS variant transcription factor 5

increases expression

benz(a)anthracene results in increased expression of ETV5 mRNA

NCBI chr11:78,608,618...78,666,221
Ensembl chr11:78,608,710...78,666,215

G

eva-1 homolog A, regulator of programmed cell death

increases expression

benz(a)anthracene results in increased expression of EVA1A mRNA

NCBI chr 4:114,593,773...114,643,011
Ensembl chr 4:114,593,341...114,643,011

G

EWS RNA-binding protein 1

increases expression

benz(a)anthracene results in increased expression of EWSR1 mRNA

NCBI chr14:79,965,365...79,994,108
Ensembl chr14:79,965,368...79,994,544

G

exocyst complex component 3-like 1

increases expression

benz(a)anthracene results in increased expression of EXOC3L mRNA

NCBI chr19:33,166,836...33,174,371
Ensembl chr19:33,166,837...33,172,486

G

exocyst complex component 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EXOC4 mRNA

NCBI chr 4:61,807,706...62,584,316
Ensembl chr 4:61,807,761...62,585,723

G

exocyst complex component 6B

decreases expression

benz(a)anthracene results in decreased expression of EXOC6B mRNA

NCBI chr 4:117,094,741...117,550,221
Ensembl chr 4:117,094,741...117,550,180

G

exosome component 7

increases expression

benz(a)anthracene results in increased expression of EXOSC7 mRNA

NCBI chr 8:122,773,607...122,798,943
Ensembl chr 8:122,773,591...122,799,270

G

fatty acid binding protein 1

increases expression

benz(a)anthracene results in increased expression of FABP1 mRNA

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

fatty acid binding protein 12

increases expression

benz(a)anthracene results in increased expression of FABP12 mRNA

NCBI chr 2:91,539,568...91,554,999
Ensembl chr 2:91,500,539...91,554,996

G

family with sequence similarity 107, member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FAM107A mRNA

NCBI chr15:16,608,362...16,630,398
Ensembl chr15:16,607,205...16,630,396

G

family with sequence similarity 110, member D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM110D mRNA

NCBI chr 5:146,471,048...146,474,019
Ensembl chr 5:146,471,049...146,474,056

G

family with sequence similarity 133, member B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM133B mRNA

NCBI chr 4:30,589,646...30,616,291
Ensembl chr 4:30,589,635...30,616,040

G

family with sequence similarity 135, member A

increases expression

benz(a)anthracene results in increased expression of FAM135A mRNA

NCBI chr 9:26,420,116...26,500,803
Ensembl chr 9:26,420,528...26,500,717

G

family with sequence similarity 13, member C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM13C mRNA

NCBI chr20:18,065,625...18,187,792
Ensembl chr20:18,065,628...18,187,592

G

family with sequence similarity 193, member B

affects expression

benz(a)anthracene affects the expression of FAM193B mRNA

NCBI chr17:9,066,818...9,099,511
Ensembl chr17:9,066,707...9,099,508

G

FAM20B, glycosaminoglycan xylosylkinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM20B mRNA

NCBI chr13:68,801,663...68,839,979
Ensembl chr13:68,801,669...68,839,915

G

family with sequence similarity 76, member B

increases expression

benz(a)anthracene results in increased expression of FAM76B mRNA

NCBI chr 8:10,689,396...10,711,847
Ensembl chr 8:10,688,963...10,711,861

G

FERM, ARH/RhoGEF and pleckstrin domain protein 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of FARP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FARP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr15:98,124,304...98,363,299
Ensembl chr15:98,182,329...98,363,299

G

Fas-activated serine/threonine kinase

increases expression
multiple interactions

benz(a)anthracene results in increased expression of FASTK mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FASTK mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:10,732,273...10,736,332
Ensembl chr 4:10,732,256...10,737,430

G

F-box and leucine-rich repeat protein 12

increases expression

benz(a)anthracene results in increased expression of FBXL12 mRNA

NCBI chr 8:19,175,864...19,183,373
Ensembl chr 8:19,160,352...19,183,607

G

F-box and leucine-rich repeat protein 13

increases expression

benz(a)anthracene results in increased expression of FBXL13 mRNA

NCBI chr 4:13,414,880...13,607,079
Ensembl chr 4:13,414,926...13,641,494

G

F-box and leucine-rich repeat protein 20

increases expression

benz(a)anthracene results in increased expression of FBXL20 mRNA

NCBI chr10:83,080,568...83,143,680
Ensembl chr10:83,086,551...83,144,162

G

Fc epsilon receptor II

increases expression
multiple interactions

benz(a)anthracene results in increased expression of FCER2A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FCER2A mRNA

PMID:26377693 PMID:27858113

NCBI chr12:1,742,809...1,754,476
Ensembl chr12:1,742,815...1,754,476

G

Fc mu receptor

increases expression

benz(a)anthracene results in increased expression of FCMR mRNA

NCBI chr13:42,337,363...42,351,706
Ensembl chr13:42,337,414...42,351,653

G

Fc receptor-like A

increases expression

benz(a)anthracene results in increased expression of FCRLA mRNA

NCBI chr13:83,160,453...83,170,170
Ensembl chr13:83,160,398...83,170,762

G

FYVE, RhoGEF and PH domain containing 6

decreases expression

benz(a)anthracene results in decreased expression of FGD6 mRNA

NCBI chr 7:28,597,609...28,712,908
Ensembl chr 7:28,597,609...28,712,456

G

fibroblast growth factor 7

increases expression

benz(a)anthracene results in increased expression of FGF7 mRNA

NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929

G

fibroblast growth factor 9

increases expression

benz(a)anthracene results in increased expression of FGF9 mRNA

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309

G

FGFR1 oncogene partner 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of FGFR1OP2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FGFR1OP2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:179,491,602...179,512,630
Ensembl chr 4:179,491,599...179,512,630

G

fibrinogen gamma chain

increases expression

benz(a)anthracene results in increased expression of FGG mRNA

NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322

G

fin bud initiation factor homolog

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FIBIN mRNA

NCBI chr 3:96,942,405...96,944,676
Ensembl chr 3:96,942,406...96,944,676

G

FIG4 phosphoinositide 5-phosphatase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FIG4 mRNA

NCBI chr20:44,600,603...44,724,047
Ensembl chr20:44,600,603...44,723,844

G

fidgetin-like 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FIGNL1 mRNA

NCBI chr14:86,368,670...86,381,728
Ensembl chr14:86,368,675...86,377,455

G

FKBP prolyl isomerase 1A

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of FKBP1A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FKBP1A mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743

G

FLII, actin remodeling protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FLII mRNA

NCBI chr10:45,394,032...45,408,051
Ensembl chr10:45,394,032...45,407,970

G

Fms related receptor tyrosine kinase 3 ligand

increases expression

benz(a)anthracene results in increased expression of FLT3L mRNA

NCBI chr 1:95,615,056...95,620,463
Ensembl chr 1:95,609,370...95,620,463

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

fragile X messenger ribonucleoprotein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMR1 mRNA

NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050

G

fructosamine 3 kinase

decreases expression

benz(a)anthracene results in decreased expression of FN3K mRNA

NCBI chr10:106,700,670...106,715,903
Ensembl chr10:106,700,670...106,715,895

G

formin binding protein 4

increases expression

benz(a)anthracene results in increased expression of FNBP4 mRNA

NCBI chr 3:76,733,012...76,763,077
Ensembl chr 3:76,733,027...76,763,079

G

fibronectin type III domain containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FNDC1 mRNA

NCBI chr 1:47,281,839...47,364,247
Ensembl chr 1:47,281,844...47,364,259

G

folate receptor beta

decreases expression

benz(a)anthracene results in decreased expression of FOLR2 mRNA

NCBI chr 1:156,200,044...156,218,380
Ensembl chr 1:156,200,060...156,205,724

G

forkhead box A2

decreases expression

benz(a)anthracene results in decreased expression of FOXA2 mRNA

NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326

G

forkhead box F1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FOXF1 mRNA

NCBI chr19:49,153,949...49,157,741
Ensembl chr19:49,153,699...49,157,738

G

forkhead box Q1

decreases expression

benz(a)anthracene results in decreased expression of FOXQ1 mRNA

NCBI chr17:32,912,744...32,915,377
Ensembl chr17:32,912,744...32,915,377
Ensembl chr17:32,912,744...32,915,377

G

forkhead box S1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FOXS1 mRNA

NCBI chr 3:141,397,012...141,398,296
Ensembl chr 3:141,397,016...141,398,281

G

Fraser extracellular matrix complex subunit 1

decreases expression

benz(a)anthracene results in decreased expression of FRAS1 mRNA

NCBI chr14:12,791,407...13,200,862
Ensembl chr14:12,793,599...13,200,726

G

Fras1 related extracellular matrix 1

decreases expression

benz(a)anthracene results in decreased expression of FREM1 mRNA

NCBI chr 5:97,321,266...97,469,523
Ensembl chr 5:97,322,538...97,469,543

G

FSHD region gene 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of FRG1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FRG1 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:50,925,783...50,946,661
Ensembl chr16:50,925,803...50,946,661

G

FERM domain containing 4B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FRMD4B mRNA

NCBI chr 4:129,895,401...130,222,070
Ensembl chr 4:129,895,708...130,084,197

G

fascin actin-bundling protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FSCN3 mRNA

NCBI chr 4:57,042,797...57,052,224
Ensembl chr 4:57,042,797...57,052,404

G

Fus RNA binding protein

increases expression

benz(a)anthracene results in increased expression of FUS mRNA

NCBI chr 1:182,576,479...182,590,417
Ensembl chr 1:182,576,545...182,590,414

G

frizzled class receptor 4

increases expression

benz(a)anthracene results in increased expression of FZD4 mRNA

NCBI chr 1:143,279,934...143,288,799
Ensembl chr 1:143,280,065...143,285,724

G

frizzled class receptor 6

increases expression

benz(a)anthracene results in increased expression of FZD6 mRNA

NCBI chr 7:70,055,012...70,086,781
Ensembl chr 7:70,055,068...70,086,776

G

gamma-aminobutyric acid type B receptor subunit 1

increases expression

benz(a)anthracene results in increased expression of GABBR1 mRNA

NCBI chr20:1,464,534...1,494,114
Ensembl chr20:1,464,534...1,493,994

G

growth arrest and DNA-damage-inducible, alpha

increases expression

benz(a)anthracene metabolite results in increased expression of GADD45A protein; benz(a)anthracene results in increased expression of GADD45A mRNA

PMID:22236718 PMID:31051210

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest and DNA-damage-inducible, gamma

decreases expression

benz(a)anthracene results in decreased expression of GADD45G mRNA

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

polypeptide N-acetylgalactosaminyltransferase 15

decreases expression

benz(a)anthracene results in decreased expression of GALNT15 mRNA

NCBI chr16:7,227,232...7,267,002
Ensembl chr16:7,227,271...7,267,014

G

growth arrest-specific 1

decreases expression

benz(a)anthracene results in decreased expression of GAS1 mRNA

NCBI chr17:4,482,168...4,485,153

G

growth arrest specific 5

increases expression

benz(a)anthracene results in increased expression of GAS5 mRNA

NCBI chr13:73,303,611...73,306,932

G

growth arrest specific 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GAS6 mRNA

NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904

G

golgi associated kinase 1B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GASK1B mRNA

NCBI chr 2:165,047,689...165,112,479
Ensembl chr 2:165,047,684...165,112,477

G

GATA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GATA2 mRNA

NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761

G

1,4-alpha-glucan branching enzyme 1

decreases expression

benz(a)anthracene results in decreased expression of GBE1 mRNA

NCBI chr11:8,734,806...9,000,226
Ensembl chr11:8,734,820...9,000,210

G

guanylate binding protein family member 6

decreases expression

benz(a)anthracene results in decreased expression of GBP6 mRNA

NCBI chr14:4,730,286...4,756,508
Ensembl chr14:4,730,453...4,839,062
Ensembl chr14:4,730,453...4,839,062

G

GRIP and coiled-coil domain containing 2

increases expression

benz(a)anthracene results in increased expression of GCC2 mRNA

NCBI chr20:26,247,394...26,293,613
Ensembl chr20:26,247,404...26,293,613

G

glucagon receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GCGR mRNA

NCBI chr10:105,808,474...105,816,641
Ensembl chr10:105,808,473...105,816,640

G

glial cells missing transcription factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GCM1 mRNA

NCBI chr 8:78,925,687...78,938,924
Ensembl chr 8:78,925,687...78,938,924

G

growth differentiation factor 10

increases expression

benz(a)anthracene results in increased expression of GDF10 mRNA

NCBI chr16:9,237,182...9,250,537
Ensembl chr16:9,237,261...9,249,343

G

growth differentiation factor 15

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

glial cell derived neurotrophic factor

increases expression

benz(a)anthracene results in increased expression of GDNF mRNA

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

GDNF family receptor alpha 4

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of GFRA4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GFRA4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:118,254,937...118,262,252
Ensembl chr 3:118,255,402...118,258,329

G

gap junction protein, alpha 5

decreases expression

benz(a)anthracene results in decreased expression of GJA5 mRNA

NCBI chr 2:184,602,407...184,621,952
Ensembl chr 2:184,564,475...184,621,952

G

gap junction protein, beta 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GJB1 mRNA

NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925

G

gap junction protein, gamma 2

decreases expression

benz(a)anthracene results in decreased expression of GJC2 mRNA

NCBI chr10:43,962,642...43,971,358
Ensembl chr10:43,962,642...43,970,467

G

gastrokine 2

increases expression

benz(a)anthracene results in increased expression of GKN2 mRNA

NCBI chr 4:119,778,326...119,824,366
Ensembl chr 4:119,818,280...119,824,363

G

GLIS family zinc finger 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GLIS2 mRNA

NCBI chr10:10,951,157...10,978,524
Ensembl chr10:10,951,371...10,971,578

G

glycosyltransferase 8 domain containing 1

decreases expression

benz(a)anthracene results in decreased expression of GLT8D1 mRNA

NCBI chr16:6,192,269...6,207,227
Ensembl chr16:6,192,300...6,207,229

G

glycosyltransferase 8 domain containing 2

decreases expression

benz(a)anthracene results in decreased expression of GLT8D2 mRNA

NCBI chr 7:21,029,534...21,081,081
Ensembl chr 7:21,029,525...21,081,080

G

geminin, DNA replication inhibitor

increases expression
multiple interactions

benz(a)anthracene results in increased expression of GMNN mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GMNN mRNA

PMID:26377693 PMID:27858113

NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054

G

gon-4 like

decreases expression

benz(a)anthracene results in decreased expression of GON4L mRNA

NCBI chr 2:174,233,461...174,306,636
Ensembl chr 2:174,233,461...174,306,634

G

glycerophosphocholine phosphodiesterase 1

increases expression

benz(a)anthracene results in increased expression of GPCPD1 mRNA

NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517

G

glycerol-3-phosphate dehydrogenase 1

multiple interactions
increases activity

benz(a)anthracene inhibits the reaction [Dehydroepiandrosterone results in increased activity of GPD1 protein]
benz(a)anthracene results in increased activity of GPD1 protein

NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529

G

glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GPIHBP1 mRNA

NCBI chr 7:107,285,584...107,288,702
Ensembl chr 7:107,285,654...107,288,702

G

G protein-coupled receptor 174

increases expression

benz(a)anthracene results in increased expression of GPR174 mRNA

NCBI chr X:72,355,452...72,396,146
Ensembl chr X:72,355,033...72,397,658

G

G protein-coupled receptor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GPR4 mRNA

NCBI chr 1:78,865,376...78,877,126
Ensembl chr 1:78,865,409...78,876,599

G

GPRIN family member 3

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of GPRIN3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GPRIN3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:88,572,062...88,657,369
Ensembl chr 4:88,563,607...88,657,429

G

glutathione peroxidase 6

increases expression

benz(a)anthracene results in increased expression of GPX6 mRNA

NCBI chr17:43,408,472...43,416,091
Ensembl chr17:43,408,472...43,416,091

G

GRAM domain containing 1A

increases expression

benz(a)anthracene results in increased expression of GRAMD1A mRNA

NCBI chr 1:86,367,001...86,393,348
Ensembl chr 1:86,367,001...86,393,336

G

GRAM domain containing 1C

decreases expression

benz(a)anthracene results in decreased expression of GRAMD1C mRNA

NCBI chr11:56,633,229...56,718,570
Ensembl chr11:56,633,227...56,718,570

G

growth factor receptor bound protein 10

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of GRB10 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRB10 mRNA

PMID:26377693 PMID:27858113

NCBI chr14:86,495,051...86,602,800
Ensembl chr14:86,495,054...86,602,806

G

growth regulating estrogen receptor binding 1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of GREB1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GREB1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633

G

galectin-related inter-fiber protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRIFIN mRNA

NCBI chr12:14,080,170...14,082,892
Ensembl chr12:14,080,910...14,082,877

G

G protein-coupled receptor kinase 3

increases expression

benz(a)anthracene results in increased expression of GRK3 mRNA

NCBI chr12:43,624,778...43,735,375
Ensembl chr12:43,624,897...43,731,262

G

gastrin releasing peptide

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRP mRNA

NCBI chr18:59,388,679...59,402,061
Ensembl chr18:59,388,274...59,402,061

G

gamma-secretase activating protein

increases expression

benz(a)anthracene results in increased expression of GSAP mRNA

NCBI chr 4:13,813,046...13,907,875
Ensembl chr 4:13,813,046...13,907,814

G

glutathione S-transferase alpha 1

decreases expression

benz(a)anthracene results in decreased expression of GSTA1 mRNA

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase alpha 2

multiple interactions
increases activity
increases expression

1-(5-isoquinolinylsulfonyl)-3-methylpiperazine inhibits the reaction [benz(a)anthracene results in increased activity of GSTA2 protein]; Dexamethasone promotes the reaction [benz(a)anthracene results in increased activity of GSTA2 protein]; Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of GSTA2 mRNA]; Staurosporine inhibits the reaction [benz(a)anthracene results in increased activity of GSTA2 protein]

PMID:7587946 PMID:26377693

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

general transcription factor IIIC subunit 2

increases expression

benz(a)anthracene results in increased expression of GTF3C2 mRNA

NCBI chr 6:25,196,439...25,221,338
Ensembl chr 6:25,197,268...25,220,490

G

GTP binding protein 2

increases expression

benz(a)anthracene results in increased expression of GTPBP2 mRNA

NCBI chr 9:14,813,964...14,823,419
Ensembl chr 9:14,813,964...14,823,241

G

granzyme A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GZMA mRNA

NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:44,740,569...44,752,493

G

H1.2 linker histone, cluster member

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H1F2 mRNA

NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635

G

H1.4 linker histone, cluster member

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H1F4 mRNA

NCBI chr17:41,486,574...41,487,355
Ensembl chr17:41,486,560...41,487,403

G

H2A.X variant histone

increases expression

benz(a)anthracene metabolite results in increased expression of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

hydroxyacylglutathione hydrolase-like

increases expression

benz(a)anthracene results in increased expression of HAGHL mRNA

NCBI chr10:14,804,957...14,809,495
Ensembl chr10:14,804,997...14,807,665

G

HAUS augmin-like complex, subunit 4

increases expression

benz(a)anthracene results in increased expression of HAUS4 mRNA

NCBI chr15:27,994,530...28,006,147
Ensembl chr15:27,994,532...28,005,938

G

HAUS augmin-like complex, subunit 5

increases expression

benz(a)anthracene results in increased expression of HAUS5 mRNA

NCBI chr 1:85,912,371...85,924,327
Ensembl chr 1:85,912,374...85,923,337

G

HCK proto-oncogene, Src family tyrosine kinase

increases expression

benz(a)anthracene results in increased expression of HCK mRNA

NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693

G

histone deacetylase 10

increases expression

benz(a)anthracene results in increased expression of HDAC10 mRNA

NCBI chr 7:120,199,126...120,205,850
Ensembl chr 7:120,199,129...120,204,228

G

HEAT repeat containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HEATR1 mRNA

NCBI chr17:58,053,288...58,093,895
Ensembl chr17:58,051,700...58,093,948

G

helicase with zinc finger 2

decreases expression

benz(a)anthracene results in decreased expression of HELZ2 mRNA

NCBI chr 3:168,338,813...168,353,219
Ensembl chr 3:168,338,813...168,353,159

G

HECT and RLD domain containing E3 ubiquitin protein ligase family member 1

increases expression

benz(a)anthracene results in increased expression of HERC1 mRNA

NCBI chr 8:66,857,169...67,070,318
Ensembl chr 8:66,856,935...67,070,312

G

HECT and RLD domain containing E3 ubiquitin protein ligase 3

increases expression

benz(a)anthracene results in increased expression of HERC3 mRNA

NCBI chr 4:87,952,202...88,042,492
Ensembl chr 4:87,952,274...88,042,488

G

hes family bHLH transcription factor 2

increases expression

benz(a)anthracene results in increased expression of HES2 mRNA

NCBI chr 5:162,667,190...162,668,235
Ensembl chr 5:162,667,190...162,668,235

G

HIC ZBTB transcriptional repressor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HIC1 mRNA

NCBI chr10:60,014,520...60,019,475
Ensembl chr10:60,011,528...60,019,475

G

hypoxia inducible lipid droplet-associated

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HILPDA mRNA

NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557

G

hexokinase domain containing 1

increases expression

benz(a)anthracene results in increased expression of HKDC1 mRNA

NCBI chr20:30,335,322...30,373,792
Ensembl chr20:30,335,628...30,373,867

G

HLF transcription factor, PAR bZIP family member

increases expression
multiple interactions

benz(a)anthracene results in increased expression of HLF mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HLF mRNA

PMID:26377693 PMID:27858113

NCBI chr10:75,154,244...75,211,884
Ensembl chr10:75,154,507...75,211,935

G

histocompatibility minor 13

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H13 mRNA

NCBI chr 3:141,145,792...141,183,557
Ensembl chr 3:141,145,782...141,184,703

G

hemicentin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMCN1 mRNA

NCBI chr13:62,615,461...63,084,524
Ensembl chr13:62,615,461...63,084,524

G

high mobility group box 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGB1 mRNA

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

high mobility group nucleosomal binding domain 2

increases expression

benz(a)anthracene results in increased expression of HMGN2 mRNA

NCBI chr 5:146,192,126...146,195,580
Ensembl chr 5:146,192,126...146,195,521
Ensembl chr16:146,192,126...146,195,521

G

high mobility group nucleosome binding domain 5

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of HMGN5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGN5 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:74,085,871...74,094,488
Ensembl chr X:74,085,875...74,094,441

G

histamine N-methyltransferase

decreases expression

benz(a)anthracene results in decreased expression of HNMT mRNA

NCBI chr 3:6,591,804...6,623,821
Ensembl chr 3:6,591,463...6,624,012

G

heterogeneous nuclear ribonucleoprotein A2/B1

increases expression

benz(a)anthracene results in increased expression of HNRNPA2B1 mRNA

NCBI chr 4:80,534,659...80,545,297
Ensembl chr 4:80,534,651...80,545,249

G

heterogeneous nuclear ribonucleoprotein C

decreases expression

benz(a)anthracene results in decreased expression of HNRNPC mRNA

NCBI chr15:24,779,593...24,809,213
Ensembl chr15:24,779,450...24,809,183

G

heterogeneous nuclear ribonucleoprotein D-like

increases expression

benz(a)anthracene results in increased expression of HNRNPDL mRNA

NCBI chr14:9,557,430...9,563,659
Ensembl chr14:9,557,425...9,562,506

G

heterogeneous nuclear ribonucleoprotein F

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HNRNPF mRNA

NCBI chr 4:151,083,262...151,104,464
Ensembl chr 4:151,083,062...151,109,038

G

heterogeneous nuclear ribonucleoprotein H1

decreases expression

benz(a)anthracene results in decreased expression of HNRNPH1 mRNA

NCBI chr10:34,692,868...34,702,849
Ensembl chr10:34,693,555...34,702,846

G

HPS1, biogenesis of lysosomal organelles complex 3 subunit 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HPS1 mRNA

NCBI chr 1:241,551,180...241,577,292
Ensembl chr 1:241,551,175...241,577,268

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7

increases expression

benz(a)anthracene results in increased expression of HSD3B7 mRNA

NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442

G

heat shock protein family A (Hsp70) member 1A

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of HSPA1A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HSPA1A mRNA

PMID:26377693 PMID:27858113

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 8

decreases expression

benz(a)anthracene results in decreased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

heat shock protein family D (Hsp60) member 1

decreases expression

benz(a)anthracene results in decreased expression of HSPD1 mRNA

NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662

G

HIV-1 Tat interactive protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HTATIP2 mRNA

NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629

G

HIV-1 Tat specific factor 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of HTATSF1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HTATSF1 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:134,935,426...134,949,607
Ensembl chr X:134,935,426...134,949,607

G

hormonally upregulated Neu-associated kinase

increases expression
multiple interactions

benz(a)anthracene results in increased expression of HUNK mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HUNK mRNA

PMID:26377693 PMID:27858113

NCBI chr11:29,641,122...29,758,392
Ensembl chr11:29,640,775...29,757,526

G

hyaluronidase 1

decreases expression

benz(a)anthracene results in decreased expression of HYAL1 mRNA

NCBI chr 8:108,250,668...108,254,519
Ensembl chr 8:108,250,667...108,260,210

G

islet cell autoantigen 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ICA1 mRNA

NCBI chr 4:36,656,475...36,804,705
Ensembl chr 4:36,656,475...36,804,298

G

inducible T-cell co-stimulator ligand

increases expression

benz(a)anthracene results in increased expression of ICOSL mRNA

NCBI chr20:10,600,420...10,610,718
Ensembl chr20:10,600,420...10,610,703

G

inhibitor of DNA binding 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ID1 mRNA

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

alpha-L-iduronidase

increases expression

benz(a)anthracene results in increased expression of IDUA mRNA

NCBI chr14:1,031,588...1,059,494
Ensembl chr14:1,032,171...1,046,522

G

immediate early response 3

increases expression

benz(a)anthracene results in increased expression of IER3 mRNA

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

immediate early response 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IER5 mRNA

NCBI chr13:67,270,134...67,272,226
Ensembl chr13:67,270,135...67,272,227

G

intermediate filament family orphan 1

increases expression

benz(a)anthracene results in increased expression of IFFO1 mRNA

NCBI chr 4:157,945,075...157,962,302
Ensembl chr 4:157,945,107...157,962,302

G

interferon, alpha-inducible protein 27

decreases expression

benz(a)anthracene results in decreased expression of IFI27L1 mRNA

NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294

G

interferon, alpha-inducible protein 27 like 2B

decreases expression

benz(a)anthracene results in decreased expression of IFI27L2A mRNA

NCBI chr 6:122,598,872...122,600,358
Ensembl chr 6:122,598,872...122,600,360

G

interferon-induced protein 44

decreases expression

benz(a)anthracene results in decreased expression of IFI44 mRNA

NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844

G

interferon-induced protein with tetratricopeptide repeats 3

decreases expression

benz(a)anthracene results in decreased expression of IFIT3 mRNA

NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307

G

insulin-like growth factor binding protein 5

decreases expression

benz(a)anthracene results in decreased expression of IGFBP5 mRNA

NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156

G

IGF-like family receptor 1

affects expression

benz(a)anthracene affects the expression of IGFLR1 mRNA

NCBI chr 1:85,818,428...85,821,032
Ensembl chr 1:85,816,326...85,821,030

G

immunoglobulin superfamily, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IGSF3 mRNA

NCBI chr 2:188,811,394...188,899,645
Ensembl chr 2:188,811,380...188,899,645

G

immunoglobulin superfamily, member 6

increases expression

benz(a)anthracene results in increased expression of IGSF6 mRNA

NCBI chr 1:175,610,167...175,620,662
Ensembl chr 1:175,610,167...175,620,722

G

IKAROS family zinc finger 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IKZF4 mRNA

NCBI chr 7:1,063,283...1,102,940
Ensembl chr 7:1,056,890...1,084,341

G

interleukin 18 receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IL18R1 mRNA

NCBI chr 9:42,727,416...42,760,971
Ensembl chr 9:42,727,869...42,760,715

G

interleukin 1 alpha

increases expression

benz(a)anthracene results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

decreases expression

benz(a)anthracene results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 4 induced 1

increases expression

benz(a)anthracene results in increased expression of IL4I1 mRNA

NCBI chr 1:95,299,457...95,324,564
Ensembl chr 1:95,295,601...95,324,562

G

interleukin 6

increases secretion
multiple interactions
increases expression

benz(a)anthracene results in increased secretion of IL6 protein
[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased secretion of IL6 protein; AHR protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]; Curcumin inhibits the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6 mRNA]; RELA protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]; Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of IL6 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased secretion of IL6 protein]

PMID:8156173 PMID:22643241 PMID:23396138 PMID:25433334

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 7 receptor

increases expression

benz(a)anthracene results in increased expression of IL7R mRNA

NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757

G

interleukin enhancer binding factor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ILF2 mRNA

NCBI chr 2:175,952,174...175,971,191
Ensembl chr 2:175,952,186...175,971,337

G

inflammation and lipid regulator with UBA-like and NBR1-like domains

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ILRUN mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ILRUN mRNA

PMID:26377693 PMID:27858113

NCBI chr20:5,809,931...5,876,197
Ensembl chr20:5,809,936...5,876,012

G

InaF motif containing 2

decreases expression

benz(a)anthracene results in decreased expression of INAFM2 mRNA

NCBI chr 3:105,728,208...105,733,766

G

inka box actin regulator 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of INKA2 mRNA

NCBI chr 2:193,185,275...193,200,643
Ensembl chr 2:193,185,275...193,200,642

G

INO80 complex subunit B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of INO80B mRNA

NCBI chr 4:115,627,907...115,631,069
Ensembl chr 4:115,627,908...115,631,456

G

inositol polyphosphate-5-phosphatase K

increases expression

benz(a)anthracene results in increased expression of INPP5K mRNA

NCBI chr10:60,474,262...60,495,813
Ensembl chr10:60,475,897...60,496,773

G

integrator complex subunit 6 like

increases expression

benz(a)anthracene results in increased expression of INTS6L mRNA

NCBI chr X:134,258,117...134,325,706
Ensembl chr X:134,258,125...134,309,617

G

IQ motif containing E

increases expression

benz(a)anthracene results in increased expression of IQCE mRNA

NCBI chr12:13,943,290...13,982,708
Ensembl chr12:13,943,487...13,982,693

G

IQ motif and Sec7 domain ArfGEF 3

increases expression

benz(a)anthracene results in increased expression of IQSEC3 mRNA

NCBI chr 4:154,610,933...154,707,310
Ensembl chr 4:154,610,934...154,707,310

G

inositol 1,4,5-triphosphate receptor associated 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of IRAG2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IRAG2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:178,088,902...178,143,569
Ensembl chr 4:178,088,507...178,143,557

G

interferon regulatory factor 2 binding protein 2

decreases expression

benz(a)anthracene results in decreased expression of IRF2BP2 mRNA

NCBI chr19:54,559,417...54,565,096
Ensembl chr19:54,560,128...54,566,642

G

interferon regulatory factor 2 binding protein-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IRF2BPL mRNA

NCBI chr 6:106,527,179...106,531,294
Ensembl chr 6:106,528,053...106,530,401

G

interferon regulatory factor 7

decreases expression

benz(a)anthracene results in decreased expression of IRF7 mRNA

NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832

G

ISG15 ubiquitin-like modifier

decreases expression

benz(a)anthracene results in decreased expression of ISG15 mRNA

NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435

G

integrin subunit alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ITGA1 mRNA

NCBI chr 2:46,646,125...46,812,237
Ensembl chr 2:46,653,193...46,812,238

G

integrin subunit alpha 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of ITGA2 mRNA
Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of ITGA2 mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of ITGA2 mRNA]

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

integrin subunit alpha 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ITGA7 mRNA

NCBI chr 7:1,360,125...1,388,886
Ensembl chr 7:1,359,940...1,388,450

G

integrin subunit beta 1

decreases expression

benz(a)anthracene results in decreased expression of ITGB1 mRNA

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

inter-alpha-trypsin inhibitor heavy chain 4

increases expression

benz(a)anthracene results in increased expression of ITIH4 mRNA

NCBI chr16:6,080,539...6,095,710
Ensembl chr16:6,080,539...6,095,708

G

ITPRIP like 2

decreases expression

benz(a)anthracene results in decreased expression of ITPRIPL2 mRNA

NCBI chr 1:172,801,152...172,803,047
Ensembl chr 1:172,796,849...172,802,950

G

intersectin 1

decreases expression

benz(a)anthracene results in decreased expression of ITSN1 mRNA

NCBI chr11:30,978,590...31,160,645
Ensembl chr11:30,978,590...31,160,645

G

IZUMO family member 4

affects expression

benz(a)anthracene affects the expression of IZUMO4 mRNA

NCBI chr 7:9,007,276...9,010,428
Ensembl chr 7:9,007,280...9,010,032

G

jade family PHD finger 1

decreases expression

benz(a)anthracene results in decreased expression of JADE1 mRNA

NCBI chr 2:124,543,233...124,596,361
Ensembl chr 2:124,543,286...124,596,354

G

Janus kinase 3

increases expression

benz(a)anthracene results in increased expression of JAK3 mRNA

NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of JUN mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of JUN mRNA]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

KN motif and ankyrin repeat domains 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KANK4 mRNA

NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555

G

kazrin, periplakin interacting protein

increases expression

benz(a)anthracene results in increased expression of KAZN mRNA

NCBI chr 5:154,392,793...155,381,567
Ensembl chr 5:154,392,793...154,779,074

G

potassium voltage-gated channel subfamily E regulatory subunit 3

increases expression
multiple interactions

benz(a)anthracene results in increased expression of KCNE3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KCNE3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:154,523,903...154,530,865
Ensembl chr 1:154,523,830...154,532,020

G

potassium channel tetramerisation domain containing 12b

increases expression

benz(a)anthracene results in increased expression of KCTD12B mRNA

NCBI chr X:17,643,707...17,654,820
Ensembl chr X:17,643,615...17,654,820

G

kinesin family member 21B

increases expression

benz(a)anthracene results in increased expression of KIF21B mRNA

NCBI chr13:47,576,129...47,626,112
Ensembl chr13:47,576,160...47,626,127

G

kinesin family member 26B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KIF26B mRNA

NCBI chr13:90,282,821...90,689,058
Ensembl chr13:90,283,404...90,682,811

G

kinesin family member C2

affects expression

benz(a)anthracene affects the expression of KIFC2 mRNA

NCBI chr 7:108,380,634...108,388,364
Ensembl chr 7:108,376,011...108,388,484

G

KIT proto-oncogene receptor tyrosine kinase

increases expression

benz(a)anthracene results in increased expression of KIT mRNA

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

KIT ligand

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of KITL mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KITL mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214

G

KLF transcription factor 12

decreases expression

benz(a)anthracene results in decreased expression of KLF12 mRNA

NCBI chr15:76,628,778...77,062,000
Ensembl chr15:76,637,654...77,062,056

G

KLF transcription factor 5

decreases expression

benz(a)anthracene results in decreased expression of KLF5 mRNA

NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445

G

kelch domain containing 8B

affects expression

benz(a)anthracene affects the expression of KLHDC8B mRNA

NCBI chr 8:109,141,594...109,146,584
Ensembl chr 8:109,141,594...109,146,918

G

kelch domain containing 9

increases expression

benz(a)anthracene results in increased expression of KLHDC9 mRNA

NCBI chr13:83,790,390...83,794,080
Ensembl chr13:83,790,269...83,793,354

G

kelch-like family member 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KLHL5 mRNA

NCBI chr14:43,144,254...43,206,192
Ensembl chr14:43,144,257...43,184,238

G

kelch-like family member 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KLHL6 mRNA

NCBI chr11:80,970,917...81,010,593
Ensembl chr11:80,970,917...81,009,677

G

killer cell lectin like receptor D1

increases expression

benz(a)anthracene results in increased expression of KLRD1 mRNA

NCBI chr 4:163,044,920...163,056,568
Ensembl chr 4:163,045,067...163,056,518

G

lysine methyltransferase 2D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KMT2D mRNA

NCBI chr 7:129,980,744...130,022,088
Ensembl chr 7:129,962,887...130,020,325

G

lysine methyltransferase 5A

decreases expression

benz(a)anthracene results in decreased expression of KMT5A mRNA

NCBI chr12:32,139,353...32,167,777
Ensembl chr12:32,139,178...32,162,711

G

lysine methyltransferase 5B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KMT5B mRNA

NCBI chr 1:201,000,444...201,049,819
Ensembl chr 1:201,000,444...201,049,819

G

KRAB-A domain containing 1

increases expression

benz(a)anthracene results in increased expression of KRBA1 mRNA

NCBI chr 4:77,341,654...77,363,075
Ensembl chr 4:77,340,959...77,363,613

G

keratin 15

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KRT15 mRNA

NCBI chr10:85,066,797...85,070,614
Ensembl chr10:85,066,802...85,171,799

G

keratin 31

increases expression

benz(a)anthracene results in increased expression of KRT31 mRNA

NCBI chr10:84,979,393...84,982,898
Ensembl chr10:84,979,352...84,982,832

G

keratinocyte associated protein 3

decreases expression

benz(a)anthracene results in decreased expression of KRTCAP3 mRNA

NCBI chr 6:25,120,938...25,122,522
Ensembl chr 6:25,120,938...25,122,507

G

kynurenine aminotransferase 1

decreases expression

benz(a)anthracene results in decreased expression of KYAT1 mRNA

NCBI chr 3:13,459,598...13,493,308
Ensembl chr 3:13,459,591...13,493,355

G

laminin subunit alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LAMA1 mRNA

NCBI chr 9:107,692,770...107,816,847
Ensembl chr 9:107,692,770...107,817,478

G

LIM and SH3 protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LASP1 mRNA

NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292

G

lebercilin LCA5 like

increases expression

benz(a)anthracene results in increased expression of LCA5L mRNA

NCBI chr11:35,460,646...35,495,133
Ensembl chr11:35,461,118...35,495,047

G

ligand dependent nuclear receptor corepressor-like

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of LCORL mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LCORL mRNA

PMID:26377693 PMID:27858113

NCBI chr14:65,271,339...65,407,732
Ensembl chr14:65,271,135...65,404,174

G

left right determination factor 1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of LEFTY1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LEFTY1 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:92,649,226...92,659,722
Ensembl chr13:92,656,323...92,659,720

G

leukocyte receptor cluster member 8

increases expression

benz(a)anthracene results in increased expression of LENG8 mRNA

NCBI chr 1:70,040,785...70,052,662
Ensembl chr 1:70,040,785...70,052,488

G

LEO1 homolog, Paf1/RNA polymerase II complex component

decreases expression

benz(a)anthracene results in decreased expression of LEO1 mRNA

NCBI chr 8:76,199,547...76,223,983
Ensembl chr 8:76,199,099...76,223,983

G

leptin receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LEPR mRNA

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

galectin 1

increases expression

benz(a)anthracene results in increased expression of LGALS1 mRNA

NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345

G

galectin 4

affects expression

benz(a)anthracene affects the expression of LGALS4 mRNA

NCBI chr 1:84,124,766...84,132,481
Ensembl chr 1:84,124,764...84,132,481

G

LHFPL tetraspan subfamily member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LHFPL3 mRNA

G

Lck interacting transmembrane adaptor 1

affects expression

benz(a)anthracene affects the expression of LIME1 mRNA

NCBI chr 3:168,490,535...168,496,627
Ensembl chr 3:168,490,074...168,493,127

G

lipase A, lysosomal acid type

decreases expression

benz(a)anthracene results in decreased expression of LIPA mRNA

NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633

G

lipin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LPIN1 mRNA

NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097

G

LRAT domain containing 1

decreases expression

benz(a)anthracene results in decreased expression of LRATD1 mRNA

NCBI chr 6:36,916,969...36,922,143
Ensembl chr 6:36,913,469...36,922,319

G

LDL receptor related protein 12

increases expression

benz(a)anthracene results in increased expression of LRP12 mRNA

NCBI chr 7:70,941,068...71,012,409
Ensembl chr 7:70,941,068...71,012,441

G

leucine rich repeat containing 36

increases expression

benz(a)anthracene results in increased expression of LRRC36 mRNA

NCBI chr19:33,292,074...33,342,426
Ensembl chr19:33,292,074...33,360,141

G

leucine rich repeat containing 45

affects expression

benz(a)anthracene affects the expression of LRRC45 mRNA

NCBI chr10:105,994,468...106,002,425
Ensembl chr10:105,993,087...106,002,424

G

leucine rich repeat containing 71

increases expression

benz(a)anthracene results in increased expression of LRRC71 mRNA

NCBI chr 2:173,194,792...173,207,448
Ensembl chr 2:173,194,792...173,207,448

G

leucine rich repeat containing 75B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LRRC75B mRNA

NCBI chr20:13,100,302...13,106,503
Ensembl chr20:13,100,302...13,106,503

G

leucine-rich repeat kinase 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of LRRK1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LRRK1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:119,844,360...119,972,885
Ensembl chr 1:119,845,146...119,979,734

G

leucine rich repeat neuronal 4

decreases expression

benz(a)anthracene results in decreased expression of LRRN4 mRNA

NCBI chr 3:120,138,093...120,150,877
Ensembl chr 3:120,139,410...120,150,831

G

leucine-rich repeats and transmembrane domains 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of LRTM2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LRTM2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:152,485,863...152,508,248
Ensembl chr 4:152,485,866...152,500,377

G

LSM family member 14B

increases expression

benz(a)anthracene results in increased expression of LSM14B mRNA

NCBI chr 3:167,125,633...167,136,417
Ensembl chr 3:167,125,628...167,136,432

G

leukocyte specific transcript 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LST1 mRNA

NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997

G

leukotriene C4 synthase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LTC4S mRNA

NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651

G

LUC7-like 3 pre-mRNA splicing factor

decreases expression

benz(a)anthracene results in decreased expression of LUC7L3 mRNA

NCBI chr10:79,240,050...79,276,555
Ensembl chr10:79,240,563...79,276,538

G

lumican

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LUM mRNA

NCBI chr 7:32,358,990...32,365,794
Ensembl chr 7:32,358,614...32,365,793

G

lymphocyte antigen 6 family member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LY6A mRNA

NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981

G

lymphatic vessel endothelial hyaluronan receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LYVE1 mRNA

NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309

G

lysozyme-like 4

increases expression

benz(a)anthracene results in increased expression of LYZL4 mRNA

NCBI chr 8:121,248,129...121,255,366
Ensembl chr 8:121,248,168...121,255,353

G

leucine zipper like post translational regulator 1

increases expression

benz(a)anthracene results in increased expression of LZTR1 mRNA

NCBI chr11:83,487,717...83,503,896
Ensembl chr11:83,487,717...83,503,633

G

leucine zipper tumor suppressor family member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LZTS3 mRNA

NCBI chr 3:117,850,286...117,861,132
Ensembl chr 3:117,851,702...117,860,081

G

MAGE family member H1

increases expression

benz(a)anthracene results in increased expression of MAGEH1 mRNA

NCBI chr X:18,350,015...18,351,271
Ensembl chr X:18,349,774...18,351,516

G

membrane associated guanylate kinase, WW and PDZ domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MAGI3 mRNA

NCBI chr 2:191,514,726...191,717,048
Ensembl chr 2:191,518,506...191,716,735

G

magnesium transporter 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MAGT1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MAGT1 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:71,038,489...71,079,704
Ensembl chr X:71,038,489...71,079,699

G

MALT1 paracaspase

increases expression

benz(a)anthracene results in increased expression of MALT1 mRNA

NCBI chr18:58,942,282...58,996,318
Ensembl chr18:58,942,299...58,994,260

G

mesencephalic astrocyte-derived neurotrophic factor

decreases expression

benz(a)anthracene results in decreased expression of MANF mRNA

NCBI chr 8:107,500,856...107,551,595
Ensembl chr 8:107,548,352...107,551,438

G

monoamine oxidase A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAOA mRNA

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

mitogen-activated protein kinase kinase kinase 14

increases expression

benz(a)anthracene results in increased expression of MAP3K14 mRNA

NCBI chr10:88,165,349...88,215,558
Ensembl chr10:88,165,351...88,215,523

G

mitogen activated protein kinase kinase kinase kinase 2

increases expression

benz(a)anthracene results in increased expression of MAP4K2 mRNA

NCBI chr 1:203,645,098...203,660,782
Ensembl chr 1:203,645,153...203,660,331

G

mitogen-activated protein kinase kinase kinase kinase 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAP4K4 mRNA

NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698

G

mitogen activated protein kinase 14

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased phosphorylation of MAPK14 protein]

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen-activated protein kinase 8 interacting protein 3

affects expression

benz(a)anthracene affects the expression of MAPK8IP3 mRNA

NCBI chr10:13,918,417...13,958,335
Ensembl chr10:13,918,400...13,958,273

G

membrane associated ring-CH-type finger 1

increases expression

benz(a)anthracene results in increased expression of MARCHF1 mRNA

NCBI chr16:23,255,551...24,114,290
Ensembl chr16:23,258,799...24,114,277

G

macrophage receptor with collagenous structure

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MARCO mRNA

NCBI chr13:31,616,278...31,648,521
Ensembl chr13:31,616,278...31,648,521

G

MARVEL domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MARVELD3 mRNA

NCBI chr19:37,908,727...37,923,420
Ensembl chr19:37,905,638...37,923,420

G

methionine adenosyltransferase 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAT1A mRNA

NCBI chr16:16,983,084...17,001,284
Ensembl chr16:16,983,022...17,001,274

G

methionine adenosyltransferase 2A

decreases expression

benz(a)anthracene results in decreased expression of MAT2A mRNA

NCBI chr 4:104,489,877...104,495,447
Ensembl chr 4:104,488,466...104,495,493

G

MAP3K12 binding inhibitory protein 1

increases expression

benz(a)anthracene results in increased expression of MBIP mRNA

NCBI chr 6:73,808,133...73,825,394
Ensembl chr 6:73,808,133...73,825,374

G

membrane bound O-acyltransferase domain containing 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MBOAT2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MBOAT2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:41,471,135...41,597,599
Ensembl chr 6:41,471,161...41,593,485

G

melanoma cell adhesion molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MCAM mRNA

NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571

G

minichromosome maintenance complex component 6

increases expression

benz(a)anthracene results in increased expression of MCM6 mRNA

NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960

G

mucolipin TRP cation channel 3

increases expression

benz(a)anthracene results in increased expression of MCOLN3 mRNA

NCBI chr 2:235,008,716...235,042,885
Ensembl chr 2:234,966,010...235,043,047

G

MDM2 proto-oncogene

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MDM2 mRNA

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

MDM4 regulator of p53

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MDM4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MDM4 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:44,432,596...44,516,165
Ensembl chr13:44,406,213...44,474,226

G

midasin AAA ATPase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MDN1 mRNA

NCBI chr 5:47,055,435...47,190,426
Ensembl chr 5:47,055,447...47,186,332

G

MDS1 and EVI1 complex locus

decreases expression

benz(a)anthracene results in decreased expression of MECOM mRNA

NCBI chr 2:112,909,353...113,464,583
Ensembl chr 2:112,909,321...113,464,590

G

maternally expressed 3

affects expression

benz(a)anthracene affects the expression of MEG3 mRNA

NCBI chr 6:128,491,808...128,524,010

G

multiple EGF-like-domains 6

increases expression

benz(a)anthracene results in increased expression of MEGF6 mRNA

NCBI chr 5:164,738,272...164,839,142
Ensembl chr 5:164,738,352...164,839,139

G

meiosis specific with OB-fold

decreases expression

benz(a)anthracene results in decreased expression of MEIOB mRNA

NCBI chr10:13,833,170...13,865,684
Ensembl chr10:13,833,750...13,865,046

G

mesoderm posterior bHLH transcription factor 1

increases expression

benz(a)anthracene results in increased expression of MESP1 mRNA

NCBI chr 1:133,738,357...133,739,875
Ensembl chr 1:133,738,357...133,739,875

G

methyltransferase 18, RPL3 N3(tau)-histidine

increases expression

benz(a)anthracene results in increased expression of METTL18 mRNA

NCBI chr13:76,345,888...76,348,798
Ensembl chr13:76,345,957...76,348,836

G

microfibril associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MFAP2 mRNA

NCBI chr 5:153,312,068...153,320,266
Ensembl chr 5:153,314,711...153,320,259

G

microfibril associated protein 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MFAP4 mRNA

NCBI chr10:46,167,158...46,170,176
Ensembl chr10:46,167,217...46,170,155

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression

benz(a)anthracene results in increased expression of MFSD2A mRNA

NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690

G

alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MGAT2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MGAT2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:87,656,360...87,658,849
Ensembl chr 6:87,656,349...87,658,177

G

monoglyceride lipase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MGLL mRNA

NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179

G

O-6-methylguanine-DNA methyltransferase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MGMT mRNA

NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756

G

MIA SH3 domain ER export factor 3

decreases expression

benz(a)anthracene results in decreased expression of MIA3 mRNA

NCBI chr13:94,970,421...95,012,071
Ensembl chr13:94,970,424...95,011,972

G

microtubule associated monooxygenase, calponin and LIM domain containing 1

increases expression

benz(a)anthracene results in increased expression of MICAL1 mRNA

NCBI chr20:44,974,137...44,986,089
Ensembl chr20:44,974,138...44,986,089

G

mitotic deacetylase associated SANT domain protein

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MIDEAS mRNA
benz(a)anthracene results in decreased expression of MIDEAS mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:103,784,779...103,854,470
Ensembl chr 6:103,787,873...103,829,178

G

microRNA 181d

increases expression

benz(a)anthracene results in increased expression of MIR181D mRNA

NCBI chr19:23,983,706...23,983,788
Ensembl chr19:23,983,706...23,983,788

G

microRNA 200c

increases expression

benz(a)anthracene results in increased expression of MIR200C mRNA

NCBI chr 4:157,523,679...157,523,747

G

microRNA 22

increases expression

benz(a)anthracene results in increased expression of MIR22 mRNA

NCBI chr10:60,307,039...60,307,133
Ensembl chr10:60,307,039...60,307,133

G

microRNA 221

increases expression

benz(a)anthracene results in increased expression of MIR221 mRNA

NCBI chr X:3,429,465...3,429,573
Ensembl chr X:3,429,465...3,429,573

G

microRNA 23b

increases expression

benz(a)anthracene results in increased expression of MIR23B mRNA

NCBI chr17:1,813,667...1,813,763
Ensembl chr17:1,813,667...1,813,763

G

microRNA 33

decreases expression

benz(a)anthracene results in decreased expression of MIR33A mRNA

NCBI chr 7:113,713,855...113,713,923
Ensembl chr 7:113,713,855...113,713,923

G

microRNA let-7b

increases expression

benz(a)anthracene results in increased expression of MIRLET7B mRNA

NCBI chr 7:116,804,186...116,804,270
Ensembl chr 7:116,804,186...116,804,270

G

marker of proliferation Ki-67

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MKI67 mRNA

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

MKKS centrosomal shuttling protein

decreases expression

benz(a)anthracene results in decreased expression of MKKS mRNA

NCBI chr 3:124,201,877...124,221,142
Ensembl chr 3:124,201,877...124,220,162

G

melanophilin

increases expression

benz(a)anthracene results in increased expression of MLPH mRNA

NCBI chr 9:91,507,410...91,542,984
Ensembl chr 9:91,507,591...91,542,983

G

monocyte to macrophage differentiation-associated 2

decreases expression

benz(a)anthracene results in decreased expression of MMD2 mRNA

NCBI chr12:11,962,733...12,009,776
Ensembl chr12:11,962,757...12,009,773

G

matrix metallopeptidase 14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MMP14 mRNA

NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864

G

matrix metallopeptidase 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of MMP2 mRNA
Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of MMP2 mRNA]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 8

increases expression
multiple interactions

benz(a)anthracene results in increased expression of MMP8 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MMP8 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520

G

multimerin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MMRN2 mRNA

NCBI chr16:9,705,925...9,727,405
Ensembl chr16:9,705,892...9,727,405

G

myeloid cell nuclear differentiation antigen

decreases expression

benz(a)anthracene results in decreased expression of MNDA mRNA

NCBI chr13:86,017,888...86,035,556
Ensembl chr13:86,017,892...86,034,201

G

MORC family CW-type zinc finger 4

decreases expression

benz(a)anthracene results in decreased expression of MORC4 mRNA

NCBI chr X:103,477,366...103,529,026
Ensembl chr X:103,480,603...103,528,956

G

macrophage expressed 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MPEG1 mRNA

NCBI chr 1:209,452,176...209,456,692
Ensembl chr 1:209,452,133...209,458,855

G

M-phase phosphoprotein 10

decreases expression

benz(a)anthracene results in decreased expression of MPHOSPH10 mRNA

NCBI chr 1:117,948,134...117,964,149
Ensembl chr 1:117,948,134...117,964,149

G

myoregulin

decreases expression

benz(a)anthracene results in decreased expression of MRLN mRNA

NCBI chr20:18,406,789...18,423,805
Ensembl chr20:18,406,707...18,428,418

G

mitochondrial ribosomal protein S6

decreases expression

benz(a)anthracene results in decreased expression of MRPS6 mRNA

NCBI chr11:31,295,358...31,348,483
Ensembl chr11:31,295,614...31,348,484

G

membrane spanning 4-domains A1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of MS4A1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MS4A1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:207,906,370...207,927,028
Ensembl chr 1:207,906,374...207,918,512

G

membrane spanning 4-domains A4A

increases expression

benz(a)anthracene results in increased expression of MS4A4A mRNA

NCBI chr 1:208,060,507...208,085,121
Ensembl chr 1:208,046,971...208,085,119

G

membrane spanning 4-domains A8

increases expression

benz(a)anthracene results in increased expression of MS4A8A mRNA

NCBI chr 1:207,730,665...207,744,260
Ensembl chr 1:207,730,665...207,744,324

G

mesothelin

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MSLN mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MSLN mRNA

PMID:26377693 PMID:27858113

NCBI chr10:14,771,946...14,781,382
Ensembl chr10:14,771,961...14,777,643

G

macrophage scavenger receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MSR1 mRNA

NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676

G

mitochondrially encoded cytochrome c oxidase I

decreases expression

benz(a)anthracene results in decreased expression of COX1 mRNA

NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND4L mRNA

NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
Ensembl chr MT:9,870...10,166

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ND6 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND6 mRNA

PMID:26377693 PMID:27858113

NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like

increases expression
multiple interactions

benz(a)anthracene results in increased expression of MTHFD1L mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MTHFD1L mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905

G

myotubularin related protein 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MTMR10 mRNA

NCBI chr 1:117,859,355...117,910,839
Ensembl chr 1:117,859,267...117,910,849

G

metaxin 3

decreases expression

benz(a)anthracene results in decreased expression of MTX3 mRNA

NCBI chr 2:24,066,332...24,079,708
Ensembl chr 2:24,066,365...24,079,670

G

mucin 4, cell surface associated

increases expression

benz(a)anthracene results in increased expression of MUC4 mRNA

NCBI chr11:68,008,245...68,053,242

G

MX dynamin like GTPase 1

decreases expression

benz(a)anthracene results in decreased expression of MX2 mRNA

NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507

G

myeloid-associated differentiation marker

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of MYADM mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MYADM mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:65,864,180...65,874,701
Ensembl chr 1:65,864,173...65,874,035

G

myosin IG

increases expression
multiple interactions

benz(a)anthracene results in increased expression of MYO1G mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MYO1G mRNA

PMID:26377693 PMID:27858113

NCBI chr14:81,386,701...81,401,843
Ensembl chr14:81,386,701...81,401,843

G

myomesin 3

decreases expression

benz(a)anthracene results in decreased expression of MYOM3 mRNA

NCBI chr 5:147,992,737...148,043,282
Ensembl chr 5:147,992,737...148,043,274

G

nucleosome assembly protein 1-like 4

decreases expression

benz(a)anthracene results in decreased expression of NAP1L4 mRNA

NCBI chr 1:198,709,697...198,746,093
Ensembl chr 1:198,709,701...198,746,020

G

N-acetyltransferase 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NAT8 mRNA

NCBI chr 4:118,279,521...118,284,671
Ensembl chr 4:118,270,954...118,281,763

G

N-acetyltransferase 8B

decreases expression

benz(a)anthracene results in decreased expression of NAT8B mRNA

NCBI chr 4:118,359,445...118,364,351
Ensembl chr 4:118,359,443...118,363,563

G

neurobeachin-like 1

decreases expression

benz(a)anthracene results in decreased expression of NBEAL1 mRNA

NCBI chr 9:61,575,154...61,743,896
Ensembl chr 9:61,575,356...61,736,750

G

non-SMC condensin I complex, subunit H

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NCAPH mRNA

NCBI chr 3:114,371,937...114,399,178
Ensembl chr 3:114,371,941...114,399,180

G

nuclear cap binding protein subunit 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of NCBP2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NCBP2 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:68,821,026...68,829,863
Ensembl chr11:68,817,740...68,851,885

G

nuclear cap binding subunit 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NCBP3 mRNA

NCBI chr10:57,665,716...57,695,432
Ensembl chr10:57,665,716...57,695,432

G

neutral cholesterol ester hydrolase 1

increases expression

benz(a)anthracene results in increased expression of NCEH1 mRNA

NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588

G

NDC80 kinetochore complex component

decreases expression

benz(a)anthracene results in decreased expression of NDC80 mRNA

NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924

G

NADPH dependent diflavin oxidoreductase 1

decreases expression

benz(a)anthracene results in decreased expression of NDOR1 mRNA

NCBI chr 3:8,062,629...8,070,873
Ensembl chr 3:8,062,630...8,070,860

G

nebulin

decreases expression

benz(a)anthracene results in decreased expression of NEB mRNA

NCBI chr 3:36,613,677...36,811,618
Ensembl chr 3:36,613,716...36,811,574

G

N-terminal EF-hand calcium binding protein 1

decreases expression

benz(a)anthracene results in decreased expression of NECAB1 mRNA

NCBI chr 5:28,357,859...28,578,642
Ensembl chr 5:28,357,859...28,578,642
Ensembl chr 5:28,357,859...28,578,642

G

nectin cell adhesion molecule 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PVRL1 mRNA

NCBI chr 8:44,101,776...44,164,863
Ensembl chr 8:44,101,776...44,189,787

G

neural precursor cell expressed, developmentally down-regulated 9

multiple interactions

[benz(a)anthracene co-treated with TNF protein] results in increased expression of NEDD9 mRNA

NCBI chr17:23,289,793...23,468,026
Ensembl chr17:23,282,326...23,468,019

G

nuclear envelope integral membrane protein 2

increases expression

benz(a)anthracene results in increased expression of NEMP2 mRNA

NCBI chr 9:48,861,252...48,880,565
Ensembl chr 9:48,861,252...48,880,512

G

neuraminidase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NEU2 mRNA

NCBI chr 9:88,218,494...88,267,356
Ensembl chr 9:88,249,135...88,267,355

G

nuclear factor of activated T-cells 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NFATC1 mRNA

NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028

G

nuclear factor, erythroid 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NFE2 mRNA

NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108

G

nuclear factor, interleukin 3 regulated

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of NFIL3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NFIL3 mRNA

PMID:26377693 PMID:27858113

NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858

G

NFKB inhibitor alpha

multiple interactions

[benz(a)anthracene co-treated with TNF protein] results in increased phosphorylation of and results in increased degradation of NFKBIA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NFKB inhibitor delta

increases expression

benz(a)anthracene results in increased expression of NFKBID mRNA

NCBI chr 1:85,679,353...85,690,415
Ensembl chr 1:85,680,861...85,690,447

G

nuclear factor related to kappa B binding protein

increases expression

benz(a)anthracene results in increased expression of NFRKB mRNA

NCBI chr 8:29,831,802...29,863,360
Ensembl chr 8:29,831,812...29,863,359

G

nonhomologous end-joining factor 1

decreases expression

benz(a)anthracene results in decreased expression of NHEJ1 mRNA

NCBI chr 9:76,526,322...76,622,488
Ensembl chr 9:76,526,324...76,622,444

G

NHERF family PDZ scaffold protein 1

increases expression

benz(a)anthracene results in increased expression of NHERF1 mRNA

NCBI chr10:100,403,189...100,420,290
Ensembl chr10:100,403,069...100,420,598

G

NHL repeat containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NHLRC2 mRNA

NCBI chr 1:255,589,743...255,648,904
Ensembl chr 1:255,589,742...255,651,408

G

natural killer cell triggering receptor

affects expression
multiple interactions

benz(a)anthracene affects the expression of NKTR mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NKTR mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:121,380,010...121,420,495
Ensembl chr 8:121,382,436...121,418,314

G

NLR family, CARD domain containing 5

decreases expression

benz(a)anthracene results in decreased expression of NLRC5 mRNA

NCBI chr19:10,477,638...10,581,023
Ensembl chr19:10,477,628...10,562,121

G

nitric oxide synthase trafficking

decreases expression

benz(a)anthracene results in decreased expression of NOSTRIN mRNA

NCBI chr 3:53,904,746...53,970,995
Ensembl chr 3:53,904,827...53,970,988

G

notch receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NOTCH1 mRNA

NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531

G

NADPH oxidase organizer 1

increases expression

benz(a)anthracene results in increased expression of NOXO1 mRNA

NCBI chr10:13,723,253...13,726,008
Ensembl chr10:13,721,473...13,726,061

G

nephrocystin 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of NPHP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NPHP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:114,960,650...115,016,234
Ensembl chr 3:114,960,650...115,016,234

G

natriuretic peptide receptor 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPR3 mRNA

NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955

G

neuropeptide Y receptor Y1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPY1R mRNA

NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759

G

NAD(P)H quinone dehydrogenase 1

increases activity
increases expression
multiple interactions

benz(a)anthracene results in increased activity of NQO1 protein
benz(a)anthracene results in increased expression of NQO1 mRNA
1-(5-isoquinolinylsulfonyl)-3-methylpiperazine inhibits the reaction [benz(a)anthracene results in increased activity of NQO1 protein]; Dexamethasone inhibits the reaction [benz(a)anthracene results in increased activity of NQO1 protein]; Dexamethasone inhibits the reaction [benz(a)anthracene results in increased expression of NQO1 mRNA]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [benz(a)anthracene results in increased activity of NQO1 protein]]; Staurosporine inhibits the reaction [benz(a)anthracene results in increased activity of NQO1 protein]

PMID:7587946 PMID:9029048 PMID:17253728

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group D, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NR1D1 mRNA

NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705

G

nuclear receptor subfamily 1, group D, member 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of NR1D2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NR1D2 mRNA

PMID:26377693 PMID:27858113

NCBI chr15:7,524,257...7,550,553
Ensembl chr15:7,524,257...7,550,553

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

NR3C1 protein promotes the reaction [Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]]

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

nuclear receptor binding protein 2

decreases expression

benz(a)anthracene results in decreased expression of NRBP2 mRNA

NCBI chr 7:107,798,642...107,805,225
Ensembl chr 7:107,799,497...107,805,230

G

neuronal cell adhesion molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NRCAM mRNA

NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992

G

neuregulin 4

increases expression

benz(a)anthracene results in increased expression of NRG4 mRNA

NCBI chr 8:55,586,253...55,677,829
Ensembl chr 8:55,592,893...55,677,483

G

nuclear receptor binding SET domain protein 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of NSD1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NSD1 mRNA

PMID:26377693 PMID:27858113

NCBI chr17:9,311,963...9,426,373
Ensembl chr17:9,315,237...9,425,358

G

neuronal vesicle trafficking associated 2

increases expression

benz(a)anthracene results in increased expression of NSG2 mRNA

NCBI chr10:15,601,594...15,661,441
Ensembl chr10:15,601,596...15,661,441

G

neutral sphingomyelinase activation associated factor

increases expression

benz(a)anthracene results in increased expression of NSMAF mRNA

NCBI chr 5:19,517,795...19,578,773
Ensembl chr 5:19,518,348...19,577,627

G

5'-nucleotidase domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NT5DC2 mRNA

NCBI chr16:6,322,485...6,330,538
Ensembl chr16:6,322,236...6,330,537

G

neurotrophin 3

increases expression

benz(a)anthracene results in increased expression of NTF3 mRNA

NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596

G

netrin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NTN1 mRNA

NCBI chr10:52,899,933...53,098,591
Ensembl chr10:52,899,934...53,085,326

G

nudix hydrolase 13

increases expression

benz(a)anthracene results in increased expression of NUDT13 mRNA

NCBI chr15:4,001,787...4,022,404
Ensembl chr15:4,001,794...4,022,293

G

nuclear FMR1 interacting protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NUFIP2 mRNA

NCBI chr10:62,574,922...62,607,729
Ensembl chr10:62,574,882...62,600,346

G

nuclear protein 1, transcriptional regulator

increases expression

benz(a)anthracene results in increased expression of NUPR1 mRNA

NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281

G

nuclear RNA export factor 1

affects expression

benz(a)anthracene affects the expression of NXF1 mRNA

NCBI chr 1:205,655,442...205,668,637
Ensembl chr 1:205,655,375...205,668,636

G

neurexophilin and PC-esterase domain family, member 2

decreases expression

benz(a)anthracene results in decreased expression of NXPE2 mRNA

NCBI chr 8:48,661,708...48,695,555
Ensembl chr 8:48,661,708...48,698,035

G

neurexophilin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NXPH3 mRNA

NCBI chr10:80,456,283...80,459,949
Ensembl chr10:80,455,429...80,462,415

G

2'-5' oligoadenylate synthetase 2

decreases expression

benz(a)anthracene results in decreased expression of OAS2 mRNA

NCBI chr12:35,802,824...35,830,778
Ensembl chr12:35,806,759...35,829,371

G

O-GlcNAcase

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of OGA mRNA
benz(a)anthracene results in decreased expression of OGA mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:244,598,285...244,633,835
Ensembl chr 1:244,598,292...244,634,359

G

O-linked N-acetylglucosamine (GlcNAc) transferase

affects expression

benz(a)anthracene affects the expression of OGT mRNA

NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146

G

oxysterol binding protein-like 3

increases expression

benz(a)anthracene results in increased expression of OSBPL3 mRNA

NCBI chr 4:79,346,583...79,523,523
Ensembl chr 4:79,350,349...79,523,393

G

purinergic receptor P2X 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of P2RX7 mRNA

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

proliferation-associated 2G4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PA2G4 mRNA

NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331

G

PABPN1 like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PABPN1L mRNA

NCBI chr19:50,669,965...50,673,409
Ensembl chr19:50,669,967...50,673,366

G

phenylalanine hydroxylase

decreases expression

benz(a)anthracene results in decreased expression of PAH mRNA

NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130

G

p21 (RAC1) activated kinase 3

decreases expression

benz(a)anthracene results in decreased expression of PAK3 mRNA

NCBI chr X:107,116,308...107,374,342
Ensembl chr X:107,260,898...107,368,314

G

palladin, cytoskeletal associated protein

decreases expression

benz(a)anthracene results in decreased expression of PALLD mRNA

NCBI chr16:28,228,006...28,621,349
Ensembl chr16:27,981,354...28,621,337

G

palmdelphin

increases expression
multiple interactions

benz(a)anthracene results in increased expression of PALMD mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PALMD mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:204,889,526...204,941,355
Ensembl chr 2:204,889,533...204,941,519

G

poly(A) specific ribonuclease subunit PAN2

affects expression

benz(a)anthracene affects the expression of PAN2 mRNA

NCBI chr 7:729,146...747,744
Ensembl chr 7:729,562...747,744

G

pantothenate kinase 3

decreases expression

benz(a)anthracene results in decreased expression of PANK3 mRNA

NCBI chr10:20,229,129...20,252,955
Ensembl chr10:20,229,129...20,252,955

G

pantothenate kinase 4

increases expression

benz(a)anthracene results in increased expression of PANK4 mRNA

NCBI chr 5:165,525,340...165,542,139
Ensembl chr 5:165,525,402...165,542,135

G

poly (A) polymerase alpha

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PAPOLA mRNA

NCBI chr 6:124,682,015...124,734,706
Ensembl chr 6:124,682,105...124,734,468

G

progestin and adipoQ receptor family member 7

increases expression

benz(a)anthracene results in increased expression of PAQR7 mRNA

NCBI chr 5:146,709,159...146,720,577
Ensembl chr 5:146,708,900...146,720,673

G

prostate androgen-regulated mucin-like protein 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of PARM1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PARM1 mRNA

PMID:26377693 PMID:27858113

NCBI chr14:16,468,309...16,577,339
Ensembl chr14:16,468,459...16,577,314

G

poly (ADP-ribose) polymerase 1

increases cleavage

benz(a)anthracene results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

PAX3 and PAX7 binding protein 1

increases expression

benz(a)anthracene results in increased expression of PAXBP1 mRNA

NCBI chr11:30,272,037...30,301,504
Ensembl chr11:30,272,037...30,301,648

G

PDZ binding kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PBK mRNA

NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014

G

PBX homeobox 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PBX1 mRNA

NCBI chr13:80,278,766...80,588,563
Ensembl chr13:80,278,770...80,588,594

G

protocadherin 17

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PCDH17 mRNA

NCBI chr15:60,222,088...60,316,172
Ensembl chr15:60,222,004...60,313,999

G

protocadherin alpha subfamily C, 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of PCDHAC2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PCDHAC2 mRNA

PMID:26377693 PMID:27858113

Ensembl chr18:28,581,225...28,846,211

G

protocadherin gamma subfamily A, 9

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of PCDHGA9 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PCDHGA9 mRNA

PMID:26377693 PMID:27858113

NCBI chr18:29,564,614...29,667,865

G

piccolo (presynaptic cytomatrix protein)

increases expression

benz(a)anthracene results in increased expression of PCLO mRNA

NCBI chr 4:19,691,439...20,050,015
Ensembl chr 4:19,695,315...20,049,885

G

Purkinje cell protein 2

increases expression

benz(a)anthracene results in increased expression of PCP2 mRNA

NCBI chr12:1,681,659...1,683,899
Ensembl chr12:1,681,659...1,683,899

G

Purkinje cell protein 4-like 1

increases expression

benz(a)anthracene results in increased expression of PCP4L1 mRNA

NCBI chr13:83,588,992...83,612,631
Ensembl chr13:83,588,992...83,609,966

G

proprotein convertase subtilisin/kexin type 4

increases expression

benz(a)anthracene results in increased expression of PCSK4 mRNA

NCBI chr 7:9,381,366...9,389,589
Ensembl chr 7:9,381,361...9,389,585

G

phosphate cytidylyltransferase 2, ethanolamine

decreases expression

benz(a)anthracene results in decreased expression of PCYT2 mRNA

NCBI chr10:105,888,769...105,896,182
Ensembl chr10:105,888,775...105,896,172

G

phosphodiesterase 4A

increases expression
multiple interactions

benz(a)anthracene results in increased expression of PDE4A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PDE4A mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:19,690,816...19,753,538
Ensembl chr 8:19,703,290...19,751,961

G

phosphodiesterase 5A

decreases expression

benz(a)anthracene results in decreased expression of PDE5A mRNA

NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701

G

phosphodiesterase 6C

decreases expression

benz(a)anthracene results in decreased expression of PDE6C mRNA

NCBI chr 1:235,909,583...235,965,435
Ensembl chr 1:235,909,775...235,965,315

G

phosphodiesterase 9A

increases expression

benz(a)anthracene results in increased expression of PDE9A mRNA

NCBI chr20:9,469,809...9,562,949
Ensembl chr20:9,469,848...9,562,948

G

platelet derived growth factor receptor beta

increases expression

benz(a)anthracene results in increased expression of PDGFRB mRNA

NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843

G

protein disulfide isomerase family A, member 2

increases expression

benz(a)anthracene results in increased expression of PDIA2 mRNA

NCBI chr10:15,215,824...15,218,937
Ensembl chr10:15,215,824...15,220,931

G

PDZ and LIM domain 5

decreases expression

benz(a)anthracene results in decreased expression of PDLIM5 mRNA

NCBI chr 2:230,952,251...231,120,329
Ensembl chr 2:230,952,248...231,120,275

G

phosphatidylethanolamine binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PEBP1 mRNA

NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862

G

platelet and endothelial cell adhesion molecule 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PECAM1 mRNA

NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116

G

period circadian regulator 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER1 mRNA

NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431

G

period circadian regulator 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of PER2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

period circadian regulator 3

increases expression
multiple interactions

benz(a)anthracene results in increased expression of PER3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:161,460,228...161,495,404
Ensembl chr 5:161,459,533...161,495,607

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2

increases expression

benz(a)anthracene results in increased expression of PFKFB2 mRNA

NCBI chr13:42,147,473...42,174,699
Ensembl chr13:42,147,478...42,174,699

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PFKFB3 mRNA

NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125

G

post-GPI attachment to proteins 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of PGAP2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PGAP2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:156,591,540...156,618,116
Ensembl chr 1:156,591,615...156,618,114

G

progesterone receptor

multiple interactions
increases expression

bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [benz(a)anthracene results in increased expression of PGR mRNA]]; Tetradecanoylphorbol Acetate inhibits the reaction [benz(a)anthracene results in increased expression of PGR mRNA]

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

PH domain containing endocytic trafficking adaptor 2

increases expression

benz(a)anthracene results in increased expression of PHETA2 mRNA

NCBI chr 7:113,855,437...113,861,910
Ensembl chr 7:113,857,249...113,861,871

G

PHD finger protein 19

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHF19 mRNA

NCBI chr 3:18,175,281...18,197,289
Ensembl chr 3:18,175,282...18,196,405

G

PHD finger protein 20-like 1

decreases expression

benz(a)anthracene results in decreased expression of PHF20L1 mRNA

NCBI chr 7:98,330,580...98,396,526
Ensembl chr 7:98,330,580...98,396,526

G

PHD finger protein 21A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PHF21A mRNA

NCBI chr 3:78,158,760...78,331,903
Ensembl chr 3:78,194,549...78,331,865

G

pleckstrin homology-like domain, family A, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHLDA3 mRNA

NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335

G

PH domain and leucine rich repeat protein phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHLPP1 mRNA

NCBI chr13:22,308,532...22,530,978
Ensembl chr13:22,308,548...22,530,977

G

phosphotyrosine interaction domain containing 1

increases expression

benz(a)anthracene results in increased expression of PID1 mRNA

NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044

G

polymeric immunoglobulin receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PIGR mRNA

NCBI chr13:42,298,905...42,326,877
Ensembl chr13:42,298,914...42,326,875

G

phosphatidylinositol glycan anchor biosynthesis, class T

increases expression

benz(a)anthracene results in increased expression of PIGT mRNA

NCBI chr 3:153,227,749...153,236,922
Ensembl chr 3:153,227,420...153,236,887

G

PIH1 domain containing 2

increases expression

benz(a)anthracene results in increased expression of PIH1D2 mRNA

NCBI chr 8:50,966,885...50,976,901
Ensembl chr 8:50,966,885...50,975,656

G

paired immunoglobin-like type 2 receptor alpha

increases expression

benz(a)anthracene results in increased expression of PILRA mRNA

NCBI chr12:17,787,169...17,798,149
Ensembl chr12:17,787,127...17,798,094

G

Pim-1 proto-oncogene, serine/threonine kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PIM1 mRNA

NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174

G

PICALM interacting mitotic regulator

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PIMREG mRNA

NCBI chr10:56,669,603...56,674,540
Ensembl chr10:56,669,675...56,674,791

G

PIN2/TERF1 interacting, telomerase inhibitor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PINX1 mRNA

NCBI chr15:38,097,896...38,157,143
Ensembl chr15:38,097,886...38,157,140

G

phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PIP4P1 mRNA

NCBI chr15:24,146,854...24,150,739
Ensembl chr15:24,146,856...24,150,702

G

PITPNM family member 3

increases expression

benz(a)anthracene results in increased expression of PITPNM3 mRNA

NCBI chr10:56,674,697...56,766,552
Ensembl chr10:56,676,261...56,766,584

G

cAMP-dependent protein kinase inhibitor gamma

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PKIG mRNA

NCBI chr 3:152,330,477...152,398,085
Ensembl chr 3:152,366,041...152,398,082

G

protein kinase N3

increases expression
multiple interactions

benz(a)anthracene results in increased expression of PKN3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PKN3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:13,350,082...13,363,572
Ensembl chr 3:13,335,041...13,363,567

G

phospholipase A2, group IID

increases expression

benz(a)anthracene results in increased expression of PLA2G2D mRNA

NCBI chr 5:151,016,010...151,022,531
Ensembl chr 5:151,018,870...151,022,525

G

phospholipase A2 group VI

increases expression

benz(a)anthracene results in increased expression of PLA2G6 mRNA

NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114

G

phospholipase A2 group VII

increases expression

benz(a)anthracene results in increased expression of PLA2G7 mRNA

NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476

G

placenta associated 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLAC8 mRNA

NCBI chr14:9,052,601...9,074,264
Ensembl chr14:9,063,048...9,074,264

G

plasminogen activator, tissue type

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PLAT mRNA

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

phospholipase C beta 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of PLCB1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLCB1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:122,059,988...122,772,896
Ensembl chr 3:122,060,031...122,772,869

G

phospholipase C, delta 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLCD4 mRNA

NCBI chr 9:76,115,523...76,158,602
Ensembl chr 9:76,117,168...76,142,453

G

pleckstrin homology domain containing A8

decreases expression

benz(a)anthracene results in decreased expression of PLEKHA8 mRNA

NCBI chr 4:83,723,470...83,774,081
Ensembl chr 4:83,723,561...83,774,081

G

pleckstrin homology and coiled-coil domain containing D1

increases expression

benz(a)anthracene results in increased expression of PLEKHD1 mRNA

NCBI chr 6:100,340,655...100,371,942
Ensembl chr 6:100,340,655...100,371,941

G

pleckstrin homology and RhoGEF domain containing G6

increases expression

benz(a)anthracene results in increased expression of PLEKHG6 mRNA

NCBI chr 4:158,163,443...158,182,628
Ensembl chr 4:158,162,969...158,182,271

G

polo-like kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLK2 mRNA

NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947

G

polo-like kinase 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLK5 mRNA

NCBI chr 7:9,346,777...9,367,923
Ensembl chr 7:9,346,777...9,355,196

G

phospholipid phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PPAP2A mRNA

NCBI chr 2:44,439,002...44,500,430
Ensembl chr 2:44,438,994...44,501,268

G

plexin A2

decreases expression

benz(a)anthracene results in decreased expression of PLXNA2 mRNA

NCBI chr13:106,163,103...106,358,979
Ensembl chr13:106,163,103...106,358,979

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PMAIP1 mRNA

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

peripheral myelin protein 22

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PMP22 mRNA

NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714

G

PNN interacting serine and arginine rich protein

affects expression

benz(a)anthracene affects the expression of PNISR mRNA

NCBI chr 5:35,395,965...35,422,852
Ensembl chr 5:35,395,965...35,422,844

G

PNMA family member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PNMA2 mRNA

NCBI chr15:41,111,942...41,119,649
Ensembl chr15:41,112,009...41,121,427

G

pinin, desmosome associated protein

decreases expression

benz(a)anthracene results in decreased expression of PNN mRNA

NCBI chr 6:76,758,138...76,766,451
Ensembl chr 6:76,758,117...76,766,889

G

DNA polymerase gamma 2, accessory subunit

increases expression

benz(a)anthracene results in increased expression of POLG2 mRNA

NCBI chr10:91,712,586...91,723,008
Ensembl chr10:91,712,586...91,723,008

G

DNA polymerase eta

increases expression

benz(a)anthracene results in increased expression of POLH mRNA

NCBI chr 9:14,778,355...14,813,210
Ensembl chr 9:14,777,888...14,812,723

G

DNA polymerase kappa

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of POLK mRNA

NCBI chr 2:27,822,228...27,882,331
Ensembl chr 2:27,822,679...27,882,313

G

DNA polymerase mu

increases expression

benz(a)anthracene results in increased expression of POLM mRNA

NCBI chr14:80,707,075...80,716,677
Ensembl chr14:80,706,345...80,717,086

G

RNA polymerase I subunit B

decreases expression

benz(a)anthracene results in decreased expression of POLR1B mRNA

NCBI chr 3:116,333,910...116,358,385
Ensembl chr 3:116,333,889...116,358,379

G

paraoxonase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PON2 mRNA

NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248

G

POU class 2 homeobox associating factor 1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of POU2AF1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of POU2AF1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:51,521,813...51,548,819
Ensembl chr 8:51,474,015...51,548,819

G

peroxisome proliferator activated receptor alpha

increases expression

benz(a)anthracene results in increased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

PPARG coactivator 1 alpha

decreases expression

benz(a)anthracene results in decreased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

PPFIA binding protein 1

decreases expression

benz(a)anthracene results in decreased expression of PPFIBP1 mRNA

NCBI chr 4:179,807,579...179,951,428
Ensembl chr 4:179,808,794...179,951,428

G

peptidylprolyl isomerase G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PPIG mRNA

NCBI chr 3:54,484,023...54,512,929
Ensembl chr 3:54,484,023...54,512,926

G

protoporphyrinogen oxidase

affects expression

benz(a)anthracene affects the expression of PPOX mRNA

NCBI chr13:83,697,661...83,701,998
Ensembl chr13:83,664,891...83,701,805

G

protein phosphatase 1, regulatory subunit 3C

decreases expression

benz(a)anthracene results in decreased expression of PPP1R3C mRNA

NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961

G

protein phosphatase 4, regulatory subunit 4

increases expression

benz(a)anthracene results in increased expression of PPP4R4 mRNA

NCBI chr 6:122,663,172...122,753,988
Ensembl chr 6:122,663,344...122,753,384

G

protein kinase AMP-activated non-catalytic subunit gamma 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRKAG3 mRNA

NCBI chr 9:76,295,715...76,304,959
Ensembl chr 9:76,295,715...76,304,959

G

protein kinase C, beta

increases expression

benz(a)anthracene results in increased expression of PRKCB mRNA

NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536

G

protein kinase C, delta

multiple interactions

[rottlerin results in decreased activity of PRKCD protein] inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]]; PRKCD protein affects the susceptibility to [Tetradecanoylphorbol Acetate co-treated with benz(a)anthracene]

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

protein kinase C, epsilon

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRKCE mRNA

NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719

G

prolactin

multiple interactions

[Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

prolactin receptor

decreases expression

benz(a)anthracene results in decreased expression of PRLR mRNA

NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718

G

proline dehydrogenase

increases expression

benz(a)anthracene results in increased expression of PRODH mRNA

NCBI chr11:82,910,043...82,927,305
Ensembl chr11:82,910,137...82,927,305

G

proline and serine rich 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of PROSER2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PROSER2 mRNA

PMID:26377693 PMID:27858113

NCBI chr17:72,151,961...72,187,524
Ensembl chr17:72,151,872...72,185,825

G

protein Z, vitamin K-dependent plasma glycoprotein

increases expression

benz(a)anthracene results in increased expression of PROZ mRNA

NCBI chr16:76,450,013...76,463,558
Ensembl chr16:76,450,013...76,463,480

G

pre-mRNA processing factor 38B

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of PRPF38B mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRPF38B mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:196,553,224...196,562,271
Ensembl chr 2:196,553,225...196,562,250

G

pre-mRNA processing factor 39

increases expression

benz(a)anthracene results in increased expression of PRPF39 mRNA

NCBI chr 6:83,088,981...83,113,826
Ensembl chr 6:83,088,986...83,113,825

G

pre-mRNA processing factor 40 homolog B

increases expression

benz(a)anthracene results in increased expression of PRPF40B mRNA

NCBI chr 7:130,392,611...130,454,053
Ensembl chr 7:130,432,112...130,454,052

G

pre-mRNA processing factor 4B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRPF4B mRNA

NCBI chr17:29,985,343...30,020,285
Ensembl chr17:29,985,343...30,019,625

G

proline rich 5 like

increases expression

benz(a)anthracene results in increased expression of PRR5L mRNA

NCBI chr 3:88,001,951...88,173,532
Ensembl chr 3:88,003,617...88,082,763

G

proline rich 7 (synaptic)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRR7 mRNA

NCBI chr17:9,164,375...9,173,669
Ensembl chr17:9,165,269...9,172,536

G

proline rich and Gla domain 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRRG3 mRNA

NCBI chr X:149,666,498...149,689,353
Ensembl chr X:149,670,257...149,677,373

G

serine protease 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRSS12 mRNA

NCBI chr 2:211,624,134...211,684,126
Ensembl chr 2:211,624,134...211,684,126

G

serine protease 23

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRSS23 mRNA

NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091

G

PC4 and SRSF1 interacting protein 1

decreases expression

benz(a)anthracene results in decreased expression of PSIP1 mRNA

NCBI chr 5:97,847,010...97,879,280
Ensembl chr 5:97,847,015...97,879,257

G

proline and serine rich coiled-coil 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PSRC1 mRNA

NCBI chr 2:196,022,361...196,026,874
Ensembl chr 2:196,022,361...196,026,874

G

polypyrimidine tract binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTBP1 mRNA

NCBI chr 7:9,842,574...9,852,332
Ensembl chr 7:9,842,574...9,852,397

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[benz(a)anthracene co-treated with TNF protein] results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

prothymosin alpha

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTMA mRNA

NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333

G

protein tyrosine phosphatase, non-receptor type 5

decreases expression

benz(a)anthracene results in decreased expression of PTPN5 mRNA

NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:97,620,642...97,679,882

G

protein tyrosine phosphatase, non-receptor type 6

increases expression

benz(a)anthracene results in increased expression of PTPN6 mRNA

NCBI chr 4:157,526,034...157,550,783
Ensembl chr 4:157,526,035...157,550,984

G

protein tyrosine phosphatase, non-receptor type 9

decreases expression

benz(a)anthracene results in decreased expression of PTPN9 mRNA

NCBI chr 8:57,391,290...57,472,352
Ensembl chr 8:57,391,259...57,470,952

G

protein tyrosine phosphatase, receptor type, B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTPRB mRNA

NCBI chr 7:51,953,375...52,034,751
Ensembl chr 7:51,930,015...52,034,748

G

protein tyrosine phosphatase, receptor type, G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PTPRG mRNA

NCBI chr15:12,871,706...13,552,186
Ensembl chr15:12,871,721...13,554,094

G

RAB11 family interacting protein 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of RAB11FIP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RAB11FIP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:64,886,902...64,917,491
Ensembl chr16:64,884,676...64,917,491

G

RAB44, member RAS oncogene family

increases expression

benz(a)anthracene results in increased expression of RAB44 mRNA

NCBI chr20:7,164,576...7,198,473
Ensembl chr20:7,164,720...7,198,468

G

rabaptin, RAB GTPase binding effector protein 2

affects expression

benz(a)anthracene affects the expression of RABEP2 mRNA

NCBI chr 1:181,010,305...181,026,651
Ensembl chr 1:181,010,305...181,026,648

G

RAD51 recombinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAD51 mRNA

NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035

G

retinoic acid induced 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAI2 mRNA

NCBI chr X:32,948,656...33,011,222
Ensembl chr X:32,948,656...33,011,264

G

Ral GTPase activating protein catalytic subunit alpha 2

increases expression

benz(a)anthracene results in increased expression of RALGAPA2 mRNA

NCBI chr 3:133,658,725...133,938,821
Ensembl chr 3:133,659,761...133,938,916

G

receptor activity modifying protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAMP3 mRNA

NCBI chr14:81,527,404...81,544,905
Ensembl chr14:81,527,385...81,544,902

G

Rap1 GTPase-activating protein

increases expression

benz(a)anthracene results in increased expression of RAP1GAP mRNA

NCBI chr 5:149,873,987...149,939,254
Ensembl chr 5:149,892,019...149,939,253

G

Ras association (RalGDS/AF-6) and pleckstrin homology domains 1

increases expression

benz(a)anthracene results in increased expression of RAPH1 mRNA

NCBI chr 9:61,907,476...61,990,170
Ensembl chr 9:61,907,758...61,961,209

G

retinoic acid receptor, alpha

increases expression

benz(a)anthracene results in increased expression of RARA mRNA

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

RASD family, member 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of RASD2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASD2 mRNA

PMID:26377693 PMID:27858113

NCBI chr19:13,594,291...13,605,016
Ensembl chr19:13,594,291...13,605,016

G

RasGEF domain family, member 1C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASGEF1C mRNA

NCBI chr10:34,227,483...34,293,676
Ensembl chr10:34,227,483...34,293,675

G

RAS guanyl releasing protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASGRP3 mRNA

NCBI chr 6:19,895,361...19,993,945
Ensembl chr 6:19,895,390...19,958,578

G

RAS-like family 11 member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RASL11A mRNA

NCBI chr12:8,258,148...8,260,909
Ensembl chr12:8,258,159...8,262,576

G

Ras association domain family member 4

decreases expression

benz(a)anthracene results in decreased expression of RASSF4 mRNA

NCBI chr 4:149,897,525...149,932,658
Ensembl chr 4:149,897,543...149,932,411

G

RB binding protein 6, ubiquitin ligase

increases expression

benz(a)anthracene results in increased expression of RBBP6 mRNA

NCBI chr 1:177,503,988...177,537,397
Ensembl chr 1:177,503,313...177,535,678

G

RNA binding motif protein 15B

decreases expression

benz(a)anthracene results in decreased expression of RBM15B mRNA

NCBI chr 8:107,543,613...107,546,678
Ensembl chr 8:107,525,898...107,551,696

G

RNA binding motif protein 26

increases expression

benz(a)anthracene results in increased expression of RBM26 mRNA

NCBI chr15:81,884,783...81,964,245
Ensembl chr15:81,887,219...81,964,118

G

RNA binding motif protein 3

decreases expression

benz(a)anthracene results in decreased expression of RBM3 mRNA

NCBI chr X:14,348,909...14,352,387
Ensembl chr X:14,348,910...14,353,580

G

RNA binding motif protein 33

affects expression

benz(a)anthracene affects the expression of RBM33 mRNA

NCBI chr 4:6,980,807...7,088,334
Ensembl chr 4:6,983,970...7,089,918

G

RNA binding motif protein 39

increases expression

benz(a)anthracene results in increased expression of RBM39 mRNA

NCBI chr 3:144,662,998...144,696,222
Ensembl chr 3:144,663,001...144,696,213

G

RNA binding motif protein, X-linked

increases expression

benz(a)anthracene results in increased expression of RBMX mRNA

NCBI chr X:135,305,237...135,314,806
Ensembl chr X:135,305,325...135,314,743

G

retinol binding protein 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of RBP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RBP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:99,025,218...99,046,740
Ensembl chr 8:99,025,206...99,046,743

G

recombination signal binding protein for immunoglobulin kappa J region-like

increases expression

benz(a)anthracene results in increased expression of RBPJL mRNA

NCBI chr 3:153,134,044...153,147,421
Ensembl chr 3:153,134,140...153,146,513

G

retinol dehydrogenase 5

increases expression

benz(a)anthracene results in increased expression of RDH5 mRNA

NCBI chr 7:1,341,172...1,346,863
Ensembl chr 7:1,340,934...1,351,558

G

receptor accessory protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REEP1 mRNA

NCBI chr 4:103,746,004...103,862,347
Ensembl chr 4:103,745,633...103,862,338

G

receptor accessory protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REEP2 mRNA

NCBI chr18:26,438,130...26,447,165
Ensembl chr18:26,438,346...26,447,161

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

RELA protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

REV1, DNA directed polymerase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REV1 mRNA

NCBI chr 9:40,278,100...40,351,764
Ensembl chr 9:40,278,101...40,351,576

G

regulator of G-protein signaling 11

increases expression

benz(a)anthracene results in increased expression of RGS11 mRNA

NCBI chr10:15,222,804...15,231,062
Ensembl chr10:15,222,803...15,231,060

G

regulator of G-protein signaling 12

increases expression
multiple interactions

benz(a)anthracene results in increased expression of RGS12 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RGS12 mRNA

PMID:26377693 PMID:27858113

NCBI chr14:75,715,925...75,824,012
Ensembl chr14:75,715,934...75,794,596

G

regulator of G-protein signaling 2

increases expression

benz(a)anthracene results in increased expression of RGS2 mRNA

NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385

G

regulator of G-protein signaling 3

increases expression

benz(a)anthracene results in increased expression of RGS3 mRNA

NCBI chr 5:76,022,038...76,161,895
Ensembl chr 5:76,022,001...76,161,894

G

regulator of G-protein signaling 7 binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RGS7BP mRNA

NCBI chr 2:36,133,944...36,231,505
Ensembl chr 2:36,139,201...36,231,505

G

regulator of G-protein signaling 9

increases expression

benz(a)anthracene results in increased expression of RGS9 mRNA

NCBI chr10:94,195,265...94,270,892
Ensembl chr10:94,197,054...94,270,892

G

ras homolog family member B

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of RHOB mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RHOB mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108

G

ras homolog family member C

increases expression

benz(a)anthracene results in increased expression of RHOC mRNA

NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306

G

ras homolog family member U

decreases expression

benz(a)anthracene results in decreased expression of RHOU mRNA

NCBI chr19:51,641,476...51,651,249
Ensembl chr19:51,641,227...51,650,552

G

reproductive homeobox 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RHOX8 mRNA

NCBI chr X:116,584,742...116,588,365
Ensembl chr X:116,584,582...116,588,365

G

Ras and Rab interactor 2

decreases expression

benz(a)anthracene results in decreased expression of RIN2 mRNA

NCBI chr 3:133,086,858...133,303,604
Ensembl chr 3:133,086,749...133,303,604

G

RHO family interacting cell polarization regulator 2

increases expression

benz(a)anthracene results in increased expression of RIPOR2 mRNA

NCBI chr17:40,323,748...40,547,482
Ensembl chr17:40,323,867...40,548,092

G

ripply transcriptional repressor 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RIPPLY3 mRNA

NCBI chr11:33,648,471...33,656,587
Ensembl chr11:33,648,486...33,656,584

G

regulator of microtubule dynamics 1

increases expression

benz(a)anthracene results in increased expression of RMDN1 mRNA

NCBI chr 5:33,070,267...33,093,922
Ensembl chr 5:33,070,265...33,127,328

G

ribonuclease A family member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RNASE10 mRNA

NCBI chr15:24,226,687...24,229,149
Ensembl chr15:24,226,691...24,228,561

G

ribonuclease H2, subunit B

increases expression
multiple interactions

benz(a)anthracene results in increased expression of RNASEH2B mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RNASEH2B mRNA

PMID:26377693 PMID:27858113

NCBI chr15:36,541,200...36,592,016
Ensembl chr15:36,541,218...36,584,118

G

ring finger protein 144A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RNF144A mRNA

NCBI chr 6:42,899,767...43,019,769
Ensembl chr 6:42,903,174...43,020,012

G

ring finger protein 169

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RNF169 mRNA

NCBI chr 1:154,250,462...154,311,867
Ensembl chr 1:154,254,473...154,311,653

G

Rho-associated coiled-coil containing protein kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ROCK2 mRNA

NCBI chr 6:39,679,116...39,774,033
Ensembl chr 6:39,679,082...39,774,031

G

RAR-related orphan receptor C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RORC mRNA

NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907

G

RNA polymerase II associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RPAP2 mRNA

NCBI chr14:2,109,044...2,187,343
Ensembl chr14:2,109,053...2,187,350

G

reprimo, TP53 dependent G2 arrest mediator homolog

increases expression

benz(a)anthracene results in increased expression of RPRM mRNA

NCBI chr 3:38,539,581...38,540,998
Ensembl chr 3:38,539,581...38,540,998

G

ribosomal protein S27-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RPS27L mRNA

NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418

G

ribonucleotide reductase catalytic subunit M1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RRM1 mRNA

NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261

G

ribonucleotide reductase regulatory subunit M2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RRM2 mRNA

NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773

G

RRN3 homolog, RNA polymerase I transcription factor

increases expression

benz(a)anthracene results in increased expression of RRN3 mRNA

NCBI chr10:2,129,949...2,165,381
Ensembl chr10:2,129,978...2,165,663

G

ribosomal RNA processing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RRP1 mRNA

NCBI chr20:10,260,892...10,272,141
Ensembl chr20:10,260,870...10,272,144

G

ribosomal RNA processing 12

decreases expression

benz(a)anthracene results in decreased expression of RRP12 mRNA

NCBI chr 1:240,672,378...240,705,992
Ensembl chr 1:240,672,382...240,706,018

G

retinoschisin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RS1 mRNA

NCBI chr X:33,962,440...33,992,203
Ensembl chr X:33,963,657...33,992,115

G

radical S-adenosyl methionine domain containing 2

decreases expression

benz(a)anthracene results in decreased expression of RSAD2 mRNA

NCBI chr 6:43,046,514...43,059,737
Ensembl chr 6:43,047,658...43,059,699

G

RT1 class II, locus DOa

increases expression
multiple interactions

benz(a)anthracene results in increased expression of H2-OA mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H2-OA mRNA

PMID:26377693 PMID:27858113

NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577

G

RT1 class II, locus DOb

increases expression
multiple interactions

benz(a)anthracene results in increased expression of H2-OB mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H2-OB mRNA

PMID:26377693 PMID:27858113

NCBI chr20:4,619,418...4,625,627
Ensembl chr20:4,619,816...4,625,667

G

regulator of telomere elongation helicase 1

increases expression

benz(a)anthracene results in increased expression of RTEL1 mRNA

NCBI chr 3:168,427,247...168,465,349
Ensembl chr 3:168,419,579...168,465,348

G

receptor (chemosensory) transporter protein 3

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of RTP3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RTP3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:110,970,154...110,975,000
Ensembl chr 8:110,970,160...110,974,699

G

RUN and FYVE domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RUFY2 mRNA

NCBI chr20:25,626,958...25,658,157
Ensembl chr20:25,621,999...25,658,186

G

RUN and FYVE domain containing 4

increases expression

benz(a)anthracene results in increased expression of RUFY4 mRNA

NCBI chr 9:75,702,937...75,727,719
Ensembl chr 9:75,703,750...75,723,525

G

RWD domain containing 3

increases expression

benz(a)anthracene results in increased expression of RWDD3 mRNA

NCBI chr 2:209,233,622...209,254,842
Ensembl chr 2:209,233,622...209,248,853

G

S100 calcium binding protein A14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S100A14 mRNA

NCBI chr 2:176,008,395...176,010,423
Ensembl chr 2:176,008,395...176,010,423

G

S100 calcium binding protein A6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S100A6 mRNA

NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180

G

sphingosine-1-phosphate receptor 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of S1PR1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S1PR1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:203,624,752...203,629,110
Ensembl chr 2:203,621,587...203,629,681

G

SAC3 domain containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SAC3D1 mRNA

NCBI chr 1:203,414,184...203,416,563
Ensembl chr 1:203,414,187...203,416,604

G

sterile alpha motif domain containing 9 like

decreases expression

benz(a)anthracene results in decreased expression of SAMD9L mRNA

NCBI chr 4:31,362,054...31,376,412
Ensembl chr 4:31,361,669...31,376,415

G

Sin3A-associated protein 25

increases expression

benz(a)anthracene results in increased expression of SAP25 mRNA

NCBI chr12:19,055,762...19,057,425
Ensembl chr12:19,055,763...19,076,089

G

stabilizer of axonemal microtubules 2

increases expression

benz(a)anthracene results in increased expression of SAXO2 mRNA

NCBI chr 1:136,596,445...136,638,444
Ensembl chr 1:136,623,493...136,638,454

G

stearoyl-CoA desaturase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SCD1 mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

sodium voltage-gated channel beta subunit 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SCN3B mRNA

NCBI chr 8:40,630,372...40,652,869
Ensembl chr 8:40,630,455...40,652,868

G

sodium voltage-gated channel beta subunit 4

increases expression

benz(a)anthracene results in increased expression of SCN4B mRNA

NCBI chr 8:45,446,580...45,462,294
Ensembl chr 8:45,446,215...45,462,292

G

short coiled-coil protein

decreases expression

benz(a)anthracene results in decreased expression of SCOC mRNA

NCBI chr19:24,659,651...24,689,237
Ensembl chr19:24,659,651...24,693,217

G

SCY1 like pseudokinase 3

increases expression

benz(a)anthracene results in increased expression of SCYL3 mRNA

NCBI chr13:76,278,428...76,303,038
Ensembl chr13:76,278,428...76,301,716

G

stromal cell derived factor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SDF4 mRNA

NCBI chr 5:166,586,581...166,606,661
Ensembl chr 5:166,586,390...166,604,521

G

selectin L

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SELL mRNA

NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456

G

semaphorin 3C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SEMA3C mRNA

NCBI chr 4:17,583,212...17,747,234
Ensembl chr 4:17,583,212...17,746,534

G

septin 11

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SEPTIN11 mRNA

NCBI chr14:14,844,759...14,990,856
Ensembl chr14:14,844,580...14,990,853

G

septin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SEPTIN3 mRNA

NCBI chr 7:113,783,217...113,811,089
Ensembl chr 7:113,783,095...113,811,087

G

stress-associated endoplasmic reticulum protein family member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERP2 mRNA

NCBI chr15:51,879,882...51,903,958
Ensembl chr15:51,879,877...51,904,785

G

serpin family A member 10

increases expression

benz(a)anthracene results in increased expression of SERPINA10 mRNA

NCBI chr 6:122,756,106...122,764,544
Ensembl chr 6:122,756,108...122,764,544

G

serpin family B member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINB10 mRNA

NCBI chr13:23,553,348...23,571,182
Ensembl chr13:23,553,430...23,571,182

G

serpin family B member 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINB1A mRNA

NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102

G

serpin family E member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

SERTA domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SERTAD2 mRNA

NCBI chr14:94,733,637...94,838,200
Ensembl chr14:94,733,579...94,838,313

G

sestrin 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SESN2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SESN2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

SET domain containing 1B, histone lysine methyltransferase

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SETD1B mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SETD1B mRNA

PMID:26377693 PMID:27858113

NCBI chr12:33,395,963...33,421,671
Ensembl chr12:33,396,120...33,426,934

G

SET domain containing 4

increases expression

benz(a)anthracene results in increased expression of SETD4 mRNA

NCBI chr11:32,829,509...32,859,162
Ensembl chr11:32,838,063...32,858,243

G

SFI1 centrin binding protein

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SFI1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SFI1 mRNA

PMID:26377693 PMID:27858113

NCBI chr14:77,990,965...78,048,352
Ensembl chr14:77,990,965...78,048,255

G

stratifin

decreases expression

benz(a)anthracene results in decreased expression of SFN mRNA

NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314

G

secreted frizzled-related protein 2

decreases expression

benz(a)anthracene results in decreased expression of SFRP2 mRNA

NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063

G

sideroflexin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SFXN2 mRNA

NCBI chr 1:245,447,014...245,459,312
Ensembl chr 1:245,447,015...245,468,411
Ensembl chr 1:245,447,015...245,468,411

G

sphingomyelin synthase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SGMS1 mRNA

NCBI chr 1:229,996,673...230,259,591
Ensembl chr 1:229,998,119...230,259,603

G

SH3 domain containing 19

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SH3D19 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SH3D19 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:171,356,244...171,516,042
Ensembl chr 2:171,356,251...171,515,561

G

SH3 and PX domains 2A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SH3PXD2A mRNA

NCBI chr 1:246,153,660...246,359,806
Ensembl chr 1:246,160,502...246,360,166

G

SHC adaptor protein 3

decreases expression

benz(a)anthracene results in decreased expression of SHC3 mRNA

NCBI chr17:13,652,247...13,772,710
Ensembl chr17:13,651,202...13,772,710

G

SHC adaptor protein 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SHC4 mRNA

NCBI chr 3:112,880,598...112,974,216
Ensembl chr 3:112,880,600...112,974,366

G

shisa family member 2

increases expression

benz(a)anthracene results in increased expression of SHISA2 mRNA

NCBI chr15:33,806,715...33,811,013
Ensembl chr15:33,805,958...33,811,013

G

shieldin complex subunit 2

decreases expression

benz(a)anthracene results in decreased expression of SHLD2 mRNA

NCBI chr16:9,544,940...9,640,323
Ensembl chr16:9,548,660...9,639,965

G

signal-induced proliferation-associated 1 like 2

increases expression

benz(a)anthracene results in increased expression of SIPA1L2 mRNA

NCBI chr19:53,389,792...53,540,466
Ensembl chr19:53,389,805...53,540,428

G

sirtuin 4

increases expression

benz(a)anthracene results in increased expression of SIRT4 mRNA

NCBI chr12:41,125,533...41,139,440
Ensembl chr12:41,131,262...41,139,439

G

src kinase associated phosphoprotein 1

increases expression

benz(a)anthracene results in increased expression of SKAP1 mRNA

NCBI chr10:81,425,472...81,732,651
Ensembl chr10:81,425,525...81,732,650

G

solute carrier family 15 member 2

affects expression

benz(a)anthracene affects the expression of SLC15A2 mRNA

NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225

G

solute carrier family 19 member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC19A2 mRNA

NCBI chr13:76,601,975...76,616,175
Ensembl chr13:76,601,900...76,616,172

G

solute carrier family 25 member 33

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC25A33 mRNA

NCBI chr 5:160,195,040...160,219,961
Ensembl chr 5:160,195,042...160,219,961

G

solute carrier family 25, member 45

increases expression

benz(a)anthracene results in increased expression of SLC25A45 mRNA

NCBI chr 1:203,166,362...203,174,473
Ensembl chr 1:203,166,683...203,174,473

G

solute carrier family 26, member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC26A10 mRNA

NCBI chr 7:62,995,165...63,005,099
Ensembl chr 7:62,995,381...63,004,087

G

solute carrier family 26 member 11

increases expression

benz(a)anthracene results in increased expression of SLC26A11 mRNA

NCBI chr10:104,613,498...104,635,873
Ensembl chr10:104,613,564...104,635,970

G

solute carrier family 26 member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC26A4 mRNA

NCBI chr 6:48,107,575...48,153,762
Ensembl chr 6:48,107,588...48,145,703

G

solute carrier family 2 member 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC2A6 mRNA

NCBI chr 3:10,348,395...10,355,208
Ensembl chr 3:10,348,395...10,355,208

G

solute carrier family 2 member 9

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC2A9 mRNA

NCBI chr14:72,328,334...72,461,981
Ensembl chr14:72,328,320...72,461,981

G

solute carrier family 30 member 1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of SLC30A1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC30A1 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:103,491,037...103,494,910
Ensembl chr13:103,491,037...103,494,910

G

solute carrier family 35 member D1

decreases expression

benz(a)anthracene results in decreased expression of SLC35D1 mRNA

NCBI chr 5:117,928,628...117,981,289
Ensembl chr 5:117,934,352...117,981,311

G

solute carrier family 35, member G2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC35G2 mRNA

NCBI chr 8:101,085,579...101,113,339
Ensembl chr 8:101,085,545...101,113,349

G

solute carrier family 36 member 2

increases expression

benz(a)anthracene results in increased expression of SLC36A2 mRNA

NCBI chr10:39,278,002...39,306,082
Ensembl chr10:39,278,046...39,306,082

G

solute carrier family 3 member 2

increases expression

benz(a)anthracene results in increased expression of SLC3A2 mRNA

NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931

G

solute carrier family 43, member 3

decreases expression

benz(a)anthracene results in decreased expression of SLC43A3 mRNA

NCBI chr 3:70,008,160...70,030,324
Ensembl chr 3:70,009,313...70,029,749

G

solute carrier family 45, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC45A4 mRNA

NCBI chr 7:105,478,886...105,550,160
Ensembl chr 7:105,481,792...105,550,170

G

solute carrier family 46, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC46A3 mRNA

NCBI chr12:7,140,610...7,157,093
Ensembl chr12:7,140,668...7,157,092

G

solute carrier family 49 member 4

decreases expression

benz(a)anthracene results in decreased expression of SLC49A4 mRNA

NCBI chr11:64,995,629...65,068,929
Ensembl chr11:64,995,679...65,068,926

G

solute carrier family 50 member 1

increases expression

benz(a)anthracene results in increased expression of RAG1AP1 mRNA

NCBI chr 2:174,677,985...174,680,366
Ensembl chr 2:174,677,708...174,680,366

G

solute carrier family 5 member 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC5A12 mRNA

NCBI chr 3:97,179,326...97,228,405
Ensembl chr 3:97,179,326...97,228,405

G

solute carrier family 5 member 3

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SLC5A3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC5A3 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:31,313,847...31,316,293
Ensembl chr11:31,295,476...31,318,883

G

solute carrier family 66 member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC66A3 mRNA

NCBI chr 6:39,774,801...39,786,554
Ensembl chr 6:39,774,808...39,786,303

G

solute carrier family 7 member 11

decreases expression

benz(a)anthracene results in decreased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

solute carrier family 7 member 5

increases expression

benz(a)anthracene results in increased expression of SLC7A5 mRNA

NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823

G

solute carrier family 8 member A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC8A1 mRNA

NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628

G

solute carrier organic anion transporter family, member 2b1

increases expression

benz(a)anthracene results in increased expression of SLCO2B1 mRNA

NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353

G

SMG1, nonsense mediated mRNA decay associated PI3K related kinase

affects expression

benz(a)anthracene affects the expression of SMG1 mRNA

NCBI chr 1:172,441,892...172,543,667
Ensembl chr 1:172,444,936...172,543,698

G

sphingomyelin phosphodiesterase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SMPD2 mRNA

NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441

G

SMAD specific E3 ubiquitin protein ligase 2

decreases expression

benz(a)anthracene results in decreased expression of SMURF2 mRNA

NCBI chr10:91,761,798...91,862,485
Ensembl chr10:91,761,807...91,862,488

G

snail family transcriptional repressor 1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [benz(a)anthracene results in increased expression of SNAI1 mRNA]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of SNAI1 mRNA]

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

synaptosome associated protein 23

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SNAP23 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SNAP23 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:107,514,088...107,546,177
Ensembl chr 3:107,514,131...107,544,320

G

synaptosome associated protein 47

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SNAP47 mRNA

NCBI chr10:44,192,886...44,234,435
Ensembl chr10:44,191,218...44,234,424

G

sushi, nidogen and EGF-like domains 1

affects expression

benz(a)anthracene affects the expression of SNED1 mRNA

NCBI chr 9:93,774,087...93,834,003
Ensembl chr 9:93,774,119...93,830,694

G

small nucleolar RNA host gene 11

affects expression

benz(a)anthracene affects the expression of SNHG11 mRNA

NCBI chr 3:147,031,367...147,037,043

G

small nucleolar RNA, H/ACA box 47

decreases expression

benz(a)anthracene results in decreased expression of SNORA47 mRNA

NCBI chr 2:26,594,260...26,594,397
Ensembl chr 2:26,594,260...26,594,397

G

small nucleolar RNA, H/ACA box 74A

decreases expression

benz(a)anthracene results in decreased expression of SNORA74A mRNA

NCBI chr18:27,157,765...27,157,961
Ensembl chr18:27,157,765...27,157,961

G

small nucleolar RNA, C/D box 123

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SNORD123 mRNA

NCBI chr 2:83,306,918...83,306,987
Ensembl chr 2:83,306,918...83,306,987

G

small nuclear ribonucleoprotein U1 subunit 70

decreases expression

benz(a)anthracene results in decreased expression of SNRNP70 mRNA

NCBI chr 1:95,856,038...95,876,434
Ensembl chr 1:95,856,036...95,876,392

G

syntrophin, beta 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SNTB1 mRNA

NCBI chr 7:87,060,926...87,329,315
Ensembl chr 7:87,060,926...87,329,315

G

sorbitol dehydrogenase

increases expression
multiple interactions

benz(a)anthracene results in increased expression of SORD mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SORD mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133

G

SRY-box transcription factor 17

increases expression
multiple interactions

benz(a)anthracene results in increased expression of SOX17 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SOX17 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228

G

SRY-box transcription factor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SOX4 mRNA

NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665

G

spermatogenesis associated 1

increases expression

benz(a)anthracene results in increased expression of SPATA1 mRNA

NCBI chr 2:235,349,126...235,394,578
Ensembl chr 2:235,349,127...235,394,502

G

spermatogenesis associated 22

decreases expression

benz(a)anthracene results in decreased expression of SPATA22 mRNA

NCBI chr10:57,945,272...57,963,081
Ensembl chr10:57,932,187...57,963,081

G

spermatogenesis associated 2-like

increases expression

benz(a)anthracene results in increased expression of SPATA2L mRNA

NCBI chr19:51,269,078...51,273,605
Ensembl chr19:51,269,078...51,273,510

G

spermatogenesis associated 7

increases expression

benz(a)anthracene results in increased expression of SPATA7 mRNA

NCBI chr 6:117,879,828...117,925,284
Ensembl chr 6:117,879,823...117,925,284

G

SPC25 component of NDC80 kinetochore complex

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SPC25 mRNA

NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959

G

signal peptidase complex subunit 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SPCS2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPCS2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:154,163,724...154,183,152
Ensembl chr 1:154,163,724...154,183,186

G

sperm flagellar 2

increases expression

benz(a)anthracene results in increased expression of SPEF2 mRNA

NCBI chr 2:58,512,489...58,694,718
Ensembl chr 2:58,512,489...58,694,664

G

Spi-B transcription factor

increases expression

benz(a)anthracene results in increased expression of SPIB mRNA

NCBI chr 1:95,018,939...95,024,804
Ensembl chr 1:95,018,947...95,024,780

G

spindlin 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SPIN1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPIN1 mRNA

PMID:26377693 PMID:27858113

NCBI chr17:14,055,685...14,105,366
Ensembl chr17:14,055,689...14,105,411

G

spondin 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SPON2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPON2 mRNA

PMID:26377693 PMID:27858113

NCBI chr14:77,505,695...77,518,001
Ensembl chr14:77,511,901...77,517,996

G

speckle type BTB/POZ protein

decreases expression

benz(a)anthracene results in decreased expression of SPOP mRNA

NCBI chr10:80,358,121...80,438,983
Ensembl chr10:80,358,124...80,483,955

G

spectrin, alpha, non-erythrocytic 1

decreases expression

benz(a)anthracene results in decreased expression of SPTAN1 mRNA

NCBI chr 3:13,241,164...13,306,047
Ensembl chr 3:13,241,217...13,306,046

G

spectrin, beta, non-erythrocytic 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPTBN1 mRNA

NCBI chr14:103,841,713...104,016,900
Ensembl chr14:103,842,684...104,008,507

G

serglycin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SRGN mRNA

NCBI chr20:30,442,810...30,479,549
Ensembl chr20:30,442,813...30,457,406

G

SRSF protein kinase 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SRPK3 mRNA

NCBI chr X:151,510,452...151,515,208
Ensembl chr X:151,510,539...151,515,198

G

serine/arginine repetitive matrix 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SRRM2 mRNA

NCBI chr10:12,815,471...12,848,750
Ensembl chr10:12,815,471...12,848,751

G

serine and arginine rich splicing factor 11

decreases expression

benz(a)anthracene results in decreased expression of SRSF11 mRNA

NCBI chr 2:247,074,623...247,101,460
Ensembl chr 2:247,074,631...247,101,425

G

serine and arginine rich splicing factor 5

affects expression

benz(a)anthracene affects the expression of SRSF5 mRNA

NCBI chr 6:100,605,165...100,610,192
Ensembl chr 6:100,605,456...100,610,177

G

serine and arginine rich splicing factor 6

increases expression

benz(a)anthracene results in increased expression of SFRS6 mRNA

NCBI chr 3:151,589,546...151,594,869
Ensembl chr 3:151,589,535...151,594,860

G

small RNA binding exonuclease protection factor La

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SSB mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SSB mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:54,616,616...54,626,203
Ensembl chr 3:54,616,619...54,626,203

G

sarcospan

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SSPN mRNA

NCBI chr 4:178,890,030...178,946,267
Ensembl chr 4:178,897,147...178,931,554

G

signal sequence receptor subunit 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SSR3 mRNA

NCBI chr 2:149,605,005...149,625,069
Ensembl chr 2:149,605,005...149,625,132

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ST6GALNAC1 mRNA

NCBI chr10:101,972,656...101,983,053
Ensembl chr10:101,972,668...101,983,053

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4

increases expression
multiple interactions

benz(a)anthracene results in increased expression of ST8SIA4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ST8SIA4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:95,990,131...96,084,661
Ensembl chr 9:95,993,503...96,084,653

G

signal transducing adaptor family member 2

increases expression

benz(a)anthracene results in increased expression of STAP2 mRNA

NCBI chr 9:828,369...838,648
Ensembl chr 9:828,372...837,219

G

signal transducer and activator of transcription 2

decreases expression

benz(a)anthracene results in decreased expression of STAT2 mRNA

NCBI chr 7:702,565...718,349
Ensembl chr 7:702,495...718,967

G

staufen double-stranded RNA binding protein 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of STAU2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of STAU2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:2,840,741...3,084,935
Ensembl chr 5:2,840,765...3,084,929

G

serine/threonine kinase 35

increases expression

benz(a)anthracene results in increased expression of STK35 mRNA

NCBI chr 3:117,016,819...117,049,131
Ensembl chr 3:117,016,950...117,048,066

G

storkhead box 2

decreases expression

benz(a)anthracene results in decreased expression of STOX2 mRNA

NCBI chr16:44,848,179...45,087,238
Ensembl chr16:44,848,078...45,085,105

G

syntaxin 17

increases expression

benz(a)anthracene results in increased expression of STX17 mRNA

NCBI chr 5:62,446,138...62,506,108
Ensembl chr 5:62,446,187...62,504,451

G

sulfatase 1

decreases expression

benz(a)anthracene results in decreased expression of SULF1 mRNA

NCBI chr 5:6,362,894...6,526,174
Ensembl chr 5:6,362,911...6,525,584

G

spectrin repeat containing nuclear envelope protein 1

decreases expression

benz(a)anthracene results in decreased expression of SYNE1 mRNA

NCBI chr 1:41,512,146...41,983,382
Ensembl chr 1:41,512,030...41,983,322

G

spectrin repeat containing nuclear envelope protein 2

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of SYNE2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SYNE2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:94,537,088...94,848,085
Ensembl chr 6:94,537,088...94,848,064

G

synaptojanin 2 binding protein

affects expression

benz(a)anthracene affects the expression of SYNJ2BP mRNA

NCBI chr 6:101,189,714...101,227,400
Ensembl chr 6:101,189,714...101,227,406

G

synaptotagmin 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SYT10 mRNA

NCBI chr 7:120,857,698...120,920,863
Ensembl chr 7:120,862,972...120,920,863

G

synaptotagmin 15

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SYT15 mRNA

NCBI chr16:9,532,478...9,543,288
Ensembl chr16:9,532,478...9,543,281

G

synoviolin 1

decreases expression

benz(a)anthracene results in decreased expression of SYVN1 mRNA

NCBI chr 1:203,339,235...203,346,137
Ensembl chr 1:203,339,619...203,346,152

G

SZT2 subunit of KICSTOR complex

increases expression

benz(a)anthracene results in increased expression of SZT2 mRNA

NCBI chr 5:131,897,250...131,943,953
Ensembl chr 5:131,897,275...131,943,904

G

TGF-beta activated kinase 1/MAP3K7 binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TAB2 mRNA

NCBI chr 1:2,375,026...2,425,115
Ensembl chr 1:2,375,490...2,424,756

G

TATA-box binding protein associated factor 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of TAF1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TAF1 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:66,640,915...66,716,543
Ensembl chr X:66,640,982...66,716,543

G

transporter 1, ATP binding cassette subfamily B member

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TAP1 mRNA

NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901

G

TatD DNase domain containing 3

increases expression

benz(a)anthracene results in increased expression of TATDN3 mRNA

NCBI chr13:102,634,254...102,649,069
Ensembl chr13:102,634,258...102,649,063

G

TBC1 domain family, member 10C

increases expression

benz(a)anthracene results in increased expression of TBC1D10C mRNA

NCBI chr 1:201,476,258...201,484,876
Ensembl chr 1:201,477,157...201,564,920

G

TBC1 domain family, member 2

increases expression

benz(a)anthracene results in increased expression of TBC1D2 mRNA

NCBI chr 5:60,884,114...60,931,717
Ensembl chr 5:60,884,124...60,931,352

G

T-box transcription factor 21

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TBX21 mRNA

NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831

G

T-box transcription factor 3

increases expression

benz(a)anthracene results in increased expression of TBX3 mRNA

NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708

G

TRPM8 channel-associated factor 1

decreases expression

benz(a)anthracene results in decreased expression of TCAF1 mRNA

NCBI chr 4:71,589,674...71,639,274
Ensembl chr 4:71,591,200...71,613,309

G

transcription elongation factor A3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TCEA3 mRNA

NCBI chr 5:148,476,941...148,509,452
Ensembl chr 5:148,476,941...148,509,448

G

transcription elongation factor A N-terminal and central domain containing 2

increases expression

benz(a)anthracene results in increased expression of TCEANC2 mRNA

NCBI chr 5:121,923,959...121,963,018
Ensembl chr 5:121,923,956...121,962,183

G

transcription factor 12

decreases expression

benz(a)anthracene results in decreased expression of TCF12 mRNA

NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201

G

transcription factor 19

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TCF19 mRNA

NCBI chr20:3,218,756...3,222,861
Ensembl chr20:3,218,693...3,223,271

G

transcription factor 7 like 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TCF7L2 mRNA

NCBI chr 1:254,785,956...254,978,967
Ensembl chr 1:254,786,091...254,978,967

G

treacle ribosome biogenesis factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TCOF1 mRNA

NCBI chr18:54,267,015...54,300,324
Ensembl chr18:54,267,026...54,300,324

G

testis development related protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TDRP mRNA

NCBI chr16:75,624,047...75,652,635
Ensembl chr16:75,624,907...75,652,420

G

tec protein tyrosine kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TEC mRNA

NCBI chr14:35,352,551...35,461,585
Ensembl chr14:35,352,829...35,461,557

G

tectonin beta-propeller repeat containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TECPR1 mRNA

NCBI chr12:10,391,587...10,420,462
Ensembl chr12:10,391,696...10,419,611

G

TEF transcription factor, PAR bZIP family member

increases expression
multiple interactions

benz(a)anthracene results in increased expression of TEF mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TEF mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:113,317,191...113,341,783
Ensembl chr 7:113,317,283...113,341,783

G

testis expressed 11

increases expression
multiple interactions

benz(a)anthracene results in increased expression of TEX11 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TEX11 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:65,932,904...66,196,525
Ensembl chr X:65,932,988...66,196,187

G

transcription factor CP2-like 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of TFCP2L1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TFCP2L1 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:29,733,813...29,793,870
Ensembl chr13:29,733,840...29,793,870

G

trefoil factor 1

increases expression
multiple interactions

benz(a)anthracene results in increased expression of TFF1 mRNA; benz(a)anthracene results in increased expression of TFF1 protein
2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]]; 2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 protein]]; [rottlerin results in decreased activity of PRKCD protein] inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 protein]]; fulvestrant inhibits the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]; fulvestrant inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]]; Go 6976 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [benz(a)anthracene results in increased expression of TFF1 protein]

PMID:22643241 PMID:26377693

NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597

G

trefoil factor 3

decreases expression

benz(a)anthracene results in decreased expression of TFF3 mRNA

NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054

G

tissue factor pathway inhibitor 2

decreases expression

benz(a)anthracene results in decreased expression of TFPI2 mRNA

NCBI chr 4:31,981,786...31,986,707
Ensembl chr 4:31,982,178...31,986,600

G

transforming growth factor, beta 1

multiple interactions

[benz(a)anthracene co-treated with TNF protein] results in increased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

THAP domain containing 7

increases expression

benz(a)anthracene results in increased expression of THAP7 mRNA

NCBI chr11:83,482,958...83,486,136
Ensembl chr11:83,483,037...83,486,436

G

thrombospondin 1

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of THBS1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THBS1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440

G

thyroid hormone receptor associated protein 3

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of THRAP3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THRAP3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:138,445,284...138,487,544
Ensembl chr 5:138,445,295...138,487,477

G

thrombospondin type 1 domain containing 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THSD4 mRNA

NCBI chr 8:60,384,636...60,984,419
Ensembl chr 8:60,386,875...61,024,995

G

thrombospondin type 1 domain containing 7A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THSD7A mRNA

NCBI chr 4:40,461,124...40,899,345
Ensembl chr 4:40,460,814...40,899,583

G

THUMPD3 antisense RNA 1

decreases expression

benz(a)anthracene results in decreased expression of GT(ROSA)26SOR mRNA

NCBI chr 4:146,210,520...146,217,026

G

thymocyte nuclear protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of THYN1 mRNA

NCBI chr 8:25,406,563...25,415,445
Ensembl chr 8:25,406,500...25,415,445

G

TRAF-interacting protein with forkhead-associated domain

increases expression

benz(a)anthracene results in increased expression of TIFA mRNA

NCBI chr 2:216,257,926...216,267,635
Ensembl chr 2:216,234,774...216,267,841

G

TIMP metallopeptidase inhibitor 1

increases expression

benz(a)anthracene results in increased expression of TIMP1 mRNA

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

timeless interacting protein

increases expression

benz(a)anthracene results in increased expression of TIPIN mRNA

NCBI chr 8:64,780,813...64,801,358
Ensembl chr 8:64,780,828...64,801,352

G

TLC domain containing 3B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TLCD3B mRNA

NCBI chr 1:181,421,104...181,439,744
Ensembl chr 1:181,422,830...181,439,743

G

TLE family member 1, transcriptional corepressor

decreases expression

benz(a)anthracene results in decreased expression of TLE1 mRNA

NCBI chr 5:85,851,827...85,934,806
Ensembl chr 5:85,851,827...85,934,774

G

TLE family member 2, transcriptional corepressor

decreases expression

benz(a)anthracene results in decreased expression of TLE2 mRNA

NCBI chr 7:8,119,049...8,135,385
Ensembl chr 7:8,119,053...8,134,306

G

TLE family member 6, subcortical maternal complex member

increases expression

benz(a)anthracene results in increased expression of TLE6 mRNA

NCBI chr 7:8,107,050...8,118,639
Ensembl chr 7:8,107,207...8,118,639

G

talin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TLN1 mRNA

NCBI chr 5:57,787,670...57,817,900
Ensembl chr 5:57,787,943...57,817,900

G

talin 2

decreases expression

benz(a)anthracene results in decreased expression of TLN2 mRNA

NCBI chr 8:67,830,920...68,252,240
Ensembl chr 8:67,834,326...68,252,219

G

toll-like receptor 1

increases expression

benz(a)anthracene results in increased expression of TLR1 mRNA

NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125

G

transmembrane channel-like 4

decreases expression

benz(a)anthracene results in decreased expression of TMC4 mRNA

NCBI chr 1:65,539,777...65,551,683
Ensembl chr 1:65,539,721...65,551,677

G

transmembrane protein with EGF-like and two follistatin-like domains 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEFF2 mRNA

NCBI chr 9:50,445,947...50,733,473
Ensembl chr 9:50,436,079...50,733,475

G

transmembrane protein 141

decreases expression

benz(a)anthracene results in decreased expression of TMEM141 mRNA

NCBI chr 3:8,439,533...8,441,491
Ensembl chr 3:8,439,533...8,441,491

G

transmembrane protein 150A

affects expression

benz(a)anthracene affects the expression of TMEM150A mRNA

NCBI chr 4:104,410,271...104,414,630
Ensembl chr 4:104,410,516...104,429,349

G

transmembrane protein 171

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEM171 mRNA

NCBI chr 2:30,035,278...30,045,996
Ensembl chr 2:30,035,278...30,045,049

G

transmembrane protein 245

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of TMEM245 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEM245 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:71,570,952...71,647,915
Ensembl chr 5:71,514,858...71,647,763

G

transmembrane protein 25

decreases expression

benz(a)anthracene results in decreased expression of TMEM25 mRNA

NCBI chr 8:45,107,116...45,112,657
Ensembl chr 8:45,107,121...45,116,389

G

transmembrane protein 42

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEM42 mRNA

NCBI chr 8:122,674,793...122,677,290
Ensembl chr 8:122,674,070...122,677,276

G

transmembrane protein 44

increases expression

benz(a)anthracene results in increased expression of TMEM44 mRNA

NCBI chr11:70,181,120...70,216,958
Ensembl chr11:70,181,345...70,216,958

G

transmembrane protein 80

decreases expression

benz(a)anthracene results in decreased expression of TMEM80 mRNA

NCBI chr 1:196,435,999...196,444,368
Ensembl chr 1:196,436,003...196,444,367
Ensembl chr 1:196,436,003...196,444,367

G

transmembrane protein 82

increases expression

benz(a)anthracene results in increased expression of TMEM82 mRNA

NCBI chr 5:153,927,486...153,931,942
Ensembl chr 5:153,927,471...153,936,979

G

tropomodulin 4

decreases expression

benz(a)anthracene results in decreased expression of TMOD4 mRNA

NCBI chr 2:182,695,709...182,700,540
Ensembl chr 2:182,695,709...182,700,540

G

tenascin C

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of TNC mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TNC mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624

G

tumor necrosis factor

multiple interactions
increases expression

[benz(a)anthracene co-treated with TNF protein] results in increased activity of AHR protein; [benz(a)anthracene co-treated with TNF protein] results in increased expression of CCL2 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of CXCL8 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of CYP1B1 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of NEDD9 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of PTGS2 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of TGFB1 mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased expression of TNF mRNA; [benz(a)anthracene co-treated with TNF protein] results in increased phosphorylation of and results in increased degradation of NFKBIA protein; [benz(a)anthracene co-treated with TNF protein] results in increased secretion of IL6 protein; AHR protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]; Curcumin inhibits the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6 mRNA]; RELA protein affects the reaction [[benz(a)anthracene co-treated with TNF protein] results in increased expression of IL6]
benz(a)anthracene results in increased expression of TNF mRNA

PMID:23396138 PMID:25433334

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 10b

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TNFRSF10B mRNA

NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467

G

TNF receptor superfamily member 13B

increases expression

benz(a)anthracene results in increased expression of TNFRSF13B mRNA

NCBI chr10:45,801,860...45,824,932
Ensembl chr10:45,801,860...45,822,987

G

TNF receptor superfamily member 13C

increases expression

benz(a)anthracene results in increased expression of TNFRSF13C mRNA

NCBI chr 7:113,736,046...113,738,523
Ensembl chr 7:113,736,055...113,738,517

G

TNF receptor superfamily member 4

increases expression

benz(a)anthracene results in increased expression of TNFRSF4 mRNA

NCBI chr 5:166,606,909...166,609,599
Ensembl chr 5:166,606,909...166,609,599

G

TNF superfamily member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

TOG array regulator of axonemal microtubules 2

increases expression

benz(a)anthracene results in increased expression of TOGARAM2 mRNA

NCBI chr 6:23,770,979...23,828,884
Ensembl chr 6:23,771,052...23,828,499

G

TOX high mobility group box family member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TOX4 mRNA

NCBI chr15:24,989,246...25,002,833
Ensembl chr15:24,988,853...25,002,833

G

tumor protein p53

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TRP53 mRNA; benz(a)anthracene promotes the reaction [Benzo(a)pyrene results in increased expression of TRP53 protein]
benz(a)anthracene results in increased expression of TRP53 protein

PMID:22120587 PMID:27858113

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tumor protein p53 inducible nuclear protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRP53INP1 mRNA

NCBI chr 5:24,253,986...24,272,250
Ensembl chr 5:24,260,568...24,267,968

G

thiamin pyrophosphokinase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TPK1 mRNA

NCBI chr 4:72,170,134...72,557,707
Ensembl chr 4:72,170,134...72,557,694

G

translocated promoter region, nuclear basket protein

decreases expression

benz(a)anthracene results in decreased expression of TPR mRNA

NCBI chr13:62,424,312...62,487,502
Ensembl chr13:62,424,312...62,487,496

G

tryptase beta 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TPSB2 mRNA

NCBI chr10:14,381,779...14,383,571
Ensembl chr10:14,382,013...14,383,569

G

TRAF3 interacting protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRAF3IP3 mRNA

NCBI chr13:104,694,802...104,719,655
Ensembl chr13:104,694,805...104,719,673

G

tribbles pseudokinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRIB2 mRNA

NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370

G

tripartite motif-containing 11

increases expression

benz(a)anthracene results in increased expression of TRIM11 mRNA

NCBI chr10:43,758,299...43,771,138
Ensembl chr10:43,758,354...43,771,138

G

tripartite motif-containing 2

decreases expression

benz(a)anthracene results in decreased expression of TRIM2 mRNA

NCBI chr 2:169,500,628...169,652,855
Ensembl chr 2:169,500,634...169,652,927

G

tripartite motif-containing 35

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of TRIM35 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TRIM35 mRNA

PMID:26377693 PMID:27858113

NCBI chr15:40,493,697...40,510,246
Ensembl chr15:40,493,755...40,510,240

G

transient receptor potential cation channel, subfamily C, member 3

increases expression

benz(a)anthracene results in increased expression of TRPC3 mRNA

NCBI chr 2:119,481,313...119,619,333
Ensembl chr 2:119,481,400...119,558,855

G

transient receptor potential cation channel, subfamily C, member 6

increases expression

benz(a)anthracene results in increased expression of TRPC6 mRNA

NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092

G

transient receptor potential cation channel, subfamily M, member 6

increases expression

benz(a)anthracene results in increased expression of TRPM6 mRNA

NCBI chr 1:216,136,407...216,320,523
Ensembl chr 1:216,170,038...216,320,520

G

transient receptor potential cation channel, subfamily V, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRPV4 mRNA

NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517

G

TruB pseudouridine synthase family member 2

increases expression

benz(a)anthracene results in increased expression of TRUB2 mRNA

NCBI chr 3:13,049,220...13,059,836
Ensembl chr 3:13,033,745...13,059,930

G

TSC22 domain family, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TSC22D1 mRNA

NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958

G

teashirt zinc finger homeobox 2

decreases expression

benz(a)anthracene results in decreased expression of TSHZ2 mRNA

NCBI chr 3:158,405,469...158,666,915
Ensembl chr 3:158,405,423...158,850,128

G

tsukushi, small leucine rich proteoglycan

increases expression

benz(a)anthracene results in increased expression of TSKU mRNA

NCBI chr 1:152,660,259...152,671,682
Ensembl chr 1:152,656,693...152,672,588

G

tetraspanin 1

increases expression

benz(a)anthracene results in increased expression of TSPAN1 mRNA

NCBI chr 5:129,646,139...129,659,383
Ensembl chr 5:129,646,993...129,652,017

G

tetraspanin 17

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TSPAN17 mRNA

NCBI chr17:9,819,212...9,826,851
Ensembl chr17:9,819,202...9,826,834

G

tetraspanin 18

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TSPAN18 mRNA

NCBI chr 3:79,160,060...79,299,907
Ensembl chr 3:79,161,662...79,299,852

G

tetraspanin 4

increases expression
multiple interactions

benz(a)anthracene results in increased expression of TSPAN4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TSPAN4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:196,571,307...196,593,842
Ensembl chr 1:196,572,228...196,617,448

G

testis specific protein, Y-linked 26

increases expression

benz(a)anthracene results in increased expression of TSPYL3 mRNA

NCBI chr 3:141,690,653...141,692,729
Ensembl chr 3:141,689,899...141,692,670

G

tetratricopeptide repeat domain 16

increases expression

benz(a)anthracene results in increased expression of TTC16 mRNA

NCBI chr 3:16,052,567...16,064,598
Ensembl chr 3:16,048,565...16,064,547

G

tetratricopeptide repeat domain 19

decreases expression

benz(a)anthracene results in decreased expression of TTC19 mRNA

NCBI chr10:46,969,723...46,997,607
Ensembl chr10:46,969,727...46,997,789

G

tetratricopeptide repeat domain 7A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TTC7 mRNA

NCBI chr 6:7,159,285...7,261,826
Ensembl chr 6:7,159,061...7,261,892

G

tubulin tyrosine ligase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TTL mRNA

NCBI chr 3:116,298,813...116,328,538
Ensembl chr 3:116,298,797...116,328,538

G

tubulin tyrosine ligase like 6

increases expression

benz(a)anthracene results in increased expression of TTLL6 mRNA

NCBI chr10:81,081,985...81,118,009
Ensembl chr10:81,091,975...81,127,234

G

tubulin, beta 2A class IIa

decreases expression

benz(a)anthracene results in decreased expression of TUBB2A mRNA

NCBI chr17:30,796,842...30,800,713
Ensembl chr17:30,747,503...30,800,714

G

tubulin gamma complex component 3

increases expression

benz(a)anthracene results in increased expression of TUBGCP3 mRNA

NCBI chr16:76,851,859...76,912,499
Ensembl chr16:76,851,810...76,912,499

G

taurine up-regulated 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TUG1 mRNA

NCBI chr14:78,519,894...78,526,927
Ensembl chr14:78,522,506...78,526,927

G

TUB like protein 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TULP4 mRNA

NCBI chr 1:46,682,416...46,813,167
Ensembl chr 1:46,682,863...46,809,688

G

taxilin alpha

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of TXLNA mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TXLNA mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:141,969,337...141,985,054
Ensembl chr 5:141,969,346...141,984,583

G

tRNA-yW synthesizing protein 5

increases expression

benz(a)anthracene results in increased expression of TYW5 mRNA

NCBI chr 9:58,961,100...58,979,188
Ensembl chr 9:58,961,106...58,979,188

G

ubiquitin-conjugating enzyme E2G 1

increases expression

benz(a)anthracene results in increased expression of UBE2G1 mRNA

NCBI chr10:57,225,963...57,306,748
Ensembl chr10:57,225,952...57,308,568

G

ubiquitin family domain containing 1

decreases expression

benz(a)anthracene results in decreased expression of UBFD1 mRNA

NCBI chr 1:176,626,003...176,640,993
Ensembl chr 1:176,625,657...176,640,993

G

ubiquilin 1

decreases expression

benz(a)anthracene results in decreased expression of UBQLN1 mRNA

NCBI chr17:6,439,002...6,477,096
Ensembl chr17:6,439,002...6,477,090

G

uncoupling protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of UCP1 mRNA

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

G

UDP glucuronosyltransferase family 1 member A6

increases expression
multiple interactions

benz(a)anthracene results in increased expression of UGT1A6 mRNA
Dexamethasone promotes the reaction [benz(a)anthracene results in increased expression of UGT1A6 mRNA]

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UPF3B, regulator of nonsense mediated mRNA decay

affects expression

benz(a)anthracene affects the expression of UPF3B mRNA

NCBI chr X:116,335,308...116,353,332
Ensembl chr X:116,335,308...116,353,236

G

uroplakin 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UPK1A mRNA

NCBI chr 1:85,859,672...85,870,147
Ensembl chr 1:85,859,671...85,870,354

G

uroplakin 3A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UPK3A mRNA

NCBI chr 7:116,128,981...116,139,950
Ensembl chr 7:116,134,874...116,139,948

G

uroplakin 3B

decreases expression

benz(a)anthracene results in decreased expression of UPK3B mRNA

NCBI chr12:20,630,231...20,637,634
Ensembl chr12:20,631,525...20,637,724

G

USH1 protein network component harmonin binding protein 1

decreases expression

benz(a)anthracene results in decreased expression of USHBP1 mRNA

NCBI chr16:18,057,321...18,067,933
Ensembl chr16:18,057,326...18,067,877

G

ubiquitin specific peptidase 18

decreases expression

benz(a)anthracene results in decreased expression of USP18 mRNA

NCBI chr 4:154,471,634...154,499,154
Ensembl chr 4:154,471,592...154,499,144

G

ubiquitin specific peptidase 2

increases expression
multiple interactions

benz(a)anthracene results in increased expression of USP2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of USP2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:44,411,457...44,439,668
Ensembl chr 8:44,411,607...44,438,331

G

UTP14A small subunit processome component

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of UTP14A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UTP14A mRNA

PMID:26377693 PMID:27858113

NCBI chr X:127,439,282...127,464,634
Ensembl chr X:127,439,268...127,464,633

G

utrophin

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of UTRN mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UTRN mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:6,720,854...7,224,313
Ensembl chr 1:6,722,594...7,224,313

G

vesicle-associated membrane protein 2

increases expression

benz(a)anthracene results in increased expression of VAMP2 mRNA

NCBI chr10:53,793,581...53,797,815
Ensembl chr10:53,793,923...53,797,809

G

vasohibin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of VASH1 mRNA

NCBI chr 6:106,330,374...106,345,740
Ensembl chr 6:106,329,123...106,345,726

G

vav guanine nucleotide exchange factor 3

decreases expression

benz(a)anthracene results in decreased expression of VAV3 mRNA

NCBI chr 2:197,011,901...197,354,321
Ensembl chr 2:197,011,831...197,354,321

G

VPS16 core subunit of CORVET and HOPS complexes

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of VPS16 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of VPS16 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:117,622,534...117,644,041
Ensembl chr 3:117,622,542...117,646,441

G

VPS39 subunit of HOPS complex

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of VPS39 mRNA

NCBI chr 3:107,266,846...107,304,884
Ensembl chr 3:107,267,310...107,304,975

G

VRK serine/threonine kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of VRK2 mRNA

NCBI chr14:100,313,771...100,434,520
Ensembl chr14:100,313,601...100,434,527

G

V-set and immunoglobulin domain containing 2

decreases expression

benz(a)anthracene results in decreased expression of VSIG2 mRNA

NCBI chr 8:37,250,107...37,255,150
Ensembl chr 8:37,250,107...37,255,150

G

V-set immunoregulatory receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of VSIR mRNA

NCBI chr20:28,281,582...28,307,262
Ensembl chr20:28,281,596...28,303,878

G

von Willebrand factor A domain containing 3A

increases expression

benz(a)anthracene results in increased expression of VWA3A mRNA

NCBI chr 1:175,293,782...175,355,588
Ensembl chr 1:175,293,873...175,355,602

G

WASP like actin nucleation promoting factor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of WASL mRNA

NCBI chr 4:53,083,536...53,132,061
Ensembl chr 4:53,083,536...53,132,022

G

WEE1 G2 checkpoint kinase

increases expression
multiple interactions

benz(a)anthracene results in increased expression of WEE1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of WEE1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688

G

WAP four-disulfide core domain 12

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of WFDC12 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of WFDC12 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:152,861,461...152,862,784
Ensembl chr 3:152,862,341...152,862,690

G

WAS/WASL interacting protein family, member 3

increases expression

benz(a)anthracene results in increased expression of WIPF3 mRNA

NCBI chr 4:83,550,075...83,629,929
Ensembl chr 4:83,550,468...83,629,386

G

WT1 transcription factor

decreases expression

benz(a)anthracene results in decreased expression of WT1 mRNA

NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643

G

XIAP associated factor 1

decreases expression

benz(a)anthracene results in decreased expression of XAF1 mRNA

NCBI chr10:56,917,378...56,929,791
Ensembl chr10:56,917,121...56,929,770

G

X-box binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of XBP1 mRNA

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

XK related, X-linked

increases expression

benz(a)anthracene results in increased expression of XKRX mRNA

NCBI chr X:97,341,158...97,353,175
Ensembl chr X:97,341,152...97,354,759

G

X-prolyl aminopeptidase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of XPNPEP2 mRNA

NCBI chr X:127,287,765...127,317,036
Ensembl chr X:127,287,979...127,317,223

G

5'-3' exoribonuclease 2

increases expression

benz(a)anthracene results in increased expression of XRN2 mRNA

NCBI chr 3:134,436,916...134,509,308
Ensembl chr 3:134,437,109...134,509,306

G

Y box binding protein 1

increases expression

benz(a)anthracene results in increased expression of YBX1 mRNA

NCBI chr 5:132,882,137...132,898,885
Ensembl chr 5:132,882,145...132,898,862

G

yippee-like 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of YPEL5 mRNA

NCBI chr 6:22,656,284...22,671,741
Ensembl chr 6:22,656,285...22,671,691

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of YWHAZ mRNA

NCBI chr 7:67,941,353...67,963,651
Ensembl chr 7:67,940,017...67,963,668

G

zinc finger and BTB domain containing 16

decreases expression

benz(a)anthracene results in decreased expression of ZBTB16 mRNA

NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011

G

zinc finger and BTB domain containing 20

affects expression

benz(a)anthracene affects the expression of ZBTB20 mRNA

NCBI chr11:57,052,129...57,791,214
Ensembl chr11:57,072,880...57,510,210

G

zinc finger and BTB domain containing 38

decreases expression

benz(a)anthracene results in decreased expression of ZBTB38 mRNA

NCBI chr 8:97,284,617...97,288,518
Ensembl chr 8:97,280,993...97,485,625

G

zinc finger CCCH type containing 6

increases expression

benz(a)anthracene results in increased expression of ZC3H6 mRNA

NCBI chr 3:116,203,466...116,254,186
Ensembl chr 3:116,204,197...116,253,282

G

zinc finger CCCH type containing 7 A

increases expression

benz(a)anthracene results in increased expression of ZC3H7A mRNA

NCBI chr10:4,473,177...4,512,668
Ensembl chr10:4,473,203...4,512,665

G

zinc finger CCHC-type containing 12

increases expression

benz(a)anthracene results in increased expression of ZCCHC12 mRNA

NCBI chr X:115,433,444...115,436,691
Ensembl chr X:115,433,259...115,436,692

G

zinc finger DHHC-type palmitoyltransferase 22

decreases expression

benz(a)anthracene results in decreased expression of ZDHHC22 mRNA

NCBI chr 6:106,629,090...106,646,996
Ensembl chr 6:106,631,609...106,638,872

G

zyg-11 related, cell cycle regulator

increases expression

benz(a)anthracene results in increased expression of ZER1 mRNA

NCBI chr 3:13,369,688...13,397,524
Ensembl chr 3:13,369,688...13,397,420

G

zinc finger, C3H1-type containing

affects expression

benz(a)anthracene affects the expression of ZFC3H1 mRNA

NCBI chr 7:51,008,251...51,064,666
Ensembl chr 7:51,007,984...51,064,661

G

zinc finger protein 280D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP280D mRNA

NCBI chr 8:72,992,655...73,080,482
Ensembl chr 8:72,992,650...73,080,480

G

zinc finger protein 346

increases expression
multiple interactions

benz(a)anthracene results in increased expression of ZFP346 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZFP346 mRNA

PMID:26377693 PMID:27858113

NCBI chr17:9,493,787...9,523,681
Ensembl chr17:9,493,803...9,523,635

G

zinc finger protein 365

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZFP365 mRNA

NCBI chr20:20,666,240...20,689,734
Ensembl chr20:20,666,240...20,691,238

G

zinc finger protein 367

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZFP367 mRNA

NCBI chr17:965,161...984,290
Ensembl chr17:965,161...984,287

G

zinc finger protein 36, C3H type-like 1

decreases expression

benz(a)anthracene results in decreased expression of ZFP36L1 mRNA

NCBI chr 6:98,930,705...98,935,748
Ensembl chr 6:98,930,718...98,935,748

G

zinc finger protein 511

increases expression

benz(a)anthracene results in increased expression of ZFP511 mRNA

NCBI chr 1:194,817,697...194,822,102
Ensembl chr 1:194,817,697...194,822,102

G

zinc finger protein 512B

increases expression

benz(a)anthracene results in increased expression of ZNF512B mRNA

NCBI chr 3:168,687,520...168,698,067
Ensembl chr 3:168,687,521...168,698,091

G

zinc finger protein 62

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ZFP62 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP62 mRNA

PMID:26377693 PMID:27858113

NCBI chr10:33,522,618...33,539,446
Ensembl chr10:33,500,323...33,542,013

G

zinc finger protein 628

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP628 mRNA

NCBI chr 1:68,913,600...68,921,186
Ensembl chr 1:68,910,401...68,921,243

G

zinc finger protein 641

increases expression

benz(a)anthracene results in increased expression of ZFP641 mRNA

NCBI chr 7:129,434,576...129,444,847
Ensembl chr 7:129,434,576...129,444,644

G

zinc finger protein 664

decreases expression

benz(a)anthracene results in decreased expression of ZFP664 mRNA

NCBI chr12:31,767,792...31,796,038
Ensembl chr12:31,767,720...31,796,545

G

zinc finger protein 692

affects expression

benz(a)anthracene affects the expression of ZFP692 mRNA

NCBI chr10:42,484,576...42,496,573
Ensembl chr10:42,488,588...42,496,018

G

zinc finger protein 704

increases expression

benz(a)anthracene results in increased expression of ZFP704 mRNA

NCBI chr 2:92,171,804...92,356,059
Ensembl chr 2:92,171,496...92,351,282

G

zinc finger protein 710

increases expression

benz(a)anthracene results in increased expression of ZFP710 mRNA

NCBI chr 1:133,966,256...134,036,593
Ensembl chr 1:134,024,267...134,036,601

G

zinc finger protein 951

increases expression

benz(a)anthracene results in increased expression of ZFP961 mRNA

NCBI chr14:5,032,494...5,048,775
Ensembl chr14:5,033,734...5,048,756

G

zinc finger FYVE-type containing 21

increases expression

benz(a)anthracene results in increased expression of ZFYVE21 mRNA

NCBI chr 6:130,873,979...130,894,618
Ensembl chr 6:130,873,912...130,894,411

G

zinc finger with KRAB and SCAN domains 3

decreases expression

benz(a)anthracene results in decreased expression of ZKSCAN3 mRNA

NCBI chr17:43,217,168...43,232,828
Ensembl chr17:43,217,222...43,232,827

G

zinc finger, matrin type 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZMAT3 mRNA

NCBI chr 2:115,106,046...115,136,888
Ensembl chr 2:115,106,966...115,136,863

G

zinc finger MYM-type containing 3

increases expression

benz(a)anthracene results in increased expression of ZMYM3 mRNA

NCBI chr X:66,528,585...66,544,234
Ensembl chr X:66,528,585...66,544,782

G

zinc finger MYM-type containing 6

decreases expression

benz(a)anthracene results in decreased expression of ZMYM6 mRNA

NCBI chr 5:139,396,374...139,444,357
Ensembl chr 5:139,396,727...139,444,279

G

zinc finger, MYND-type containing 10

increases expression

benz(a)anthracene results in increased expression of ZMYND10 mRNA

NCBI chr 8:108,220,386...108,224,745
Ensembl chr 8:108,220,386...108,224,744

G

zinc finger, MYND-type containing 15

decreases expression
multiple interactions

benz(a)anthracene results in decreased expression of ZMYND15 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZMYND15 mRNA

PMID:26377693 PMID:27858113

NCBI chr10:55,171,198...55,177,812
Ensembl chr10:55,171,198...55,177,812

G

zinc finger, MYND-type containing 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZMYND8 mRNA

NCBI chr 3:154,528,917...154,629,532
Ensembl chr 3:154,529,043...154,628,463

G

zinc finger and SCAN domain containing 26

increases expression

benz(a)anthracene results in increased expression of ZSCAN26 mRNA

NCBI chr17:43,148,063...43,168,070
Ensembl chr17:43,148,079...43,168,070

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19834
role	19810
biological role	19808
aetiopathogenetic role	19188
carcinogenic agent	18519
polycyclic arene	17034
ortho-fused polycyclic arene	9816
tetraphene	1218
7-bromomethyl-12-methyltetraphene	0
benz[a]anthracene 5,6-oxide	0
tetraphen-1-ol	0
Path 2
Term	Annotations
CHEBI ontology	19834
subatomic particle	19832
composite particle	19832
hadron	19832
baryon	19832
nucleon	19832
atomic nucleus	19832
atom	19832
main group element atom	19782
main group molecular entity	19782
s-block molecular entity	19620
hydrogen molecular entity	19607
hydrides	19113
organic hydride	18689
organic fundamental parent	18689
hydrocarbon	18431
cyclic hydrocarbon	17225
arene	17205
polycyclic arene	17034
ortho-fused polycyclic arene	9816
tetraphene	1218
7-bromomethyl-12-methyltetraphene	0
benz[a]anthracene 5,6-oxide	0
tetraphen-1-ol	0

paths to the root